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Alzheimer's disease (AD) is a progressive neurodegenerative disease 
characterized by neuropathological hallmarks that include accumulation of 
amyloid-beta (Aβ) plaques and neurofibrillary tangles, neuroinflammation and 
neuronal loss. Recent studies have found that Fyn tyrosine kinase is implicated 
in the pathogenesis of AD, mediating Aβ toxicity and tau 
hyperphosphorylation. However, no study has attempted to delineate isoform-
specific roles of Fyn in association with AD. Our preliminary data from exon 
arrays demonstrated differential alternative splicing of Fyn in AD, with 
significant increase of FynT but no change of brain-predominant FynB 
isoform in AD as compared to control brain samples. Furthermore, gene 
ontology term enrichment analyses of the exon array data and cellular markers 
correlation revealed that FynT was positively correlated with markers 
associated to reactive astrogliosis and negatively correlated with neuronal 
genes.  
This thesis thus aims to identify the isoform-specific role of FynT in AD brain 
and the possible impacts of FynT induction to the progression of AD. We 
hypothesized that FynT induction may be associated with pathological 
features in AD. In this thesis, the flow of my research follows a post-mortem-
to-bench approach, where we first identified our research target from post-
mortem brain tissues (Chapter 3) and then investigated and validated its 




In summary, using post-mortem brain tissues, we validated specific increase of 
FynT mRNA and protein expression in AD brains and determined that FynT 
induction in AD was independently associated with neurofibrillary 
degeneration and reactive astrogliosis (Chapter 3). Thus, we speculated that 
the expression of FynT and FynB may be differentially regulated by 
pathological conditions associated with AD. Primary rat mixed cortical 
cultures treated with Aβ and primary rat astrocyte cultures treated with TNFα 
demonstrated that FynT but not FynB could be specifically induced by both in 
vitro systems associated with AD in astrocytes. Furthermore, FynT was 
positively correlated with astrocytic markers in increasing populations of 
astrocytes from mixed cortical cultures (Chapter 4). Taking into account that 
previous studies have reported Fyn involvement in cytokines expression in 
immune cells, we hypothesized that FynT kinase activity can modulate 
inflammatory response in astrocytes. By employing recombinant FynT mutant 
approaches, FynT kinase activity was found to facilitate TNFα-induced 
expression of inflammatory markers in immortalized normal human astrocyte 
(iNHA), likely through modulating NF-κB signalling pathway (Chapter 5).  
In conclusion, our findings have added new perspectives to the isoform-
specific role of FynT in AD, particularly the role of FynT in modulating 
neuroinflammatory responses in astrocytes. Therefore, we speculate that the 
aberrant increased expression of FynT in AD may be targeted as a therapeutic 
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CHAPTER 1- Introduction 
1.1 Alzheimer’s disease (AD) 
Alzheimer’s disease (AD) is a neurodegenerative disease that is characterized 
by severe progressive loss of memory and cognitive abilities such as language, 
problem-solving skills and even one’s ability to conduct daily tasks. It is the 
most common form of dementia (up to 80%) that mainly affects the aged 
(Alzheimer's, 2015). A  small proportion of patients diagnosed with early-
onset AD before the age of 65 are often linked to genetic mutations of 
Amyloid precursor protein (APP), Presenilin-1 (PSEN1) and Presenilin-2 
(PSEN2) (Selkoe, 1991, Cras et al., 1998, Brouwers et al., 2008). The exact 
etiology of AD is still unclear but possible risk factors include aging, genetic 
predisposition (e.g. Apolipoprotein E epsilon 4 (APOE4)) and also 
environmental risk factors such as lifestyle and history of head trauma (Tilley 
et al., 1998, Guo et al., 2000, Xu et al., 2015).  
Currently, the global prevalence of dementia among people above 60 years of 
age has been reported to be about 5%, which is estimated to be over 46 million. 
The number is expected to double every 20 years, spiralling to approximately 
131 million in 2050. Furthermore, the prevalence of AD increases 
exponentially after the age of 65 (Qiu et al., 2009). The disease has cost huge 
economic burden globally, rounding to about US$ 818 billion in 2015 (Martin 
Prince, 2015). In Singapore, the prevalence of dementia among people above 
60 years of age as of 2015 was reported to be 10%, double the percentage of 
global prevalence (Subramaniam et al., 2015). This could be attributed to the 
rapid ageing population as well as higher prevalence of risk factors for 
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dementia, such as diabetes, hypertension and obesity (Subramaniam et al., 
2015).  
At present, there is no cure for AD and the progression from diagnosis to 
death takes about seven to ten years, with pneumonia or sepsis as the common 
causes of death (Brookmeyer et al., 2002). With the acceleration of worldwide 
population aging, there is a compelling need to develop new treatments that 
can effectively delay the onset of AD or prevent the disease.  
1.1.1 Histopathological hallmarks of AD  
Dr. Alois Alzheimer first described the case of AD in Auguste Deter, who 
displayed profound memory loss and worsening psychosocial changes before 
her death in 1906. Upon autopsy, he found extensive neuronal loss and 
abnormal deposits in and around nerve cells (Dahm, 2006). These deposits, 
namely amyloid plaques and neurofibrillary tangles (NFT), are the classical 
hallmarks of AD which are still used as post-mortem histological markers for 
definitive diagnosis of AD (Perl, 2010). Apart from amyloid plaques which 
are composed of aggregated amyloid-beta (Aβ) peptides and NFT that are 
made up of hyperphosphorylated tau protein, neuronal loss, synaptic 
dysfunction and reactive gliosis are also neuropathological features of AD 
(Beach et al., 1989, Itagaki et al., 1989, Fuller et al., 2010, Serrano-Pozo et al., 
2011). Several of these hallmarks (e.g., Aβ accumulation, synaptic 
dysfunction) can be observed even before the onset of clinical symptoms and 
are characteristic in different stages of the disease (see Figure 1.1) (Braak and 
Braak, 1991, Lichtenstein et al., 2010, Sperling et al., 2011).  
In recent years, more research has been focussed on the earlier stage of AD, 
the mild cognitive impairment (MCI) stage, where subtle changes in memory 
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can be observed yet patients are not labelled demented clinically (Petersen et 
al., 1999). Synaptic loss that has been observed in the MCI stage (Scheff et al., 
2006) is known to be the best pathological correlation of cognitive dysfunction 
in AD thus far (Terry et al., 1991, Koffie et al., 2011). 
 
 
Figure 1.1 Hypothetical model of biomarkers in AD to illustrate the 
preclinical phase of AD. Biomarkers emerging at different stages of AD 
progression; from preclinical to MCI and subsequently dementia. Changes 
plotted from maximally normal to maximally abnormal (y axis) as a function 
of disease stage (x axis). Figure adapted from (Sperling et al., 2011) with 
permission from Elsevier. 
 
1.1.2 Amyloid beta (Aβ) 
Aβ, the major component of aggregated extracellular plaques is derived from 
its precursor, APP (Masters et al., 1985, Goldgaber et al., 1987). APP is a 
transmembrane protein expressed abundantly in the brain (Zheng and Koo, 
2011). Full-length APP can be processed by the non-amyloidogenic or 
amyloidogenic pathways. Under physiological condition, APP undergoes 
processing predominantly via the non-amyloidogenic pathway. However in 
AD, there is a shift towards the amyloidogenic pathway (Fukumoto et al., 
2002, Platt et al., 2013). In the non-amyloidogenic pathway, APP is cleaved 
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by α-secretase, yielding soluble APP derivative, secreted Amyloid precursor 
protein-α (sAPPα). sAPPα has been found to be involved in several cellular 
processes including neuroprotection, possibly memory enhancement and 
modulates synaptic plasticity and excitability (Turner et al., 2003, Reinhard et 
al., 2005, Ring et al., 2007, Zheng and Koo, 2011). On the other hand, 
sequential processing of APP by β-secretase and γ-secretase generally yields 
40-42 kDa Aβ peptides. The neurotoxic Aβ1-42 peptide is highly hydrophobic 
and therefore more prone to self-aggregation, resulting in oligomerization, 
insoluble fibrils formation and subsequently formation of amyloid plaques 
mainly in the neocortex (See Figure 1.2) (Selkoe, 2002, Serrano-Pozo et al., 
2011). The toxic moiety of Aβ1-42 responsible for its neurotoxic properties has 
been identified to be Aβ25-35, the shortest fragment capable of forming large β-
sheet yet retaining toxicity of the full-length peptide (McLaurin and 
Chakrabartty, 1997, Stepanichev et al., 2006, Millucci et al., 2010).  While 
less well-studied in the field, this short fragment has been reported to be 
detected in both subiculum and entorhinal cortex of AD brains (Kubo et al., 
2003).  
Although amyloid plaques do not correlate well with the severity of AD, in 
vivo and in vitro experiments have demonstrated that aggregated Aβ can 
induce oxidative stress in neurons (Pike et al., 1993, Matsuoka et al., 2001). 
Earlier studies suggested that Aβ-induced neurotoxicity requires fibrillar 
aggregation of Aβ in vitro (Pike et al., 1993, Lorenzo and Yankner, 1994). 
However, increasing evidence has also revealed that soluble oligomeric 
species of Aβ can exert greater cytotoxic effects and induce synaptic 
dysfunction in neurons (Lambert et al., 1998, Klein et al., 2001, Dahlgren et 
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al., 2002, Lacor et al., 2007). Possible mechanisms of how oligomeric Aβ 
exerts neurotoxicity include direct perturbation of the membrane lipid bilayer 
and affecting ion homeostasis, impairing mitochondria function, inducing tau 
hyperphosphorylation and enhancing excitotoxic N-methyl-D-aspartate 
(NMDA) receptors mediated signalling by activating signalling pathways 
through engagement of PrP
C
-Fyn (Zheng et al., 2002, Du et al., 2008, 
Butterfield and Lashuel, 2010, Um et al., 2012). In addition, the neurotoxic Aβ 
has also been shown to activate both microglial and astrocytes resulting in 
increased expression of inflammatory mediators and accumulation of reactive 
oxygen species (ROS) (El Khoury et al., 1996, Simpson et al., 2010, Heneka 
et al., 2015).  
Many genetic risk factors of AD are related to APP mutations and APP 
processing genes like PSEN1 and PSEN2 of the γ-secretase (Tilley et al., 1998, 
Selkoe, 2002). Mutations in these deterministic genes lead to accelerated 
accumulation of Aβ plaques, resulting in early onset, autosomal dominant 
familial AD (Musiek and Holtzman, 2015). Furthermore, because the APP 
gene is localized on chromosome 21, neuropathology of AD can also be 
observed in trisomy 21 (Down syndrome) (Iwatsubo et al., 1995). These 
genetic evidences have provided framework for the amyloid hypothesis of AD, 
where Aβ accumulation in the brain is the primary driver of AD pathogenesis 







Figure 1.2 A pictorial summary of neuropathological events in AD. 
Transmembrane APP in neurons can be processed by non-amyloidogenic 
pathway to give sAPPα or amyloidogenic pathway in AD through β-sceretase 
and γ-secretase to give Aβ. Aβ peptides, particularly Aβ1-42, are prone to 
aggregation giving rise to extracellular Aβ plaque- a hallmark of AD. Aβ can 
also accumulate intracellularly in neurons and may facilitate tau 
phosphorylation. Glial cells, such as microglia and astrocytes, are activated in 
the presence of aggregated Aβ and secrete more inflammatory cytokines to 
propagate glial activation. Increased inflammatory mediators facilitate ROS 
production in the brain, resulting in tau hyperphosphorylation, synaptic loss 




1.1.3 Neurofibrillary tangles (NFTs) 
Apart from Aβ, the other pathological protein that undergoes aggregation in 
AD is tau. Tau is a microtubule associated protein (MAP) that is essential for 
the assembly and stabilization of microtubules in neurons (Weingarten et al., 
1975). There are at least 58 reported phosphorylation sites in tau which consist 
of a majority of serine/threonine sites as well as tyrosine sites (Wang et al., 
2013b). Abnormal phosphorylation of tau proteins causes microtubule 
destabilization which results in the aggregation of hyperphosphorylated tau 
seen in paired helical filaments (PHF). These aggregated proteins eventually 
form neuropil threads in axonal and dendritic segments, neurofibrillary tangles 
in somatodendritic compartments of neurons, and dystrophic neurites in AD 
(Iqbal et al., 2009, Serrano-Pozo et al., 2011). Unlike the less predictable 
spatiotemporal progression of amyloid deposition in AD, the pattern of 
spreading of NFT pathology is much more predictable and correlates better 
clinically with the severity and the progression of dementia in AD (Braak and 
Braak, 1991, Serrano-Pozo et al., 2011). Clinicopathological staging of NFT 
in AD by Braak and Braak (Braak and Braak, 1991) can be distinguished into 
six stages based on the extent of NFT distribution in the brain. Briefly, the first 
two stages involved the alteration of the entorhinal cortex, followed by limbic 
and hippocampal accumulation of NFT (stages three and four) and 
subsequently spreading to the neocortex as seen in Figure 1.3 (Braak and 




Figure 1.3 Spatiotemporal pattern of NFT distribution in AD. 
Purple shading with increasing intensity indicates increasing NFT densities 
distribution. Amyg: Amygdala; EC: Entorhinal cortex; CA1: Cornus ammonis 
1; Cg: Cingulate cortex; Prec: Precuneus; 4: Primary motor cortex; 3-1-2: 
Primary sensory cortex; 17: Primary visual cortex; 18: Secondary visual cortex. 
Figure adapted with permission from Cold Spring Harb Perspect Med 
2011;1:a006189 with copyright to Cold Spring Harbor Laboratory Press. 
 
The loss of neurons parallels with NFTs pathology especially in the entorhinal 
cortex (Gomez-Isla et al., 1996). Although NFT pathology demonstrates better 
clinical correlation with AD progression as compared to Aβ plaques, the status 
of tau gene, MAPT, as a risk factor for AD is not as established as the APP 
gene. Till date, tau mutations have not been identified and linked to familial 
forms of AD other than in familial frontotemporal dementia with 
Parkinsonism linked to chromosome 17 (FTDP-17T) (Wolfe, 2009). 
Nevertheless, increasing evidence based on several genomic studies suggest 
that certain MAPT variants could be associated with increased risk of AD 





1.1.4 Treatment of AD 
At present, there is no cure for AD and current available treatments only 
temporarily lessen or stabilize the clinical deterioration of the disease. 
Cholinesterase inhibitors (e.g. donepezil, rivastigmine) and the NMDA 
receptor antagonist memantine are as of now the key drug treatments for AD 
that have been approved by the Food and Drug Administration (Farlow and 
Cummings, 2007). New therapies targeting the Aβ and its precursor proteins, 
cholesterol reducing statins, other NMDA receptor antagonists and anti-
inflammatory drugs are currently under clinical trials (Helmuth, 2002, 
Schwartz and Shechter, 2010). Unfortunately, therapeutic approaches based on 
immunotherapeutic targeting of plaques (anti-Aβ antibodies) or regulation of 
Aβ (γ- or β-secretase inhibitors) have either failed at clinical trials due to 
adverse effects or have uncertain efficacy (Castello and Soriano, 2014, 
Menting and Claassen, 2014, De Strooper and Chavez Gutierrez, 2015). Hence 
new insights into the underlying molecular mechanisms of AD are needed to 
identify novel disease-modifying therapeutic targets.  
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1.2 Neuroinflammation in AD  
Neuroinflammation is a hallmark associated with numerous neurodegenerative 
disease and nervous system pathologies (Glass et al., 2010). The term 
“neuroinflammation” describes inflammation that is observed in neurological 
diseases mainly mediated by glial cells such as microglia and astrocytes in 
response to lesions or insults (Ransohoff and Brown, 2012). These cells 
become activated at the site of damage, synthesizing or releasing pro-
inflammatory cytokines, chemokines and ROS generators in the process 
known as gliosis (O'Callaghan et al., 2008). Neuroinflammation, often coined 
as a double-edged sword, is supposed to play a defensive role in response to 
insults, facilitating recovery. However, under uncontrolled situations with 
prolonged glial activation, it could exert detrimental effects in the central 
nervous system (CNS).   
Microglia activation and astrocyte dysfunction has been observed way before 
clinical symptoms of AD and MCI (Figure 1.4), suggesting that 
neuroinflammation is present even in the preclinical phases of AD 
(Lichtenstein et al., 2010). In AD, gliosis is observed near Aβ plaques and 
high expression of inflammatory mediators have been detected around plaques 
and NFT (Akiyama et al., 2000, Heneka et al., 2015). Inflammation has been 
shown to induce tau hyperphosphorylation and exacerbate tau pathology in 
AD mouse model (Kitazawa et al., 2005). These various studies suggest that 
neuroinflammation in AD may accelerate the disease progression or may even 
be a disease trigger. 
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Epidemiological studies that found association between chronic use of non-
steroidal anti-inflammatories (NSAIDs) and reduced risk of AD have sparked 
interest of using NSAIDs, such as ibuprofen, for the treatment of AD, 
highlighting the involvement of neuroinflammation in the disease (Stewart et 
al., 1997, Vlad et al., 2008). It is only in recent decades that the importance of 
neuroinflammation in AD has been appreciated in the field. Although key 
players of neuroinflammation have been identified, the exact roles of what 
glial cells play and immune-related changes in AD have not been fully 
understood (Heppner et al., 2015). A better understanding of neuroimmune 
pathways is required to grasp a fuller picture of the disease, thus broadening 
the therapeutic approaches for AD.  
 
 
Figure 1.4 Dynamic model of AD evolution. Microglia activation due to Aβ 
accumulation and neuronal damage as well as astrocyte dysfunction occurs 





1.2.1 Microglia in AD 
Ubiquitously distributed in the CNS, microglia are known as the resident 
phagocytes in the brain, constituting about 5 to 10% of the cells in the normal 
brain (Mittelbronn et al., 2001). They are derived from 
peripheral mesodermal (myeloid) tissue, unlike neurons, astrocytes and 
oligodendrocytes which are originated from the neuroectoderm (Chan et al., 
2007). During “resting state”, microglia are usually ramified in morphology, 
having small cell body and thin elaborated processes, acting as surveillants in 
the CNS. They also support tissue maintenance by secreting factors and 
participate in the protection and remodelling of synapses (Ji et al., 2013).  
In AD, microglia undergo activation in the presence of pathological stimuli 
such as neuronal death or Aβ aggregates and transform into phagocytic cells 
with amoeboid morphology (Giulian et al., 1995, Chan et al., 2007). The 
detection of soluble Aβ and its aggregates by microglia is mediated by the 
activation of a series of receptors which triggers internalization of Aβ as well 
as the production of a plethora pro-inflammatory cytokines and ROS (El 
Khoury et al., 1996, Chan et al., 2007, Heneka et al., 2015). The critical role of 
microglia in neuroinflammation in AD was further supported by recent 
Genome Wide Association Studies that discovered at least 20 gene variants 
associated with increased risk of late-onset AD which were highly encoded by 
microglia (Karch and Goate, 2015, Villegas-Llerena et al., 2015). In particular, 
the triggering receptor expressed on myeloid cells 2 (TREM2) is of high 
interest in the field. TREM2 is a highly expressed cell surface receptor of the 
immunoglobulin superfamily and is also involved in phagocytosis in microglia 
(Rivest, 2015, Wang et al., 2015). Mutation of TREM2 was associated with 
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increased risk of late-onset AD, similar extent to ApoE risk factor (Guerreiro 
et al., 2013).  
However, in many neurodegenerative diseases including AD, chronic 
neuroinflammation and “over activation” of microglia can lead to 
dysfunctional phagocytosis, exacerbating neuronal damage due to the 
secretion of a range of neurotoxins that includes pro-inflammatory mediators, 
nitric oxide and ROS (Liu et al., 2002, Streit et al., 2004, Luo and Chen, 2012). 
1.2.2 Astrocytes in AD 
Astrocytes are the most abundant and heterogeneous type of glial cells which 
occupy up to 50% of the brain volume (Davis, 2002). These stellate cells play 
supportive functions in the CNS and are also involved in pathologic processes 
(Eddleston and Mucke, 1993). Physiologically, astrocytes interact with 
endothelial cells in the blood brain barrier (BBB); regulating BBB function, 
participate in ion homeostasis, antioxidant defence of the brain as well as 
transmitter synthesis and removal of glutamate. They also act as storage cells 
for glycogen, which serves as a reserve when glucose is in short supply in the 
brain, providing metabolic support for neurons (Davis, 2002, Schousboe and 
Waagepetersen, 2005, Abbott et al., 2006, Brown and Ransom, 2007).  
For a long period of time, astrocytes were thought to play only 
neurosupportive roles in the CNS. Increasingly, numerous studies in recent 
decades have highlighted their importance especially in the context of 
neuroinflammation. Astrocytes are activated or become reactive in response to 
many CNS insults and pathologies, such as neurodegeneration, stroke or 
tumour growth (Pekny and Nilsson, 2005). Upon activation, they display 
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morphological changes, increase proliferation and size (hypertrophic) and 
express elevated levels of molecules, one of which is the glial fibrillary acidic 
protein (GFAP), an intermediate filament cytoskeletal protein specific to 
astrocytes (Eddleston and Mucke, 1993). This process is termed reactive 
astrogliosis, a prominent hallmark of many neurodegenerative diseases. 
Furthermore, due to their immunocompetent nature, they are able to produce 
cytokines and chemokines when activated (Fuller et al., 2010). In AD, the 
extent of astrogliosis was found to be associated with increasing Braak staging 
(Simpson et al., 2010).  
In vitro experiments have demonstrated the ability of reactive astrocytes to 
phagocyte and degrade Aβ deposits (Wyss-Coray et al., 2003). Although this 
is the case, activated astrocytes during chronic inflammation in AD appear to 
neglect their neurosupportive functions, enhance excitotoxicity and exhibit 
prolonged inflammatory signals, creating an inflammatory cascade (Fuller et 
al., 2010). Moreover, gliosis that causes excessive scar formation around 
lesions hinders axonal growth and neuronal recovery (Hamill et al., 2005). 
Although the role of astrocytes in neuroinflammation is not as well established 
as that of microglia, the sheer abundance of astrocytes in the CNS already 
suggests that astrocytes may have a more critical and sustained role as 
compared to microglia in prolonged neuroinflammatory processes in AD.  
1.2.3 Inflammatory mediators in AD  
There are several types of inflammatory mediators that can be expressed and 
secreted by microglia, astrocytes and even neurons in AD. These include 
cytokines and chemokines, caspases, prostanoids, complement system and 
reactive oxygen species (Rubio-Perez and Morillas-Ruiz, 2012, Heneka et al., 
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2015). Prolonged or overactivation of neuroinflammation in the brain 
aggravates synaptic dysfunction which correlates with memory decline 
observed preceding neuronal death associated with late stages of AD 
(Agostinho et al., 2010).   
Cytokines were originally known as lymphokines and monokines due to their 
initial discovery in hematopoietic cells. They are small proteins with 
molecular weight ranging from 8 to 40 kDa with biological activities that are 
important in host responses to disease, infection and immunomodulation 
(Dinarello, 2000). In AD, numerous studies have consistently shown that 
many cytokines including TNFα (Tumour necrosis factor alpha), IL-1β 
(interlukin-1 beta), IL-6, IL-8 and TGFβ (transforming growth factor beta) 
appeared to be upregulated in AD (Akiyama et al., 2000). 
1.2.4 TNFα in AD 
TNFα is a pleiotropic cytokine that has been found to be elevated in the serum, 
CSF, cortex of AD patients and Aβ stimulated microglial cultures (Fillit et al., 
1991, Tarkowski et al., 1999, Bhaskar et al., 2014). Elevated levels of soluble 
TNFα were also observed in those with MCI, indicating TNFα possible 
participation in the pathogenesis of AD even at an early stage (Tarkowski et 
al., 2003). Paracrine stimulation by TNFα can lead to expression of other 
inflammatory cytokines such as IL-1β, IL-6, IL-8, potentiating the 
inflammatory cascade (Perry et al., 2001).  
In the brain, TNFα physiological roles include regulation of BBB integrity, 
febrile responses, mediation of glutamatergic transmission as well as synaptic 
plasticity and synaptic scaling (Beattie et al., 2002, Pickering et al., 2005, 
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Stellwagen and Malenka, 2006, McCoy and Tansey, 2008). However, under 
pathological conditions, TNFα can activate both microglia and astrocyte 
during injury and was identified as the main neurotoxic agent resulting from 
Aβ-induced pro-inflammatory transcriptional changes (Combs et al., 2001, 
McCoy and Tansey, 2008). Moreover, it has been demonstrated that TNFα 
works cooperatively with interferon γ to increase production of Aβ while 
inhibiting secretion of the neuroprotective soluble APPs and is required for the 
suppression of long-term potentiation (LTP) by Aβ in vitro (Blasko et al., 
1999, Rowan et al., 2007). In AD patients, increased TNFα in serum has been 
linked to accelerated deterioration and aggravated psychiatric symptoms 
(Perry et al., 2007, Holmes et al., 2009, Holmes et al., 2011).  
These findings have made TNFα and possibly even its downstream mediators 
potential therapeutic targets for AD in the aspect of neuroinflammation. 
Etanercept (Enbrel™), a recombinant TNFα receptor: Fc fusion protein that 
binds and inactivates TNFα (Weinblatt et al., 1999) has been approved by US 
Food and Drug Administration for the treatment of several autoimmune 
diseases including rheumatoid arthritis. A 6 month, open-label pilot study in 
patients with AD ranging from mild to severe showed that perispinal 
administration of etanercept could sustain clinical improvement with better 
cognitive outcomes (Tobinick et al., 2006). However, this approach has not 
been evaluated in randomized controlled trial and remains controversial. 
Based on the hypothesis of modifying long-term, low grade peripheral 
systemic inflammation, Butchart et al., has recently completed a double-blind, 
randomized, placebo-controlled phase II trial of subcutaneous administration 
of etanercept on patients with mild to moderate AD. Although there were no 
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statistical significant differences in the improvement of cognition, behaviour, 
or global function, there were trends favouring the treatment group as 
compared to placebo. According to the authors, further testing was required in 
a larger and more heterogeneous AD patient population for validation 
(Butchart et al., 2015).  
1.2.5 IL-1 in AD 
Similar to TNFα, IL-1 is another pleiotropic pro-inflammatory cytokine that is 
upregulated in the brain of AD patients and also in people with Down’s 
syndrome before AD neuropathological changes are observed (Griffin et al., 
1989). The two major effectors of the IL-1 family, IL-1α and IL-1β are 
distinct isoforms that exert similar biological effects by acting on IL-1 
receptor IL-1RI (Gibson et al., 2004, Luheshi et al., 2011). IL-1β is 
commonly described as the classical pro-inflammatory cytokine in the brain 
and frequently measured in numerous studies (Rothwell, 1991, Luheshi et al., 
2009). Physiologically, IL-1 is known as a very potent pyrogenic agent and is 
involved in hypothalamic-pituitary adrenal activation in response to stress 
(Murakami et al., 1990, van der Meer et al., 1996). 
In AD, IL-1 is overexpressed in microglia surrounding Aβ plaques next to 
neurons in brain tissues (Griffin et al., 1995). The overexpression appeared to 
occur early in plaque pathology and can be observed in diffuse, non-neuritic 
Aβ deposits in brain samples from foetuses and young children with Down’s 
syndrome suggesting its role in plaque formation in AD (Griffin et al., 1995, 
Sheng et al., 1997). Parallel to this, in vitro experiments have shown that IL-1 
was able to induce APP gene expression (Goldgaber et al., 1989).   
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Although microglia is the predominant source of IL-1 in the brain, it can also 
be produced by many other cells including astrocytes, oligodendrocytes, 
neurons, endothelial cells and infiltrating leukocytes (Vela et al., 2002, Basu 
et al., 2004, Shaftel et al., 2008). Moreover, IL-1β can exert both autocrine 
and paracrine feedback to propagate inflammation including self- induction of 
IL-1 (Spranger et al., 1990, Shaftel et al., 2008). 
1.2.6 IL-6 in AD 
IL-6 is another cytokine frequently described to be elevated in AD 
(Baranowska-Bik et al., 2008). It has been reported that IL-6 
immunoreactivity could be detected in AD cortical neuritic plaques and not 
observed in age-matched control brains (Bauer et al., 1991, Huell et al., 1995). 
Together with both TNFα and IL-1, they are known to be the key 
inflammatory cytokines induced during the acute-phase response during 
inflammation (Heinrich et al., 1990).   
Astrocytes, microglia, neurons and endothelial cells of the CNS are capable of 
expressing IL-6 (Frei et al., 1989, Marz et al., 1998, Van Wagoner et al., 1999).  
Astrocytes, in particular, are known to exhibit strong induction of IL-6 in the 
presence of both TNFα and IL-1β (Van Wagoner et al., 1999). Physiological 
roles of IL-6 include facilitating oligodendrocyte differentiation, generation of 
astrocytes from cortical precursor cells and acting as neurotrophic factor for 
the CNS (Kahn and De Vellis, 1994, Hirota et al., 1996, Islam et al., 2009).  
Although IL-6 has several beneficial properties in the CNS, it is generally 
considered as a destructive pro-inflammatory mediator in neurodegenerative 
diseases. Transgenic mice with GFAP promoter driven expression of IL-6 
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displayed deficits in learning accompanied with neuropathological changes 
including the loss of synapse and gliosis (Fattori et al., 1995, Heyser et al., 
1997). In relation to AD, a Japanese study group has found that a genetic 
polymorphism of the IL6 gene promoter that showed tendency of higher IL-6 
expression was associated with increased risk of sporadic AD (Shibata et al., 
2002). In addition, not only does Aβ induces IL-6 expression in glial cells, IL-
6 could also similarly stimulate the expression of APP (Ringheim et al., 1998, 
Toro et al., 2001, Vukic et al., 2009). 
1.2.7 Inflammatory pathways in AD 
Nuclear factor-kappa B (NF-κB), commonly labelled as the “master regulator 
of inflammation” is activated in numerous neurodegenerative diseases where 
chronic neuroinflammation is prominent (Granic et al., 2009). Particularly in 
AD, neurons and glial cells around Aβ plaque displayed NF-κB activation 
with surrounding microglial and astrocytes expressing elevated levels of 
inflammatory cytokines, including TNFα, IL-1β, IL-6 and free radicals in an 
NF-κB dependent pathway (Terai et al., 1996, Kaltschmidt et al., 1997, 
Akama et al., 1998), Aβ peptides were also found to induce NF-κB activation 
in cultured neurons and rat brains (Kaltschmidt et al., 1997, Carrero et al., 
2012). The two classical pro-inflammatory cytokines, TNFα and IL-1β that are 
upregulated in AD, strongly activate NF-κB, propagating the 
canonical signalling pathway that results in the expression of a plethora of pro-
inflammatory cytokines and chemokines (Moynagh, 2005, Lawrence, 2009). 
Both cytokines though having their own receptors (TNFR1 and IL1RI), 
converges on an upstream IKK complex (inhibitor of kappa B (IB) kinase 
complex) that eventually phosphorylates the NF-B inhibitory protein IB, 
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releasing NF-κB into the nucleus to activate transcription of pro-inflammatory 
genes (see Figure 1.5) (Verstrepen et al., 2008). In the case of astrocytic NF-
κB activation, evidence have shown that suppression of NF-κB transcriptional 
activity in astrocytes could reduce inflammation and improve recovery which 
makes astrocytic inhibition of NF-κB an attractive target for AD therapy 
(Medeiros and LaFerla, 2013, Steardo et al., 2015),.  
Given that neuroinflammation in AD is chronic, other pathways could 
likewise contribute to the inflammatory response observed in AD. One 
example would be the activation of Mitogen-Activated Protein Kinases 
(MAPKs) signalling pathway. THE MAPK family consist of various kinases 
which includes extracellular signal–regulated kinase (ERK), c-Jun N-terminal 
kinase (JNK), and p38 kinase (p38) (Krishna and Narang, 2008). Increased 
levels of p38 kinase activity has been observed in post-mortem brain tissues of 
AD patients and was associated with NFT and Aβ plaque pathology and could 
be also detected at even early stages (Braak stages IV-V) of the disease 
indicating its involvement in AD pathogenesis (Hensley et al., 1999, Sun et al., 
2003). MAPKs can also be activated by oxidative stress triggered by ROS, 
promoting tau hyperphosphorylation via p38 signalling (Peel et al., 2004, 




Figure 1.5 Canonical NF-κB signalling pathway. This figure illustrates the 
canonical signalling pathway for NF-κB activation. It can be triggered by 
cytokines and Toll-like receptors (TLRs), resulting in the activation of RelA/ 
NF-κB p65 that regulates expression of inflammatory and cell survival genes. 
IKK (in this case IKKβ) regulates activation of the canonical pathway through 
phosphorylation of IκBs. Figure adapted with permission from Cold Spring 
Harb Perspect Biol 2009;1:a001651, with copyright to Cold Spring Harbor 
Laboratory Press. 
 
1.3 Fyn tyrosine kinase 
Fyn, the non-receptor tyrosine kinase of the Src family has important roles in 
the activation of various signal transduction pathways. The Src family kinase 
(SFK) has nine members consisting of Blk, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes 
and Yrk, with many members having oncogenic properties after mutation 
(Parsons and Parsons, 2004). They share a conserved region made up of three 
domains namely SH1 (Src homology 1), SH2 and SH3 and a unique amino-
terminal sequence ranging between 60 and 90 amino acids in length which 
distinguishes them (See Figure 1.6A) (Kefalas et al., 1995). Fyn was isolated 
as a cDNA from normal human fibroblast and possesses translational product 
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highly similar to c-Src at an identity of 86% at its Carboxyl-terminal 
(Kawakami et al., 1986, Semba et al., 1986, Kawakami et al., 1988).  
1.3.1 Fyn isoforms and their kinase activity 
There are three transcripts variants of Fyn namely FynB, FynT and FynΔ7 as a 
result of alternative splicing (Goldsmith et al., 2002). Exon 7A and 7B are 
mutually exclusive exons for FynB and FynT isoforms respectively, they both 
encode a short sequence that differs in approximately 50 amino acids, 
spanning across the end of the SH2 domain, the SH2-kinase linker segment 
and the beginning of SH1-kinase domain (Figure 1.6). FynB is highly 
expressed in the brain and other tissues whereas FynT, the thymic isoform, is 
known to be predominantly expressed in cells of hematopoietic origins like in 
T cells (Resh, 1998). FynΔ7, on the other hand, is a newly discovered 
transcript variant that lacks exon 7 and hence is presumed to have no kinase 
activity (Goldsmith et al., 2002).  
Like other SFKs, Fyn tyrosine kinase also contains two conserved tyrosine 
residues, Y416 and Y527, which have opposing effects upon phosphorylation. 
Autophosphorylation of Y416 within the kinase domain (corresponding to 
Y417 in FynT and Y420 in FynB) results in a conformational change to 
promote substrate binding and thus increase kinase activity (Figure 1.6B). 
Hence, phosphorylated Y416 has been used as a determinant of SFK catalytic 
activity. On the other hand, phosphorylation of Y527 (corresponding to Y528 
in FynT and Y531 in FynB) stabilizes a closed conformation of SFK, which 
suppresses kinase activity towards substrates. Consistently, dephosphorylation 










Figure 1.6 Structure of  Fyn tyrosine kinase. (A) Primary structure of Fyn 
tyrosine kinase with major features that include a site at SH4 (src homology 
domain 4) required for myristoylation and association with the plasma 
membrane; a unique domain; SH3 and SH2 domains; a kinase region, 
including sites for phosphotransfer (lysine 296/299, K296/K299) and auto-
phosphorylation (tyrosine 417/420, Y417/Y420); and a carboxy-terminal 
regulatory domain including the major site of tyrosine phosphorylation 
(tyrosine 528/531, Y528/Y531) (Picard et al., 2004). Exon 7 spans across SH2 
and kinase domain which encompasses a linker region. The two isoforms, 
FynB and FynT differ by 52 amino acids in this region. (Diagram not drawn to 
scale) (B) SFKs, including Fyn tyrosine kinase, are activated through 
dephosphorylation of Y527 (corresponding to Y528 in FynT and Y531 in 
FynB) and phosphorylation of Y416 within the kinase domain (corresponding 
to Y417 in FynT and Y420 in FynB), resulting in a switch from a close 
conformation to an active conformation. Figure adapted from (Harrison, 2003) 





Activated kinase Inactivated kinase 
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The linker region between the SH2 domain and kinase domain (illustrated in 
Figure 1.6) is highly variable within the SFKs including FynB and FynT. This 
region is important in regulating the autoinhibitory mechanism of the kinase 
through facilitating inter-domain interactions thereby allowing the 
conformation of the kinase to be switched between activated and inactivated 
states (Xu et al., 1997, Xu et al., 1999). Structural analyses revealed that the 
linker region of FynB engages the SH3 domain with higher affinity and 
favours a closed auto-inhibited conformation, whereas FynT has a relatively 
loose autoinhibitory conformation (Brignatz et al., 2009). The observation 
suggested that FynT may interact with substrates with higher affinity and 
exhibit enhanced kinase activity compared to FynB. Indeed, it has been 
reported that FynT, but not FynB, interact with and phosphorylate the RNA-
binding protein Sam68 (Brignatz et al., 2009). On the other hand, Davidson et 
al. attributed the variability of the N-terminus of the kinase domain and 
identified that FynT facilitated the mobilization of cytosolic calcium and 
lymphokine secretion upon T cells stimulation (Davidson et al., 1992, 
Davidson et al., 1994). In addition, genetically knock-out model of mice 
lacking just the thymic isoform FynT, similarly showed defective T-cell 
signalling in terms of reduced calcium mobilization upon T-cell activation, 
altered patterns of phosphotyrosine accumulation, and defective proliferation 
when T-cell receptor were stimulated with anti-CD3 antibodies (Appleby et al., 
1992). Although only a few studies have specifically investigated the isoform-
specific role of Fyn, these independent studies have highlighted the functional 
differences of FynB and FynT as a consequence of alternative splicing of exon 
should not be overlooked. 
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1.3.2 The roles of Fyn in the brain  
The biological functions of Fyn are diverse, ranging from T cell signalling, 
cell adhesion, mitogenic signalling, pro-inflammatory mediator production 
and also in brain function; with some of its functions appearing to be isoform-
specific (Davidson et al., 1994, Resh, 1998, Picard et al., 2004, Rajasekaran et 
al., 2013). Based on observations in Fyn mutant and knockout mouse models, 
Fyn has been proposed to have several critical roles in the brain. Fyn is 
involved in LTP induction and maintenance, which are associated with spatial 
learning and memory (Grant et al., 1992). It was also found that Fyn regulates 
dendritic spine number and morphology, indicating its role in synaptic 
function (Babus et al., 2011). In addition, Fyn phosphorylates subunits of the 
NMDA receptor which are involved in mediating tolerance to ethanol-induced 
sedation in Fyn knockout mice (Yaka et al., 2003). Furthermore, Fyn kinase 
activity is also required for the regulation of normal myelination by 
oligodendrocytes (Sperber et al., 2001) as well as in oligodendrocyte 










1.3.3 The pathogenic roles of Fyn in AD 
Fyn was first reported in relation to the disease by Sherin K. Shirazi and John 
G. Wood in 1993. They discovered the co-localization of Fyn to a subset of 
neurons stained positively with hyperphosphorylated tau (Shirazi and Wood, 
1993). Following their discovery, subsequent studies found that Fyn could 
directly interact and phosphorylate tau at Tyrosine 18 residue (Lee, 1998, Lee 
et al., 2004). A quantitative study on Fyn protein expression conducted later 
found that Fyn level was increased in the insoluble fraction of AD brain lysate 
while synapse expression of Fyn was decreased (Ho et al., 2005). 
On the other hand, independent studies focusing on the toxic effects of Aβ, 
revealed that Fyn knockout (KO) mice were protected against diffusible Aβ 
oligomers neurotoxicity in the hippocampus (Lambert et al., 1998). With the 
introduction of transgenic mouse models of AD, double transgenic mouse 
model of Fyn and APP was utilize in experiments to study the effects of Fyn 
in memory, learning and even in seizures (Chin et al., 2005, Um, 2012). It has 
been shown that Fyn kinase could induce cognitive and synaptic impairment 
in these mice (Chin et al., 2005).  
More recently, Aβ, tau and Fyn has been studied in greater details to 
investigate their possible interaction in AD (Ittner, 2010, Roberson, 2011, 
Minami et al., 2012). In 2010, Ittner et al. reported that Fyn played a critical 
role in tau-dependent Aβ toxicity at the postsynapse (Ittner, 2010). Similarly, 
Roberson et al. showed that Fyn, Aβ and tau were found to co-operatively 
impair synaptic and network function in multiple mouse models of AD 
(Roberson, 2011). Moreover, Stephen M. Strittmatter and his group has 
identified Fyn as a mediator of signal transduction downstream of the 
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cellular prion protein (PrP
C
)-Aβ oligomer complex requiring the metabotropic 
glutamate receptor mGluR5 which are involved in Aβ-Induced dendritic spine 
lost and neuronal toxicity (Um et al., 2012, Um et al., 2013). These studies 
have supported the hypothesis of Fyn inhibition as a therapeutic approach in 
AD and were also in line with proposed hypothesis of Fyn-Tau-Amyloid toxic 
triad proposed by Christian Haass and Eckhard Mandelkow (Haass, 2010). 
1.3.4 Current status of Fyn as a therapeutic target in AD 
The studies discussed above have emphasized the importance of regulation of 
Fyn expression and activity in memory and plasticity. Currently, several 
tyrosine kinase inhibitors such as Masitinib, Saracatinib that are being tested 
in AD clinical trials are capable of inhibiting Fyn although they are not 
specific to targeting Fyn exclusively. Therefore, special note has to be taken to 
consider potential side-effects of these drugs.  
Masitinib, currently in use in clinical trial to target mast cells found on both 
sides of the blood-brain barrier, is proposed as drug for reducing 
neuroinflammation and restoring compromised BBB functions in AD 
(Silverman et al., 2000, Nautiyal et al., 2008, Piette et al., 2011). It was found 
to be reasonably well tolerated in a phase II dose-ranging trial in France 
involving mild-to-moderate AD patients and was associated with cognitive 
improvement after 12 and 24 weeks (Piette et al., 2011). The launch of an 
international, multicenter phase 3 clinical trial has begun in 2013 to evaluate 
the safety and efficacy of masitinib in a larger group of mild-to-moderate AD 
patients (Nygaard et al., 2014). 
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On the other hand, saracatinib (AZD0530), proposed as a drug to target Aβ 
mediated synaptotoxicity through Fyn, has completed phase Ib trial in patients 
with AD and was also shown to be well tolerated and reasonably safe. An 
ongoing larger Phase IIa clinical trial of Saracatinib for the treatment of 




1.4 Preliminary data showing isoform-specific role of FynT in AD 
With the proposed putative pathogenic roles of Fyn in AD, one would assume 
that the brain-predominant FynB isoform is involved in the disease. Hence, no 
study has attempted to delineate possible isoform-specific roles of Fyn in AD. 
Our laboratory has previously reported genome wide profiling of AD versus 
control brains transcriptome using Affymetrix exon array platform (Tan et al., 
2010). An analysis of alternative splicing events associated with AD using the 
same database revealed that Fyn was differentially spliced in AD temporal 
cortex (Lai et al., 2014). Interestingly, we observed that FynT was specifically 
upregulated in AD while FynB remained unchanged (see Figure 1.7). These 
findings were intriguing as FynT is known to be expressed predominantly in 
cells of hematopoietic origin but not in the CNS (Cooke and Perlmutter, 1989). 
Furthermore, gene ontology term enrichment analyses of the exon array data 
(Table 1.1) and cellular markers correlation (Table 1.2) revealed that FynT 
was positively correlated with markers associated to reactive astrogliosis and 
negatively correlated with neuronal function. Hence, we felt the urge to 























Figure 1.7 Gene View display on the selective upregulation of FynT 
isoform expression in AD brain. A Gene View display of differential 
alternative splicing of Fyn was generated from Affymetrix exon array data 
with AD (red) and control (blue) samples (n = 8 for both groups). Two FynT-
specific probeset IDs (1* and 2*) were significantly up-regulated in AD as 
compared to control samples. FynB specific probeset IDs (1^, 2^ and 3^) 
showed no significant changes in AD. The y-axis is a log2 scale intensity 
value. Figure adapted from (Lee et al., 2015) with permission from John 











Table 1.1 Genes which correlate with FynT expression in AD categorized 
by GO terms 
Genes positively correlated with FynT expression   














GO:0008092 (MF) Cytoskeletal protein binding 44 3.011 7.20E-08 
GO:0015629 (CC) Actin cytoskeleton 26 3.479 4.83E-05 
GO:0048522 (BP) Positive regulation of cellular 
process 
96 1.708 3.39E-05 
GO:0007010 (BP) Cytoskeleton organization 36 2.742 3.18E-05 
GO:0016323 (CC) Basolateral plasma membrane 22 3.900 4.17E-05 
GO:0042127 (BP) Regulation of cell proliferation 51 2.152 6.50E-05 
GO:0006928 (BP) Cellular component movement 36 2.517 1.30E-04 
GO:0048523 (BP) Negative regulation of cellular 
process 
84 1.681 1.77E-04 
GO:0031012 (CC) Extracellular matrix 27 2.817 3.01E-04 
GO:0007155 (BP) Cell adhesion 44 2.088 6.18E-04 
GO:0016563 (MF) Transcription activator activity 29 2.440 4.21E-03 
Genes negatively correlated with FynT expression    








GO:0043005 (CC) Neuron projection 43 3.454 7.04E-10 
GO:0045202 (CC) Synapse 41 3.173 1.66E-08 
GO:0031982 (CC) Vesicle 53 2.173 8.18E-06 
GO:0019717 (CC) Synaptosome 15 4.849 6.04E-05 
GO:0005794 (CC) Golgi apparatus 58 1.827 2.75E-04 
GO:0016192 (BP) Vesicle-mediated transport 46 2.076 1.13E-03 
GO:0050804 (BP) Regulation of synaptic 
transmission 
19 3.632 1.21E-03 
1
Gene ontology (GO) category: biological process (BP), cellular component 
(CC), molecular function (MF).
  
2
Total number of genes correlated with FynT in the GO term. 
3
Fold enrichment is used for measuring the magnitude of enrichment.  
4
p-values adjusted for multiple testing using a false-discovery rate of 5% (see 
(Huang da et al., 2009a, Huang da et al., 2009b)). 






Table 1.2 Expression of specific cellular markers in AD vs Ctrl brain (n=8 
per group), as well as their significant correlation with FynT expression 




















(r) Ctrl AD Fold p-value 
3393744 CD3D T cell 1.846 1.995 1.11 0.27349 none in 6 
 
3351280 CD3E T cell 3.258 3.168 -1.06 0.62740 none in 6 
 
3351300 CD3G T cell 1.729 2.124 1.32 0.05716 1 out of 4 0.62503 
3402786 CD4 T cell 3.746 3.746 1.00 0.99716 none in 12 
 
2562932 CD8A T cell 4.080 4.276 1.15 0.13054 1 out of 11 0.62481 
2562965 CD8B T cell 1.460 1.571 1.08 0.40684 none in 4 
 
2328841 LCK T cell 3.361 3.668 1.24 0.02322* none in 17 
 
2495187 ZAP70 T cell 2.894 3.231 1.26 0.01812* none in 17 
 
2373842 CD45 hematopoietic 2.812 2.872 1.04 0.64841 none in 38 
 










3.143 4.475 2.52 0.01540* 3 out of 18 
0.65404 to 
0.71018 
3656990 CD11b microglia 3.431 3.627 1.15 0.16383 none in 2 
 
2902444 Iba1 microglia 4.235 4.271 1.03 0.87870 none in 9 
 
2806643 GLAST astrocyte 8.805 9.132 1.25 0.25089 9 out of 15** 
0.65104 to 
0.79985 
3759410 GFAP astrocyte 10.729 11.327 1.51 0.02510* 14 out of 14** 
0.65573 to 
0.78003 
2525533 MAP2 neuron 8.721 8.091 -1.55 0.02259* 2 out of 26 
-0.63944 to 
0.64138 
3128271 NEFL neuron 9.035 8.076 -1.94 0.02170* 10 out of 12** 
-0.62376 to 
-0.73384 
3090436 NEFM neuron 8.965 8.186 -1.71 0.04663* 2 out of 11 
-0.65343 to 
-0.71241 
3432394 RPH3A neuron 7.737 5.986 -3.37 0.00045* 27 out of 28** 
-0.64750 to 
-0.88786 
3674504 TUBB3 neuron 5.686 5.409 -1.21 0.10308 1 out of 6 -0.65120 
1




 Correlation between cellular markers and FynT expression was analysed at 
the exon-level using probesets in each transcript ID. Only those with 
significant correlation (p<0.01) were indicated with Pearson correlation 
coefficient (r) in last column. 
* 
indicated significant differentially expressed between AD vs Ctrl (p<0.05). 
**
indicated cellular marker with more than half of the probesets showing 
significant correlation with FynT expression.  





1.5 Hypotheses and objectives of the project   
This project aims to identify an isoform-specific role of FynT in AD and the 
possible impacts of FynT induction in disease progression. We employed post-
mortem brain tissues, primary cortical cultures and recombinant approaches 
which can be found in the thesis Chapter 3, 4 and 5, respectively, to address 
our specific objectives.  
Chapter 3- An isoform-specific role of FynT tyrosine kinase in Alzheimer’s 
disease  
 Hypothesis:  
FynT induction in AD may be associated with reactive astrogliosis and 
neurodegeneration. 
 Objective:  
To determine FynT immunoreactivity in association with cellular 
markers and neuropathological hallmarks in post-mortem AD brains. 
Chapter 4- Isoform-specific modulation of FynT tyrosine kinase expression in 
astrocytes under Aβ and TNFα treatment 
 Hypothesis:  
Pathological conditions of AD can specifically induce FynT expression 
in primary cortical cultures. 
 Objective:  
To study the modulation of differential FynT versus FynB expression 
in primary mixed cortical cultures and astrocytes cultures under Aβ 
and TNFα treatment. 
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Chapter 5- The functional role of FynT tyrosine kinase in modulating TNFα-
induced inflammatory response in astrocytes 
 Hypothesis: 
FynT kinase activity may modulate inflammatory responses at the late 
phase of TNFα treatment in astrocytes. 
 Objective:  
To study the role of FynT kinase activity in modulating TNFα-induced 
inflammatory signalling using recombinant FynT mutant approaches in 
immortalized normal human astrocyte.  
In brief, studies on post-mortem AD brains revealed that FynT induction was 
independently associated with neurofibrillary degeneration and reactive 
astrogliosis (Chapter 3). We thus aimed to delineate the isoform-specific role 
of FynT in neurons and astrocytes using primary cortical culture exposed to 
pathological conditions associated with AD (Chapter 4). The observation of 
TNFα-induced FynT expression in primary astrocytes prompted us to 
speculate that aberrant FynT induction may modulate astrocyte-associated 
neuroinflammatory response in AD. Hence, we focused on characterizing the 
role of FynT kinase activity in modulating TNFα signalling pathway using 











CHAPTER 2-  








CHAPTER 2- Materials and Methods 
2.1 Materials 
2.1.1 Brain tissues  
Post-mortem brain tissues were derived from twelve AD patients (five women, 
seven men) and eight elderly controls (three women, five men) originally 
recruited by OPTIMA (Oxford Project to Investigate Memory and Ageing, 
http://www.medsci.ox.ac.uk/optima). Additional control tissues (n=3; from 
two women and one man) were obtained from the Newcastle Brain Tissue 
Resource (NBTR), Newcastle upon Tyne, UK, both sites being part of the UK 
Brains for Dementia Research (BDR) network (see Table 2.1). Informed 
consent had been obtained from the patients' next-of-kin before collection of 
brains, and appropriate Institutional Review Board approvals were obtained 
for work carried out in Singapore (SingHealth IRB 2011/576/A). One 
hemisphere of each subject was processed for pathological assessments, 
including confirmation of AD using the Consortium to Establish a Registry 
for AD (CERAD) criteria (Mirra et al., 1991) as well as Braak staging (Braak 
and Braak, 1991) while the other hemisphere was fresh frozen for research. In 
this study, fresh frozen tissues samples from prefrontal (Brodmann area 9) 
and temporal (Brodmann area 22) were used as these areas were known to be 
affected by AD pathology. BA9 tissues were frozen in Optimal Cutting 
Temperature compound (OCT) for subsequent sectioning and 
immunofluorescence (IF). BA22 tissues were stored at -80°C in TRIzol® 
reagent (Invitrogen, P/N 15596-018) before processing for real-time reverse 





Table 2.1 Demographic and disease variables in AD and control subjects 
ID Tissue Source Group Age Sex PMI Braak 
OP450 OPTIMA AD 78 M 88 III/IV 
OP80 OPTIMA AD 88 F 30 III/IV 
OP133 OPTIMA AD 69 M 44 V/VI 
OP332 OPTIMA AD 62 M 97 V/VI 
OP340 OPTIMA AD 63 F 48 V/VI 
OP357 OPTIMA AD 71 M 49 V/VI 
OP378 OPTIMA AD 85 F 76 V/VI 
OP417 OPTIMA AD 67 M 30 V/VI 
OP91 OPTIMA AD 66 M 42 V/VI 
OP107* OPTIMA AD 67 F 107 V/VI 
OP279* OPTIMA AD 78 F 94 V/VI 
OP388* OPTIMA AD 83 M 29 V/VI 
188/96 Newcastle Control 82 F 26 0 
102/05 Newcastle Control 72 M 17 I/II 
144/94 Newcastle Control 86 F 40 I/II 
OP1112 OPTIMA Control 78 M 63 I/II 
OP1151 OPTIMA Control 77 M 20 I/II 
OP243 OPTIMA Control 77 M 54 I/II 
OP346 OPTIMA Control 88 F 115 I/II 
OP9 OPTIMA Control 79 F 29 I/II 
OP1044* OPTIMA Control 85 M 16 0 
OP1132* OPTIMA Control 81 F 47 I/II 
OP1146* OPTIMA Control 87 M 30 I/II 
Age, age of death (in years); Braak, neuropathologic staging according to 
Braak & Braak (Braak and Braak, 1991); PMI, post-mortem interval (in hours). 









2.1.2 Animals for primary cultures 
Pregnant Sprague Dawley rats were purchased from InVivos Pte Ltd and 
housed at SingHealth Experimental Medicine Centre with protocols approval 
from the SingHealth Institutional Animal Care and Use Committee prior the 
start of the experiments (2014/SHS/950). Embryonic brains (embryonic day 
18, E18) were used to establish primary cortical mixed cultures (see 2.2.1.1) 
and postnatal brains (Postnatal day 0 to 1, P0-1) were used to establish 
primary astrocyte cultures (see 2.2.1.2).  
2.1.3 Cell lines 
Immortalized normal human astrocytes (iNHA) were primary human 
astrocytes stably transfected with constructs encoding E6, E7 and human 
telomerase reverse transcriptase (hTERT) which were kindly provided by Dr. 
Russell O. Pieper from University of California, San Francisco (Sonoda et al., 
2001). Human embryonic kidney 293T cells (HEK293T), human glioma U-
251 MG, human glioma U-87 MG and neuroblastoma SH-SY5Y cell lines 
were obtained from the American Type Tissue Culture Collection (ATCC, 
USA). 
2.1.4 Plasmid constructs  
Open reading frame of FynT-WT (wild-type) (NM_153047) with C-terminal 
tagged of Myc-FLAG, carried by pCMV6 Entry vector was purchased from 
OriGene Technologies. Expression vector carried mutant forms of FynT-CA 
(constitutively active mutant, also known as FynT-Y528F, changed the coding 
position 1583 from A to T which mutated amino acid position 528 from 
tyrosine (TAC) to phenylalanine (TTC)) and FynT-KD (kinase dead mutant, 
also known as FynT-K296M, changed the coding position 887 from A to T 
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which mutated amino acid position 296 from lysine (AAG) to methionine 
(ATG)) (Davidson et al., 1992) were both generated by site-directed 
mutagenesis and confirmed by DNA sequencing previously.  
For NF-κB luciferase reporter assay, Renilla luciferase control reporter vector 
(pRL-CMV) was purchased from Promega while NF-κB(1) luciferase 
Reporter Vector (pNF-κB-luc) comprising five tandem repeats of NF-κB 
transcription responsive elements was purchased from Panomics.   
2.1.5 Custom-made antibodies  
Custom-made rabbit polyclonal antibodies raised specifically against FynB 
and FynT were generated by GenScript Corporation. FynB and FynT-specific 
rabbit polyclonal antibodies were prepared against synthetic peptide 
CRESLQLIKRLGNGQ (NP_002028, residues 268-281) and 
QTSGLAKDAWEVAC (NP_694592, residues 252-264), respectively, which 
are conserved between human, mouse and rat. Both peptides were conjugated 
with keyhole limpet hemocyanin to increase immunogenicity for 
immunization. Pre-immune serum and test bleed serum from rabbits after third 
immunization with enzyme-linked immunosorbent assay (ELISA) titer of 
1:256,000 were tested for FynB and FynT-specificity using Western blot 
analyses with lysates derived from FynB or FynT transfected HEK293T. The 
antibodies with low background and high specificity were then affinity 
purified and dissolved in phosphate buffer saline (PBS), pH 7.4 at a 
concentration of 0.428 mg/ml with 0.02% sodium azide as preservative. 




2.1.6 Other commercially available antibodies 
 
Table 2.2 Primary and secondary antibodies used  
Antibody Name (Catalog #) Species Dilution Company 
FynB-specific (custom-made) rabbit pAb 1:100 (IF); 
1:1000(WB) 
Genscript 
FynT-specific (custom-made) rabbit pAb 1:100 (IF); 
1:1000(WB) 
Genscript 
Total Fyn (#4023) rabbit pAb 1:1000 (WB) Cell Signaling 
β-actin (13E5), HRP conjugate 
(#5125) 
rabbit mAb 1:3000 (WB) Cell Signaling 
THE
TM
 c-Myc Tag (A00704) mouse mAb 1:500 (IF) Genscript 
Myc-Tag (71D10)(#2278) rabbit mAb 1:1000 (WB) Cell Signaling 
GFAP (GA5) (#3670) mouse mAb 1:100 (IF) Cell Signaling 
Anti-NeuN antibody  (ABN78) rabbit pAb 1:100 (IF) Millipore 
Anti-NeuN antibody, clone A60 
(MAB377) 
mouse mAb 1:100 (IF) Millipore 
Anti-NeuN antibody, clone A60 
Alexa Fluor® 555 Conjugate 
(MAB377A5) 
mouse mAb 1:100 (IF) Millipore 
Anti-MAP2, clone AP20 
(MAB3418) 
mouse mAb 1:100 (IF) Millipore 
Phospho PHF-Tau (AT8) 
(MN1020) 




mouse mAb 1:200 (IF) Medimabs 
Phospho-NF-κB p65 (Ser536) 
(93H1) (#3033) 
rabbit mAb 1:1000 (WB) Cell Signaling 
NF-κB p65 (D14E12) XP® (# 
8242) 
rabbit mAb 1:1000 (WB) Cell Signaling 
IκBα (L35A5) Mouse mAb 
(#4814) 
mouse mAb 1:1000 (WB) Cell Signaling 
Anti-mouse IgG, Alexa Fluor 
555 conjugate (#4408) 
goat pAb 1:1000 (IF) Cell Signaling 
Anti-rabbit IgG, Alexa Fluor 488 
conjugate (#4412) 
goat pAb 1:1000 (IF) Cell Signaling 
Anti-mouse IgG, Alexa Fluor 
647 conjugate (A21235) 
goat pAb 1:1000 (IF) Thermo 
Scientific 
Anti-mouse IgG, HRP-linked Ab 
(#7076) 
goat pAb 1:3000 (WB) Cell Signaling 
Anti-rabbit IgG, HRP-linked Ab 
(#7074) 
goat pAb 1:3000 (WB) Cell Signaling 
mAb= monoclonal antibody, pAb=polyclonal antibody,  IF= 






2.1.7 Primer sets 
 
Table 2.3 Primers and primer sequences 
Primer Name Forward primer seq (5'-3') Reverse primer seq (5'-3') 
FynB  CTGCTGCCGCCTAGTAGTTC GTGTTTCCATTCCAGGTACC 
FynT  CATCGAGTTGTACCCCACAA GTGTTTCCATTCCAGGTACC 
Fyn* GGCCCAGTTTGAAACACTTC 56-FAM/TGTTTCCATTCCAGGTACC 
CCL2 GCCTCCAGCATGAAAGTCTC AGATCTCCTTGGCCACAATG 
CCL5 CGCTGTCATCCTCATTGCTA GAGCACTTGCCACTGGTGTA 
CCL7 CCTCCAACATGAAAGCCTCT CCAGCCTCTGCTTAGGGATT 
CXCL10 AGGAACCTCCAGTCTCAGCA CAAAATTGGCTTGCAGGAAT 
CXCL12 TGAGAGCTCGCTTTGAGTGA CACCTTGCCAACAGTTCTGA 
CSF3 ACGAGGGTCAGGACTGTGAC GTGACAGTGGAGGGGACACT 
GMCSF ATGTGAATGCCATCCAGGAG AGGGCAGTGCTGCTTGTAGT 
IL1B AGCCAGGACAGTCAGCTCTC AAGCGGTTGCTCATCAGAAT 
IL1ra ACCAATATGCCTGACGAAGG GTGACCAGGTTGTTGTGACG 
IL6 GTCCACTGGGCACAGAACTT CAAACTGCATAGCCACTTTCC 
IL8 TAGCAAAATTGAGGCCAAGG AAACCAAGGCACAGTGGAAC 
IL23 GTGGGACACATGGATCTAAGAGAA TCAGACCCTGGTGGATCCTT 
LIF CCCTGGTCCCTACTCAACAA CTGGACCCTGACACCCTAAA 
TNFR1 GTGCCTACCCCAGATTGAGA TGTCGATTTCCCACAAACAA 
18S rRNA  CCTGCGGCTTAATTTGACTC CGCTGAGCCAGTCAGTGTAG 
α-tubulin ATGGAGCCCTGAATGTTGAC ACATCTTTGGGAACCACGTC 
β-actin  ACTGGAACGGTGAAGGTGAC AGAGAAGTGGGGTGGCTTTT 
GAPDH TGACATCAAGAAGGTGGTGAAG TTACTCCTTGGAGGCCATGTG 
Rat FynB CTGCTGCCGTCTAGTAGTTC GTGTTTCCATTCCAGGTACC 
Rat FynT CATCAAGTTGTACCCCACAA GTGTTTCCATTCCAGGTACC 
Rat Fyn* GGCCCAGTTTGAGACCCTTC 56-FAM/TGTTTCCATTCCAGGTACC 
Rat CD11B CAGCATCAGTACCAGTTCAACA CTGCAACAGAGCAGTTCAGC 
Rat GFAP TGAGGCAGAAGCTCCAAGAT CTCGAACTTCCTCCTCATGG 
Rat GLAST ATCCAGGCCAACGAAACACT CTTCATGTTTCCGATCACGA 
Rat GLT-1 CTGGGAAGAAGAACGACGAG AGTTTCTTCAGGGGCCTCAT 
Rat NeuN TTCCCACCACTCTCTTGTCC ATCAGCAGCCGCATAGACTC 
Rat TUBB3 CCCCAGCTTACCTTCCTACC CAGGCCTGGAGCCATAATAA 
Rat ENO2 ATGACCTGACGGTGACCAAC AACGTGTCCTCGGTTTCTCC 
Rat MAP2 GGTCTAGATGTTGCTGCCAAGA CGTGGCTGGACTCAATACCC 
Rat β-actin ACTGGAACGGTGAAGGCGAC TGCCGTGGATACTTGGAGTG 
Rat GAPDH GGCATTGCTCTCAATGACAA TGTGAGGGAGATGCTCAGTG 
Rat 18S rRNA CCTGCGGCTTAATTTGACTC CGCTGAGCCAGTTCAGTGTA 










2.1.8 DsiRNA duplexes  
 
Dicer-substrate RNAs (DsiRNA) were purchased from Integrated DNA 
Technologies selected using IDT’s online Predesigned DsiRNA Search Tool 
available on https://sg.idtdna.com/Scitools/Applications/Predesign/. 
Table 2.4 DsiRNA duplex sequences 
 DsiRNA duplex sequences* 
FynT specific_1 5’-  GGAUUGGCUAAAGAUGCUUGGGAag-3’ 
3’-GACCUAACCGAUUUCUACGAACCCUUC-5’ 
FynT specific_2 5’-  ACUUAACUGUGAUUGCAUCGAGUtg-3’ 
3’-AUUGAAUUGACACUAACGUAGCUCAAC-5’ 
FynT specific_3 5’-  GUGUUUCGCUGAAGUGUGGCUUGgt-3’ 
3’-CCCACAAAGCGACUUCACACCGAACCA-5’ 
NC1 Control Duplex 5’-  CGUUAAUCGCGUAUAAUACGCGUat-3’ 
3’-CAGCAAUUAGCGCAUAUUAUGCGCAUA-5’ 
* DsiRNAs are asymmetric 25/27-mer RNA duplexes with a 3’ two-
nucleotide overhang on the antisense strand and a blunt end modified with 
DNA bases (shown in lower case). 
2.1.9 Factors and Chemicals used for cell treatment 
 


















































 20 mg/ml 5 and 50 
ng/ml 
1Ultrapure water was obtained from ELGA®’s PURELAB® flex water 




2.1.10 Multiplex immunoassay analytes 
 
Table 2.6 Multiplex immunoassays analytes  
Analytes MILLIPLEX® 
Multiplex Assays Panel 
P/N 
CCL2/MCP-1 MPXHCYTO-60K 
CCL3/ MIP-1α MPXHCYTO-60K 
CCL4/ MIP-1β MPXHCYTO-60K 
CCL5/RANTES MPXHCYTO-60K 
CCL7/ MCP-3 MPXHCYTO-60K 
CXCL10/ IP-10 MPXHCYTO-60K 
CXCL12/ SDF-1 HCYP2MAG-62K 
FGF-2 MPXHCYTO-60K 
CSF2 /GM-CSF MPXHCYTO-60K 










2.2.1 Cell cultures and cell based assays related methods 
2.2.1.1 Rat cortical culture  
Primary rat cortical cultures were established from embryonic (E18) Sprague 
Dawley rats after protocol approval from the SingHealth Institutional Animal 
Care and Use Committee (2014/SHS/950). Briefly, cortices were dissected 
and meninges were removed in ice cold Hank’s balanced salt solution (HBSS). 
The cortices were then digested using a papain dissociation system 
(Worthington Biochemical Corporation, P/N LK003150), according to the 
manufacturer’s protocol. Dissociated cells were then centrifuged and 
resuspended in Neurobasal (NB) medium (Invitrogen, P/N 21103-049) 
supplemented with 2.5% B27 (Invitrogen, P/N 17504044), 0.25% 
GlutaMAX™ (Invitrogen, P/N 35050061), 1x penicillin-streptomycin 
(Invitrogen, P/N 15140-122) and with 0.1 to 1% heat-inactivated HyClone™ 
Fetal Bovine Serum (FBS) (GE healthcare, P/N SH30088.03) or without FBS. 
Cells were seeded at densities of approximately 1× 10
6
 cells per well in 6-well 
plates or 3.4× 10
4
 cells per well in 96-well plates coated with 0.1 mg/ ml
 
Poly-
D-lysine hydrobromide (Sigma, P/N P6407) and cultured at 37°C in a 
humidified 5% CO2 incubator. Half-change of media was performed on DIV4 
(days in vitro) and 1 μM AraC (mitotic inhibitor) (Sigma, P/N C1768) could 
be added at this point to obtain a purer neuronal culture. At DIV 7, culture 
medium was replaced with NB medium minus phenol red (Invitrogen, P/N 
12348017) supplemented with 2.5% B27 without antioxidants (Invitrogen, 
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P/N 10889-038), 0.25% GlutaMAX™ (Invitrogen, P/N 35050061) and the 
respective FBS concentrations.  
2.2.1.2 Rat astrocyte culture  
For primary astrocyte cultures, cultures were prepared from cortical tissues of 
P0-1 Sprague Dawley rats after protocol approval from the SingHealth 
Institutional Animal Care and Use Committee (2014/SHS/950). Isolated 
cortices were separated from the meninges in ice cold PBS, and then 
dissociated with 0.05% trypsin (Biowest, P/N X0915-100) with 0.5 mM 
EDTA (Ethylenediaminetetraacetic acid) in 1x PBS. Trypsin digestion was 
terminated by the addition of DMEM-F12 (Biowest, P/N L0090-500) 
supplemented with 10% HyClone™ FBS (GE healthcare, P/N SH30088.03) 
and 1 mM L-Glutamine (GIBCO, P/N 25030-081) with 1% Penicillin-
Streptomycin (10,000 U/mL) (GIBCO, P/N 15140-122). The cell suspension 
was filtered through Falcon 40 mm nylon cell strainer (BD Biosciences, P/N 
352340). The resultant filtrate was centrifuged and resuspended in fresh media, 
plated at 1× 10
7
 cells per 75 cm
2
 flask. The cells were grown in 5% CO2 
incubator at 37°C and media was changed on DIV3. Subsequent media 
changes were performed once every 2 days until the glial culture reached 
confluency (12-14 days). Astrocytes were enriched by vigorously shaking the 
cell culture flasks at 250 rpm in a shaker maintained at 37°C for 24 h with 
inclusion of one media change before overnight shaking to remove microglial 
and oligodendrocytes (McCarthy and de Vellis, 1980, Tamashiro et al., 2012). 
The purity of astrocytes was assessed by immunofluorescence with anti-GFAP, 
an astrocytes marker and DAPI nuclear stain (Vector Laboratories). This 
protocol of astrocytes culturing yielded up to 97% purity. For treatment, the 
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astrocytes were trypsinized and re-plated at a density of 5 x10
5
 cells per well 
in 6-well plates and treated in culture medium with reduced FBS (0.5%). 
2.2.1.3 Cell culture 
All cell lines were maintained in DMEM High Glucose w/ L-Glutamine w/ 
Sodium Pyruvate (Biowest, P/N L0104-500) supplemented with 10% Heat-
inactivated FBS (Hyclone, P/N SH30088.03) and 1x MEM non-Essential 
Amino Acids (Biowest, P/N X0557) except for SH-SY5Y which was 
maintained in DMEM - F12 (Biowest, P/N L0090-500) supplemented with 10% 
heat-inactivated HyClone™ FBS (GE healthcare, P/N SH30088.03) and 1 mM 
L-Glutamine (GIBCO, P/N 25030-081). The cells were grown in a 37 ºC 
humidified incubator with 5% CO2 and passaged at 80-90% confluence using 
0.25% trypsin (Biowest, P/N X0915-100) with 1 mM EDTA in 1x Dulbecco's 
Phosphate Buffered Saline (Biowest, P/N X0515-500). For keeping of cell 
stock, cells were resuspended in cryovials containing 600 μl of 10% DMSO 
(Sigma, P/N D8418) in culture media and kept at -80 ºC or transferred to 
liquid nitrogen for long-term storage.  
2.2.1.4 Stable clone generation 
For establishing stable clones of iNHA expressing FynT wild type (WT), 
kinase constitutively active (CA), kinase dead forms (KD) or pCMV6 Entry 
empty vector (EV), iNHA were transfected in 6-well plates (steps similar to 
transient transfection, see 2.2.1.5). One day after transfection, iNHA were 
trypsinized and seeded at a lower density in 10 cm dishes and treated with 600 
µg/ml of Geneticin® (Invitrogen) for more than two weeks to select the clones 
that stably expressed the transgene. Well separated individual clones in the 
dishes were picked, clonally expanded and confirmed for positive expression 
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using Western blot analyses. In this study, at least two independent stably 
transfected clones of FynT-WT, -CA, -KD and EV were selected for further 
analyses. 
2.2.1.5 Transfection 
For gene overexpression or gene silencing, lipofection was performed in 6-
well plates with cell densities of 2-3× 10
5 
cells per well in 2 ml culture 
medium using HilyMax transfection reagent (Dojindo Laboratories, P/N H357) 
in accordance to the manufacturer’s protocol. Briefly, 9 µl of HilyMax reagent 
was added to 120 μl Opti-MEM® I Reduced-Serum Medium (GIBCO, P/N 
31985070) containing either 3 µg of plasmid DNA or 3 μl of DsiRNA (20 
μM), respectively, mixed well and incubated for 15 min at RT. The mixture 
was then added to each well and the cells were placed back into the 37°C, 
humidified 5% CO2 incubator. Cells were proceeded with other treatment one 
day after transfection, or harvested for further analysis two days after 
transfection. For gene silencing experiments, a second transfection was 
required to be performed one day after the initial transfection to effectively 
knockdown the overexpressed gene. 
2.2.1.6 Aβ25-35 preparation 
Aβ25–35 (Sigma, P/N A4559) and Aβ35–25 (Sigma, P/N A2201) were dissolved 
in ultrapure water at a stock concentration of 1 mM and stored at -80 °C. 
Before treatment, the peptides were aged by incubating at 37°C for 24 h and 




2.2.1.7 Cell Viability Assay 
Primary rat mixed cortical cultures seeded in 96-well plates which underwent 
Aβ treatment were tested for cell viability at 48 h using Cell Counting Kit-8 
(CCK-8) (Dojindo Molecular Technologies, P/N CK04-11). The CCK-8 assay 
relies on dehydrogenase activity in live cells to convert water-soluble 
tetrazolium salt (WST-8) into orange WST-8 formazan dye which amount can 
be quantitated by absorption spectroscopy. Briefly, 10 µl of CCK-8 reagent 
was added to each well of the 96-well plates containing 100 µl of culture 
medium and placed back into the incubator for 2 h before measuring 
absorbance at 450 nm using Benchmark Plus Microplate Spectrophotometer 
System (Bio-Rad Laboratories). Percentage of cell viability was calculated as 





2.2.2 RNA isolation and gene expression assay related methods 
2.2.2.1 Human brain RNA isolation  
Frozen brain tissue samples were homogenized in 1 ml TRIzol reagent 
(Invitrogen, P/N 15596-018). After homogenization, an additional 500 μl of 
TRIzol reagent and 300 μl of chloroform: isoamyl alcohol (24: 1) were added 
and vortexed vigorously for 1 min. The mixture was incubated at room 
temperature (RT) for 10 min and then centrifuged at 16 000 g for 10 min at 
4°C. After centrifugation, the top aqueous phase was transferred to a new 
microcentrifuge tube containing 600 μl of acid phenol and 200 μl of 
chloroform: isoamyl alcohol (24:1), followed by vortexing for 1 min and 
centrifugation at 16 000 g for 5 min at RT. After centrifugation, the top 
aqueous phase was extracted with 500 μl of chloroform: isoamyl alcohol (24:1) 
by vortexing for 1 min, and centrifugation at 16 000 g for 2-3 min at RT. 
Again, the top aqueous phase was transferred to another new tube. RNA was 
precipitated by mixing the aqueous phase with an equal volume of isopropanol, 
incubation at RT for 30 min and centrifugation at 16 000 g for 10 min at 4
o
C. 
The RNA pellet was then rinsed with 75% ethanol, air dried and resuspended 
in nuclease-free water. Quantitation of RNA isolates was performed using 
Nanodrop ND-1000 spectrophotometer (Thermo Scientific). The resuspended 
RNA was stored at -80
o
C until use. 
2.2.2.2 Cell culture RNA isolation  
Culture media was removed from cells growing in 6-well plates. 1 ml of 
TRIzol reagent (Invitrogen, P/N 15596018) was added to each well to lyse the 
cells and transferred to a microcentrifuge tube. 200 μl of chloroform: isoamyl 
alcohol (24: 1) was added and vortexed vigorously for 1 min. The mixture was 
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incubated at RT for 10 min and then centrifuged at 16 000 g for 10 min at 4°C. 
After centrifugation, 500 μl of the top aqueous phase were transferred to a new 
microcentrifuge tube containing 500 μl of 70% ethanol and pipetted up down 
to mix well. RNA isolation was proceeded using NucleoSpin® RNA kit 
(Macherey-Nagel, P/N 740955) according to manufacturer’s instruction. 
Briefly, the mixture was passed through the NucleoSpin® RNA Column and 
rinsed with 350 μl of Membrane Desalting Buffer. 95 μl of DNase reaction 
mixture was added into the column to for DNA digestion and rinsed with 200 
μl RAW2. The column was then washed with RAW3 twice and spun dry 
before the RNA were eluted in 30 μl of RNase-free water. Quantitation of 
RNA isolates was performed using Nanodrop ND-1000 spectrophotometer 
(Thermo Scientific). The resuspended RNA was stored at -80
o
C until use. 
2.2.2.3 Reverse Transcription 
Total RNA was extracted from human brain tissue (2 μg) or cell culture (1 μg) 
was reverse-transcribed (RT) using High-Capacity cDNA RT kit (Applied 
Biosystems, P/N 4368814) in accordance to the manufacturer’s protocol. 
Briefly, the RNA was reconstituted in 10 μl of nuclease-free water. 10 μl of 2 
X RT master mix consisting of RT Buffer, dNTP Mix, RT Random Primers, 
MultiScribe™ Reverse Transcriptase and nuclease free water was added to the 
reconstituted RNA to give a final volume of 20 μl per reaction mixture. The 
conditions for the thermal cycler were as follows: 25°C for 10 min, 37°C for 
120 min and 85°C for 5 min. After reverse transcription, cDNA products were 
diluted with 20 μl of nuclease-free water to reduce salt interference in 




2.2.2.4 Primer Design 
The mRNA sequences (REFSEQ) of genes of interest were obtained from 
NCBI’s Entrez Nucleotide database (http://www.ncbi.nlm.nih.gov/nucleotide/) 
and used as templates for primer design. The forward and reverse primers 
were generated using Primer3 (v. 0.4.0) online software available at 
http://frodo.wi.mit.edu/primer3/. The product size range was set at 
approximately 150-300 nucleotides. Primer specificity was assessed using 
NCBI’s Primer-BLAST search tool available at: 
http://www.ncbi.nlm.nih.gov/tools/primer-blast/ (Ye et al., 2012). Further 
confirmation was done by running a standard PCR followed by gel 
electrophoresis on a 2% agarose gel containing GelRed Nucleic Acid Gel 
Stain (Biotium, P/N 41003) and visualized by UV on the Gel Doc™ machine 
(Bio-Rad Laboratories). Only primer sets that yield PCR products with the 
correct predicted sizes were used for real-time RT-PCR. 
2.2.2.5 Real-Time PCR 
Amplification of each 1 μl of diluted cDNA was done in a 15 μl reaction mix 
containing 1x SYBR Green PCR master mix (Applied Biosystems, P/N 
4309155) or GoTaq® qPCR Master Mix (Promega, P/N A6002) with 200 nM 
each of the respective forward and reverse primers (Table 2.3). Real-time PCR 
was carried out using the 7500 Fast Real-Time PCR Machine (Applied 
Biosystems). The temperature program used was as follows: 50°C for 2 min, 
95°C for 2 min and 40 cycles of 95°C for 15 s and 60°C for 1 min. All real-
time PCR assays were performed in duplicate. Standard curves of each gene 
were generated independently by 10x serial dilution of template DNA. The 
relative signal intensity of each sample was calculated according to the 
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corresponding standard curve. Melting curves were analysed for each sample 
to check for product specificity. Normalization was performed in each sample 
by dividing the relative signal intensity of gene of interest to 18S rRNA 
(human brain samples), or geometric mean of β-actin, GAPDH and 18S rRNA 
(primary rat culture and human cell culture).  
2.2.2.6 Capillary Electrophoresis 
PCR was first performed on 1 μl of diluted cDNA product in a 20 μl master 
mix containing 1x Colourless GoTaq ® Flexi buffer (Promega), 1.5 mM 
MgCl2, 200 μM dNTP, 1 unit of GoTaq® Flexi DNA Polymerase (Promega, 
P/N M8295), 250 nM of forward primer and 56-FAM labelled reverse primer 
(see Table 2.3). The temperature program used was as follows: 94°C for 3 min, 
55°C for 1.5 min, 72°C for 2 min and 22-25 cycles of 94°C for 1 min, 55°C 
for 1 min, 72°C for 1 min. The reaction ended with 72°C for 10 min and was 
maintained at 4°C until collection. Capillary electrophoresis was then 
performed using Applied Biosystems PRISM – 310 Genetic Analyzer or 
Applied Biosystems 3500xL Genetic Analyzer. 1 μl of PCR product was 
added to 12 μl of Hi-Di™ formamide (Applied Biosystems, P/N 4311320) and 
1 μl of ABI GeneScan 500 Rox size standard (Applied Biosystems, P/N 
4310361). The samples were incubated at 95°C for 4 min and immediately 
placed on ice to prevent DNA renaturation. The product size and quantity of 
each DNA amplicon in the capillary electropherograms was analysed using 
GeneScan analysis software (Applied Biosystems). Peak areas of FynT (219 
bp DNA amplicon) and FynB (228 bp DNA amplicon) in each 
electropherogram were translated into expression level and used to determine 
ratios of FynT to FynB expression. 
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2.2.2.7 High Throughput Real-Time PCR 
High Throughput Real-Time PCR was performed using a BioMark HD system 
(Fluidigm Corporation) to simultaneously study 192 samples of their 
expression of 24 genes using a 192.24 Dynamic Array™ integrated fluidic 
circuit (IFC) for Gene Expression (Fluidigm, P/N 100-6266). Specific target 
amplification (STA) was first carried out on each cDNA sample to increase 
the number of copies of target DNA. This step involved mixing cDNA with all 
the target primer pairs (pooled in advanced) at a final concentration of 0.05 
μM in 1x PreAmp Master Mix (Fluidigm Corporation, P/N 100-5580). The 
mixture was then placed into a thermal cycler for 10 cycles of amplification of 
the genes of interest. The temperature program used was as follows: 95°C for 
2 min and 10 cycles of 95°C for 15 s and 60°C for 4 min. The reaction was 
maintained at 4°C until collection. After STA, a clean-up step was performed 
to remove unincorporated primers using treating with approximately 1 U/l 
Exonuclease I (New England BioLabs, P/N M0293S) for 37°C for 30 min, and 
followed by 80°C for 15 min to stop the reaction. The end product was diluted 
10-fold in TE buffer (10 mM Tris-HCI, 1.0 mM EDTA, Invitrogen) and stored 
at -20°C until use. To prepare samples for high throughput real-time PCR, 1.8 
l of each diluted ExoI-treated STA product was added to 96-well plate 
containing mixture of 2 l of 2x SsoFast EvaGreen Supermix with low ROX 
(Biorad, P/N 1725211) and 0.2 l of Delta Gene Sample Reagent (Fluidigm, 
P/N 100-6653), vortex and remove bubbles prior adding to IFC. To prepare 
assay mix, 0.4 l of each primer set (50 M) was added to 96-well plate 
containing mixture of 2 l of 2x Assay loading reagent (Fluidigm, P/N 100-
5359) and 1.6 l of 1x DNA suspension buffer (10mM Tris, 0.1 mM EDTA, 
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pH8.0), vortex and remove bubbles prior adding to IFC. Preparation and 
loading of 192.24 Dynamic Array IFC was performed according to the 
manufacturer’s instructions based on Fluidigm 192.24 DELTAgene™ 
Fast/Standard Gene Expression Workflow (PN 100-7222 C1). Briefly, the IFC 
was made ready by injecting 150 l of control line fluid into the dedicated 
accumulator with a provided syringe and removing the blue protective film 
from the bottom of IFC, followed by pipetting 3 l of each primer reaction 
assay mix and 3 l of each sample into the respective inlets without generating 
air bubbles. Lastly, Actuation Fluid and Pressure Fluid were pipetted into the 
respective wells with indicated volume based on instructions. The 192.24 
Dynamic Array IFC was then loaded into IFC Controller RX by running the 
Load Mix (169x) script to complete the mixing of samples and assays and then 
transferred to BioMark HD system for real-time PCR and melting curve 
analysis. The temperature program used was as follows: 95°C for 1 min and 
30 cycles of 96°C for 5 s and 60°C for 20 s. The melting curve analysis 
consisted of 3 s at 60°C followed by heating up to 95°C with a ramp rate of 
1°C/ 3 s. A pooled template DNAs for all the primer sets were 10x serial 
diluted to generate standard curves for each gene. The relative signal intensity 
of each sample was calculated according to the corresponding standard curve. 
Normalization was performed in each sample by dividing the relative signal 
intensity of gene of interest to geometric mean of α-tubulin, β-actin, GAPDH 
and 18S rRNA. Primer sequences used are listed in Table 2.3. 
2.2.2.8 Dual luciferase reporter assay 
To measure the NF-κB activity in FynT clones, 3 μg of pNF-κB-luc and 0.03 
μg of pRL-CMV were co-transfected 24 h prior treatment with TNFα.  Culture 
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medium was carefully removed at the respective time points post treatment 
and the cells were rinsed with 1x PBS. Dual-Luciferase® Reporter Assay Kit 
(Promega, P/N E1910) was used for investigating the activity. Briefly, cells 
were lysed in 250 μl of 1x Passive Lysis Buffer using a cell scraper. The lysate 
was transferred to a new tube and kept at -80°C before processing. One cycle 
of freeze and thaw was performed by thawing the frozen cell suspension in 
37 °C water bath to accomplish complete lysis of the cells. The cell lysate was 
centrifuged at 16 000 g for 30 s to remove cell debris and 10 μl aliquots of the 
cell lysates were prepared in clear 1.5 ml microcentrifuge tubes for triplicate 
readings. Luminescent signals were measured by DLR-INJ-0 Promega 
protocol on Promega Glomax luminometer (2 s pre-measurement delay, 
followed by 10 s measurement period for each reporter). For the first reading, 
50 μl Luciferase Assay Reagent II was added to the aliquot of cell lysis, mixed 
well and Firefly luciferase reading was measured in the luminometer. The 
second read was obtained after addition of 50 μl Stop & Glo® Reagent and the 
Renilla luciferase reading was measured. NF-κB derived luciferase activities 
were determined by Firefly luciferase readings after normalizing for 
transfection efficiency for Renilla luciferase readings.  
2.2.3 Protein expression assay related methods 
2.2.3.1 Preparation of brain tissue for immunofluorescence 
Microscope slides (Marienfeld Superior, P/N 1005200) were coated with 0.01% 
Poly-L-lysine (Sigma, P/N P8920) for 5 min and dried at RT. Brain tissues 
from Brodmann area 9 embedded in optimum cutting temperature (OCT) were 
sectioned at thickness of 10 or 20 μm with cryostat (Leica CM1850, USA) and 
mounted onto the coated microscope slides.  
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2.2.3.2 Immunofluorescence (IF) staining  
Samples (cells seeded on coverslips or brain sections) were first fixed in 3.7% 
formaldehyde (Sigma, P/N F8775) in PBS for 10 min and rinsed twice with 
PBS. Cells on coverslips were permeabilized via incubation with 0.1% Triton 
X-100 in PBS for 5 min while the brain sections were permeabilized in ice-
cold acetone: methanol (1:1) for 10 min. After rinsing twice with PBS, 
samples were then blocked with 10% normal goat serum in PBS at RT for 1 h 
followed by incubation with primary antibodies (Table 2.2) overnight at 4
o
C. 
The excess primary antibodies were washed off with PBS and proceed with 
incubation of secondary antibodies (Table 2.2) at RT for 1 h. For brain 
sections, an additional treatment with autofluorescence eliminator reagent 
(Millipore, P/N 2160) was performed according to the manufacturer’s 
instructions to reduce autofluorescence. Briefly, sections were immersed in 70% 
ethanol for 5 min, then incubated with autofluorescence eliminator reagent for 
5 min at RT, and washed with 70% ethanol for two times. Samples were then 
mounted in 4’,6-diamidino-2-phenylindole (DAPI, blue nuclear stain) 
containing Vectashield mounting medium (Vector Laboratories, P/N H-1200), 
then visualized and captured using the Nikon A1R confocal microscopy 
system. The images were processed using Nikon NIS-Elements software. 
2.2.3.3 Preparation of protein lysates and protein quantitation 
Samples were lysed with 2X Laemmli Sample Buffer (Bio-Rad Laboratories, 
P/N 1610737) containing 65.8 mM Tris-HCl, pH 6.8, 2.1% SDS, 26.3% (w/v) 
glycerol, 0.01% bromophenol blue with addition of 5 % of β-mercaptoethanol 
and boiled for 5 min. The lysates were quantitated using 2-D Quant Kit (GE 
Healthcare, P/N 80-6483-56) which allows quantitation of protein in the 
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presence of detergents, reductants, and chaotropes. Briefly, standard curve (0–
50 µg) was prepared using the 2 mg/ml BSA standard solution. 4 μl of sample 
was added in a microcentrifuge tube with 250 μl of precipitant followed by 250 
μl of co-precipitant. The precipitated sample was centrifuged for 5 min at 10 
000 g and the supernatant was carefully removed. 50 μl of alkaline copper 
solution and 200 μl of deionized water was added and vortexed to dissolve the 
protein pellet. 500 μl of colour reagent was added and mixed instantaneously. 
The colour reagent reacts to unbound cupric ions resulting in colour density 
change that is inversely related to the concentration of the protein sample. 
Absorbance was read at 480 nm after 15 min of incubation at RT using 
Benchmark Plus Microplate Spectrophotometer System (Bio-Rad 
Laboratories). Protein concentration was estimated by comparison to the 
standard curve.  
2.2.3.4 Western blot analyses  
SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) was 
carried out in vertical gel composed of 10% polyacrylamide resolving gel and 
5 % stacking gel. Electrophoresis was performed in 1x Tris/glycine SDS 
buffer (f/c of 2.5 mM Tris, 19.2 mM glycine, and 0.01% (w/v) SDS, pH 8.3) 
(Biorad, P/N 1610732) at 120 V. PageRuler™ Plus Prestained Protein Ladder 
(Thermo Scientific, P/N SM0671) was electrophoresed alongside with the 
samples for molecular weight determination. The transfer of proteins onto 
nitrocellulose membranes were carried out using iBlot® Dry Blotting System 
with transfer stacks (Invitrogen, P/N IB301001) using program P3 and a 7 min 
transfer time. After transfer, the membranes were first rinsed with Tris-
Buffered Saline with 0.1% (v/v) Tween 20 (TBST) and blocked with Bløk-PO 
60 
 
Noise Cancelling Reagents (Millipore, P/N WBAVDP001) for 1 h at RT. 
After blocking, the membranes were rinsed three times with TBST. The 
membranes were then incubated overnight at 4
o
C with primary antibodies in 
the blocking solution at indicated dilutions (Table 2.2). Following that, the 
membranes were washed three times with TBST. Secondary antibodies 
conjugated with horseradish peroxidase (HRP) diluted in blocking solution 
were then added to the membrane and incubated for 1 h at RT. After washing 
three times in TBST, Immobilon Western Chemiluminescent HRP Substrate 
(Millipore, P/N WBKLS0500) was added and chemiluminescence was 
captured by UVIchemi image analyser (UVItec, Cambridge UK).  
2.2.3.5 Multiplex immunoassays  
TNFα-induced the release of cytokines and chemokines in iNHA was 
determined using multi-analyte profiling system. Tissue culture media of 
iNHA with or without TNFα treatment were collected at day 3, centrifuged to 
remove cell debris for 10 min at 4°C and stored at –80⁰C until use. 
Inflammatory markers were measured using MILLIPLEX® Multiplex Human 
Cytokine/Chemokine Panel I Immunoassay (Millipore, P/N MPXHCYTO-
60K) and MILLIPLEX® Multiplex Human Cytokine/Chemokine Magnetic 
Bead Panel II Immunoassay (Millipore, P/N HCYP2MAG-62K) (see Table 
2.6 for the list of analytes) according to the manufacturer’s instruction. Briefly, 
wells on plates were pre‐wetted with Assay Buffer for 10 min at RT before 
vacuum drying or decanting. First, 25 μl of Standards, QC Controls or Assay 
buffer were added to the respective wells. 25 μl of pure culture medium was 
added to the Blank, Standards and QC Control wells, while 25 μl of neat or 
diluted samples (100 fold with culture media) were added to the respective 
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wells containing Assay buffer. The plate was then incubated with agitation 
overnight at 4°C. Subsequently, the samples were washed twice with 200 μl of 
wash buffer and incubated with 25 μl of detection antibodies for 1 hour at RT 
with agitation. The samples were then incubated with 25 μl Streptavidin-
Phycoerythrin for 30 min at RT with agitation. Finally, the plate was washed 
twice with 200 μl of Wash buffer, and incubated with 150 μl of sheath fluid 
for 5 min before reading. The results were read using xPONENT® Software 
Version 3.1 on the Luminex LX200 instrument (Millipore). Analysis was 
performed using MILLIPLEX® Analyst Software Version 3.4 (Millipore). 
2.2.4 Data Analyses  
 
2.2.4.1 Image quantitation 
Five representative images per sample from three AD and three control brains 
were analysed using 'Object Count' to obtain total cell count as well as mean 
fluorescence intensity of individual cell in each channel using Nikon’s NIS-
Elements Advanced Research software. For primary culture imaging, three 
representative images per treatment derived from 4 independent experiments 
were analysed using the 'Threshold' function to obtain the mean fluorescence 
intensity of ROI (Regions of interest) after applying a fixed signal intensity 
cut-off across all samples. 
2.2.4.2 Graphs and statistical analyses 
Statistical differences for gene expression of AD and control groups were 
analysed using Mann-Whitney tests. Statistical differences for unmatched or 
matched groups (N≤5) were performed using Student’s t-tests or Student’s 
paired t-test respectively. For comparisons of gene expression between 
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different groups or treatments, one-way analyses of variance (ANOVA) with 
Bonferroni’s post-hoc tests was performed. For comparisons of gene 
expression or protein secretion between different groups with and without 
treatment, two-way analyses of variance with Bonferroni’s post-hoc tests were 
performed. To perform multiple comparison to a control, one-way analyses of 
variance (ANOVA) with Dunnett’s post-hoc test were performed. To 
demonstrate the presence of a positive or negative significant correlation 
between two parameters, Pearson’s Correlation was employed for two 
continuous data. For all analyses, two-tailed p-values of < 0.05 were 
considered to be statistically significant. Three-dimensional PCA plots and 
two-dimensional unsupervised hierarchical clustering analysis were generated 
using Partek® Genomics Suite Version 6.6 software. All other graphs were 
plotted and statistical analyses were performed using GraphPad PRISM® 
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CHAPTER 3- An isoform-specific role of FynT tyrosine kinase 
in Alzheimer’s disease 
3.1 Background  
Exon array demonstrated differential alternative splicing of Fyn in AD, with 
significant increase of FynT but no change of brain-predominant FynB in AD 
brain. In addition, gene ontology term enrichment analyses on the exon array 
data revealed that FynT expression correlated negatively with neuronal 
function and positively with reactive astrogliosis. 
3.2 Hypothesis  
FynT induction in AD may be associated with reactive astrogliosis and 
neurodegeneration. 
3.3 Experimental designs/ Approaches  
1. To confirm FynT induction in AD using real-time RT-PCR and FynT 
and FynB ratio using capillary electrophoresis. (See Results at 3.4.1) 
2. To investigate the expression profiles of FynB and FynT in primary 
neurons and astrocytes by capillary electrophoresis and 
immunofluorescence. (See Results at 3.4.2 and 3.4.3) 
3. To characterize specificity of custom-made FynT and FynB antibodies 
by Western blotting and immunofluorescence. (See Results at 3.4.3) 
4. To determine FynT immunoreactivity in association with cellular 
markers and neuropathological hallmarks in post-mortem AD brains. 





3.4.1 Selective upregulation of FynT isoform expression in AD brain 
To validate the exon array data that FynT was significantly upregulated in AD, 
real-time RT-PCR using FynB- and FynT-specific primer sets and capillary 
electrophoresis was performed. Real-time PCR confirmed that FynT was 
significantly upregulated in AD (p =0.0155, Mann-Whitney test), whereas 
there were no significant changes for FynB (Figure 3.1A). Furthermore, 
relative levels of FynB and FynT transcripts in each sample were measured by 
RT-PCR followed by capillary electrophoresis and showed that an elevated 
FynT peak in AD compared with negligible FynT in control (Figure 3.1B), 
consistent with the finding of significantly higher FynT to FynB ratio in AD 

















Figure 3.1 Selective upregulation of FynT isoform expression in AD brain. 
(A) Real-time RT-PCR determined the relative signal intensity of FynB and 
FynT in AD and control brain. (B) The proportional amount of FynT and 
FynB in AD and control brain was determined by RT-PCR followed by 
capillary electrophoresis. A representative electropherogram showed the 
relative fluorescence units (RFU) of FynT peak (219bp DNA amplicon) and 
FynB peak (228bp DNA amplicon) in AD and control samples. (C) Peak areas 
of FynT and FynB in each electropherogram were translated into expression 
level and used to determine FynT to FynB ratio of expression. The dot plot 
showed that AD samples have significantly higher FynT to FynB ratio than 
control samples (p=0.0009, Mann-Whitney test). Available samples for RT-







3.4.2 Higher proportions of FynT expression in cells of astrocytic origin 
Our preliminary data obtained from the exon array database showed that FynT 
was positively and significantly correlated with genes associated with 
cytoskeleton organization, cell adhesion, cellular movement and extracellular 
matrix (Table 1.1), as well as astrocytic markers including GFAP and GLAST 
(Table 1.2), suggesting that FynT induction in AD may be associated with 
astrocyte activation. On the other hand, FynT was negatively correlated with 
synaptic vesicles and various neuronal markers (Table 1.1). Although FynB 
has been known to be the brain predominant isoform of Fyn, the expression of 
FynT has never been explored in the brain. The observation of opposite trends 
of FynT correlation in astrocytes and neurons, prompted us to determine the 
expression profiles of FynB and FynT in these two main cell types of the brain. 
First, we obtained pure cultures of primary neurons and astrocytes, as well as 
cell-lines derived from neuronal and astrocytic origins. RT-PCR was 
performed using common primers spanning the alternative spliced exon of Fyn, 
followed by capillary electrophoresis.  
Higher proportions of endogenous FynT expression were found in primary rat 
astrocytes and cell lines of astrocytic lineage as compared to primary rat 
neurons and neuronal cell lines as illustrated in Figure 3.2A with 
representative electropherograms of neurons and astrocytes illustrated in 





















Figure 3.2 Higher proportions of FynT expression in cells of astrocytic 
origin. (A) Endogenous FynT to FynB ratios were determined by RT-PCR 
followed by capillary electrophoresis in untreated cells of neuronal (primary 
rat neurons, SH-SY5Y line) or astrocytic (primary rat astrocytes, U-87MG and 
U-251MG lines, shaded bars) origin. Data are mean ± SEM of at least three 
independent experiments for each cell type. (B) The proportional amount of 
FynT and FynB in rat neurons and rat astrocytes was determined by RT-PCR 
followed by capillary electrophoresis. Representative electropherograms 
showed the relative fluorescence units (RFU) of FynT peak (219bp DNA 







(219bp)    (228bp) 
FynT      FynB 
Rat neurons Rat astrocytes 
(219bp)    (228bp) 




3.4.3 Custom-made FynB and FynT antibodies were able to specifically 
identify their respective Fyn isoforms  
There are no commercially available Fyn isoform-specific antibodies. To 
facilitate our study, we generated custom-made rabbit polyclonal FynB and 
FynT-specific antibodies. The characterization of antibody specificities was 
done by Western blot analyses and immunostaining using HEK293T cells 
transiently transfected with either FynB or FynT construct that tagged with 
Myc-FLAG. Western blot analyses demonstrated that FynB and FynT 
antibodies were able to specifically identify their respective isoforms (Figure 
3.3A). Most importantly, FynT antibody did not cross-react with FynB, and 
vice versa. Using double IF staining, all successfully transfected cells that 
were stained positive for Myc-tag antibody were also specifically detected by 
their corresponding Fyn isoform-specific antibodies (Figure 3.3B).  
The observation of higher FynT to FynB ratio in astrocytes compared to 
neurons suggested that stronger FynT immunoreactivity may be detected in 
astrocytes. Mixed rat cortical culture with triple immunofluorescence staining 
of FynT-specific antibody, NeuN neuronal marker and GFAP astrocytic 
marker revealed that astrocytes indeed exhibited higher FynT 
immunoreactivity as compared to neurons (arrows in Figure 3.4).  
Before proceeding to investigate FynT and FynB protein expression in AD 
brain sections of prefrontal cortices, peptide neutralization was performed to 
demonstrate the specificity of FynT and FynB antibodies in the brain sections. 
To perform peptide neutralization, the antibodies were pre-incubated with a 
five-fold (by weight) excess of the respective synthetic immunizing peptides 
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(sequences can be found in Chapter 2- Materials and Methods under 2.1.5) 
overnight at 4°C in incubation buffer (10% normal goat serum in PBS), before 
proceeding with IF in brain tissues. The absence of positive immunoreactives 
in the AD brain sections after peptide neutralization procedure validated 



























Figure 3.3 Characterization of FynB and FynT isoform-specific 
antibodies. Custom-made FynB and FynT isoform-specific polyclonal 
antibodies were characterized using transiently transfected HEK293T cells 
over-expressing either FynB or FynT tagged with Myc-FLAG. (A) Western 
blot analyses using total lysates harvested by direct lysis with Sample buffer 































from HEK293T non-transfected cells (Ctrl), cells transfected with empty 
pCMV6-Entry vector (EV), or cells transfected with the tagged FynB or FynT 
constructs, were probed with custom-made anti-FynB or FynT polyclonal 
antibodies as well as with total Fyn and Myc-specific antibodies. Detection of 
Myc-tag and total Fyn confirmed successful transfection. (B) Double IF 
staining with FynB or FynT-specific polyclonal antibodies (green) and Myc-
tag antibodies (red) were demonstrated in FynB- (top two panels) and FynT- 
(bottom two panels) transfected HEK293T. The right most column depicts 
merged channels with nuclei staining by DAPI (blue). Co-staining could be 













Figure 3.4 Astrocytes exhibited higher FynT immunoreactivity as 
compared to neurons. Triple IF staining of FynT-specific polyclonal 
antibodies (green), neuronal marker NeuN (red) and astrocytic marker GFAP 
(white) was performed on mixed rat cortical culture. Cell nuclei stained by 
DAPI (blue) were shown in the merged images. White arrows indicate 
astrocytes which are stained positively with GFAP. Scale bars = 20 µm.    
 
FynT NeuN 














Figure 3.5 FynB and FynT isoform-specific antibodies demonstrated 
antigen-specific immunoreactivity in human brain tissues. Custom-made 
FynB and FynT isoform-specific polyclonal antibodies (green) costained with 
nuclear DAPI counterstain (blue) showed specific positive immunoreactivites 
in prefrontal cortex brain sections (left panel) obtained from AD patients 
which could be blocked by their respective immunizing peptides (right panel). 
Scale bars = 50 µm. 
  
FynT FynT FynT + DAPI FynT + DAPI 
FynB FynB FynB + DAPI FynB + DAPI 
  
Antibodies only Antibodies + respective peptides 
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3.4.4 Increased FynT immunoreactivity in AD prefrontal cortex 
To localize Fyn induction in AD, we employed FynB and FynT-specific 
antibodies for IF staining on prefrontal cortex (BA9) brain sections obtained 
from patients with AD and control. In general, weak FynT immunoreactivity 
was found in control prefrontal cortex (top left panel in Figure 3.6A); whilst in 
AD, a subgroup of cells with intense staining could be detected (Figure 3.6A, 
top right panel). Image quantitation revealed that a significantly higher 
percentage of strong FynT-staining cells (4.8  0.6%) was found in AD 
(Figure 3.6B, red circle) compared to control brains (0.8  0.5%, Figure 3.6B, 
blue circle). In contrast, FynB immunoreactivities were uniformly prominent 
in both AD and control sections (Figure 3.6A, bottom panels), with no 
significant differences in percentage of stained cells (Figure 3.6B, red and blue 




Figure 3.6 Increased FynT immunoreactivity in AD prefrontal cortex. (A) 
Representative IF staining of prefrontal cortex using FynT-specific antibody 
(green, upper panel) or FynB-specific antibody (green, lower panel) with 
nuclear DAPI counterstain (blue) were compared between AD and control. 
Scale bars = 50 µm. (B) Dot plot presents the mean of percentage of cells 
(defined by DAPI-positive staining) that stained positive for FynB (circle) and 
FynT (triangle) in AD (red, n=3) and control (blue, n=3) prefrontal cortex. The 
mean value in each sample is calculated by the percentage of positive cells in 




FynT + DAPI FynT + DAPI 
FynB + DAPI FynB + DAPI 
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3.4.5 FynT localization to a subset of neurons in AD 
To determine whether FynT upregulation in AD could be localized to neurons, 
double IF staining was performed using Fyn isoform-specific antibodies and 
neuronal marker NeuN in AD and control prefrontal cortex. The strong FynT 
immunoreactivities were localized in NeuN-positive stained neurons (Figure 
3.7A, white arrows). Only a subset of NeuN-positive neurons co-stained with 
FynT. In contrast, the majority of neurons stained positive for FynB (Figure 
3.7B), supporting the previously established neuronal localization for FynB 
(Cooke and Perlmutter, 1989). Therefore, FynT upregulation in AD seems to 





Figure 3.7 FynT localization to a subset of neurons in AD. Representative 
double IF staining of (A) FynT and (B) FynB (green) with neuronal marker 
NeuN (red) in AD and control prefrontal cortex. Nuclei were counterstained 
with DAPI (blue). White arrows in (A) indicated cells that were positively co-


























3.4.6 FynT localization to reactive astrocytes in AD 
Besides neurons, Figure 3.8 shows that FynT immunoreactivities were 
localized to cells that stained positive for GFAP at the thickened processes 
(white arrows in top panels) and hypertrophic cytoplasm (white arrows in 
middle panels), both of which are characteristic of reactive astrocytes. FynT 
immunoreactivity was observed to be relatively stronger in hypertrophic 
cytoplasm than in the GFAP-positive processes. However, the weaker but 
specific FynT staining of the astrocytic processes in AD brain could still be 
resolved (white arrows, Figure 3.8 top left panel) even in the presence of 
strong FynT signals in adjacent non-GFAP cells (putatively neurons, see 
Figure 3.7A). On the other hand, corresponding GFAP-positive processes in 
control brain appeared thinner and showed non-specific background stain for 
FynT (Figure 3.8, white arrows in bottom panels). This data showed that at 
least a proportion of FynT immunoreactivities were localized to reactive 





Figure 3.8 FynT localization to reactive astrocytes in AD.  Representative 
double IF staining of FynT (green) and astrocytic marker GFAP (red) in the 
prefrontal cortex of AD (first two panels) and control brain (last panel). Nuclei 
were counterstained with DAPI (blue). White arrows indicated astrocytes. 











3.4.7 Increased FynT in NFT-bearing neurons concomitant with 
decreased FynB immunoreactivity 
Fyn is known to co-stain with NFTs (Shirazi and Wood, 1993, Ho et al., 2005). 
Using FynT and FynB-specific antibodies, Fyn isoform-specific association 
with NFT could now be examined. The AT8 antibody which recognizes 
phosphorylated tau at Serine 202 and Threonine 205 detects both neuropil 
threads as well as NFT-bearing neurons in AD prefrontal cortex (Figure 3.9A, 
red channels). Interestingly, cells with intense FynT immunoreactivity in AD 
sections were exclusively co-stained with AT8, manifesting as yellow 
fluorescence signals of NFT-bearing neurons in merged images (Figure 3.9A 
top right panel, white arrows). In contrast, FynB immunoreactivity was 
relatively weak in NFT-bearing neurons (Figure 3.9A bottom panels, white 
arrows) compared to the adjacent AT8-negative stained neurons. Mean 
fluorescence intensities of FynB and FynT in AT8-positive versus adjacent 
AT8-negative cells were both significantly different with increased FynT and 
decreased FynB in AT8-positive cells (Figure 3.9B). Furthermore, FynT 
immunoreactivity also co-localized with another antibody (Tyr18) specific for 
tau phosphorylated at tyrosine 18 (pY18), a site previously shown to be 

















Figure 3.9 Increased FynT in NFT-bearing neurons concomitant with 
decreased FynB immunoreactivity. (A) Representative double IF staining of 
phosphorylated tau marker AT8 (red) and FynT (green, top panel) or FynB 
(green, bottom panel) counterstained with DAPI (blue) in the prefrontal cortex 
of AD brain. White arrows indicated NFT-bearing cells. Scale bars = 20 µm. 
(B) Mean fluorescence intensities of FynT or FynB in NFT-bearing neurons 
(defined by AT8-positive staining) and surrounding AT8-negative cells within 
each representative image are analysed in pairs. Five representative images 
were included in each sample. Three AD samples were under studied. 







Figure 3.10 FynT co-localized with pTau (Tyr18) immunoreactivity in 
NFT-bearing neurons. Representative double immunofluorescence staining 
of FynT (green) and pTau (Tyr18) (red) counterstained with DAPI (blue) in 
the prefrontal cortex of AD brain. White arrows indicated NFT-bearing cells. 





3.5.1 FynT upregulation in AD  
Fyn kinase is postulated to be involved in several aspects of AD pathogenesis, 
and the current study has elucidated an isoform-specific role for Fyn by 
identifying a selective upregulation of the FynT isoform in AD brain. In view 
of a previous report showing an increase of Fyn kinase activity but no change 
of Fyn protein levels in AD brain (Larson et al., 2012), it can be postulated 
that the abundant, unchanged expression of FynB in AD could have masked 
an increase in FynT expression when using non isoform-specific antibodies. It 
is also possible that the reported increase in Fyn kinase activity in AD could 
be contributed by FynT upregulation because FynT has been shown to exhibit 
enhanced kinase activity as compared to FynB (Davidson et al., 1994, 
Brignatz et al., 2009).  
An independent finding showed that the differential expression of Fyn in AD 
brain was only observed in brain tissue processed with fractionation, showing 
increased expression in insoluble fraction and decreased expression in soluble 
fraction (How et al, 2005). We observed that specific upregulation of FynT 
isoform in NFT-bearing neurons, suggesting that FynT is likely to be found in 
the insoluble fractions of AD brain.  
3.5.2 FynT in association with tau phosphorylation and NFT formation 
A major finding this chapter is the neuronal FynT induction in association 
with tau pathology in AD. In consistency with a previous report showing 
phosphorylation of Fyn-catalysed Tyr18 on tau was localized in NFT but not 
neuropil threads (Lee, 2004), we also showed that FynT stained NFT but not 
neuropil threads (Figure 3.8). Hence, it is conceivable that FynT may be the 
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major modulator of tau hyper-phosphorylation in addition to direct 
phosphorylation at Tyr18, as pTau immunoreactivities (AT8 and Tyr18) 
colocalized exclusively with FynT, but not with adjacent neurons strongly 
staining for FynB. Furthermore, Bhaskar et al. (Bhaskar et al., 2005) also 
demonstrated that Fyn may bind tau isoforms with different affinities, 
suggesting the possibility of complex interactions between Fyn and tau 
isoforms. An independent study demonstrated that Tyr18 phosphorylation is 
important in mediating Fyn-tau interaction and influences the cellular 
trafficking of tau to detergent-resistant membrane microdomains (Usardi et al., 
2011), suggesting that Fyn may modulate tau solubility. However, whether the 
co-staining of FynT and phosphorylated tau may implicate their interaction 
and affect their cellular trafficking is unknown which warrant further 
investigation.  
It has also been proposed that aberrant hyper-phosphorylated tau is closely 
associated with cell cycle re-entry in post-mitotic neurons which may account 
for a substantial fraction of neuronal loss in AD brain, and that the process 
involves the activation of three kinases including Fyn (Seward et al., 2013). 
Inhibition of Fyn kinase or mutation at the Fyn-catalysed Tyr18 on tau, were 
both able to block the BrdU uptake of primary neurons, suggesting that Fyn 
kinase activity could be essential for ectopic neuronal cell cycle re-entry 
(Seward et al., 2013). The demonstrated link between FynT expression and 
NFT-bearing neurons prompts us to postulate that FynT may modulate the 
ectopic cell cycle re-entry and subsequently lead to neuron degeneration. 
Furthermore, whilst previous studies reported higher Fyn immunoreactivity in 
NFT-bearing neurons in AD (Shirazi and Wood, 1993, Lee, 2004, Ho et al., 
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2005), our data now suggest that FynT is the predominant isoform associated 
with the NFT. Intriguingly, the increased FynT expression was accompanied 
by apparently weaker FynB immunoreactivity in the NFT-bearing neurons 
(Figure 3.9), suggesting that the upregulated FynT reflects a modulation of the 
alternative splicing machinery which favours the FynT isoform, and that this 
‘switching’ to FynT may be associated with AD pathogenesis. Differential 
alternatively-spliced transcripts in human brains associated with aging and 
neurodegeneration including AD have been detected simultaneously with 
altered expression of various splicing regulators (Tollervey et al., 2011). 
Furthermore, aberrant tau exon 10 splicing found in some sporadic AD was 
associated with a dysregulation of alternative splicing (Glatz et al., 2006). In 
view of the close relationship between FynT and tau in NFT-bearing neurons, 
we speculate that during NFT formation, alternative splicing machinery may 
be activated to modulate tau exon 10 splicing, as well as Fyn exon 7 splicing 
to favour FynT expression.  
3.5.3 FynT in association with reactive astrogliosis  
Another important finding of this chapter relates to FynT and astrocyte 
activation. Astrocyte-mediated neuroinflammation responses have long been 
postulated to play a role in AD (Fuller et al., 2009, Steele and Robinson, 2012, 
Medeiros and LaFerla, 2013). In this study, we speculate that the increased 
FynT expression may be partly due to higher numbers of reactive astrocytes in 
the AD brain supported by significant positive correlation between FynT and 
astrocytic markers in our preliminary data. Furthermore, higher proportions of 
endogenous FynT expression were found in primary rat astrocytes and glioma 
cell lines as compared to primary rat neurons and neuroblastoma cell lines 
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(Figure 3.2). Additionally, while comparing the modulation of astrocytic FynT 
expression between AD and control prefrontal cortex, we observed that FynT 
immunoreactivity was clearly localized to the thickened processes and 
hypertrophic cytoplasm of activated astrocytes in the AD brain (in addition to 
NFT-bearing neurons), compared to only weak signals in the control sections. 
Given that astrogliosis is a hallmark of AD, where astrocytes increase in 
proliferation and size alongside with the elevation of genes expression 
(Eddleston and Mucke, 1993, Fuller et al., 2010), these results further supports 
our hypothesis that the upregulation of FynT expression in AD brain is 
associated with astrocyte activation.   
3.6 Summary 
This chapter provides evidence that isoform-specific upregulation of FynT 
may be independently associated with neurofibrillary degeneration and 
reactive astrogliosis in AD. Furthermore, alternative splicing of Fyn may be an 
important mechanism in disease pathogenesis or response. However, further 
studies are needed to elucidate the upstream signalling and molecular 
mechanisms underlying FynT modulation as well as the precise nature of its 
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CHAPTER 4- Isoform-specific modulation of FynT tyrosine 
kinase expression in astrocytes under Aβ and TNFα treatment 
4.1 Background 
In the previous chapter, it was demonstrated that FynT upregulation in AD 
was associated with tau pathology as well as reactive astrogliosis. In this 
chapter, we would like to recapitulate the abnormal induction of FynT 
expression in AD brain using an in vitro system, by exposing primary mixed 
cortical or astrocytic culture to pathological conditions associated with AD 
including Aβ and TNFα treatment and monitoring the changes in FynT and 
FynB expression.  
4.2 Hypothesis 
Pathological conditions of AD can specifically induce FynT expression in 
primary cortical cultures. 
4.3 Experimental designs/ Approaches 
1. To establish an in vitro system for studying effects of Aβ using 
primary rat mixed cortical cultures with Aβ25-35 treatment. (See Results 
at 4.4.1 and 4.4.2).   
2. To investigate FynT versus FynB tyrosine kinase modulation by Aβ 
treatment in primary rat mixed cortical cultures. (See Results at 4.4.3)  
3. To determine whether FynT induction could be associated with 
increased number of astrocytes in primary rat mixed cortical cultures, 
the cultures were maintained in media with increasing FBS 
concentration and monitored for FynB and FynT expression. (See 
Results at 4.4.4) 
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4. To investigate FynT versus FynB tyrosine kinase modulation by Aβ 
and TNFα treatment in primary rat astrocyte cultures. (see Results at 
4.4.5 and 4.4.6) 
5. To determine the possible regulatory mechanisms of astrocytic FynT 





4.4.1 Aβ25-35 exhibited a cytotoxic effect on primary rat mixed cortical 
culture 
Aβ treatment is known to induce neuronal degeneration and activate astrocytes 
in vitro (Pike et al., 1992, Pike et al., 1994, Pike et al., 1996). Aβ25-35, the toxic 
moiety of Aβ was used for treatment of primary neuronal culture (Kaminsky 
et al., 2010). An optimization experiment was performed on Aβ25-35 -treated 
primary rat mixed cortical culture to determine the suitable concentration of 
Aβ25-35 used for subsequent experiments, significant reduction in cell viability 
was observed at a concentration of 20 μM (ANOVA p < 0.05) and above for 
Aβ25-35 peptide at the 48 h time point (Figure 4.1A). In contrast, the inverse 
peptide Aβ35-25, did not result in any significant reduction of cell viability even 
at 40 μM, indicating that the toxic effect of the short Aβ25-35 was sequence 
specific. Visible disintegration of dendrites could also be observed in the 

















Figure 4.1 Aβ25-35 exhibited cytotoxic effect on rat mixed cortical culture.  
(A) Cell viability upon Aβ treatment was determined using CCK-8 assay. Bar 
charts represent the percentage of cell viability which set the OD measurement 
of untreated control (0 µM) to 100%. Mixed cortical cultures were treated with 
0, 5, 10, 20 and 40 μM Aβ25-35 or Aβ35-25 for 48 h. Values are mean ± SEM of 
five replicates. *Significantly different (one-way ANOVA with Dunnett’s post-
hoc test p < 0.05). (B) Phase contrast images of rat mixed cortical cultures 
without treatment (Ctrl), with 20 μM Aβ25-35 or 20 μM Aβ35-25 treatment were 
























Ctrl 20 μM Aβ25-35 20 μM Aβ35-25 
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4.4.2 Aβ25-35 treatment modulated neuronal and astrocytic markers 
expression in primary rat mixed cortical culture  
Expression levels of neuronal and astrocytic markers in a primary rat mixed 
cortical culture treated with Aβ25-35 were measured using real-time RT-PCR. 
At 48 h, significant induction of astrocytic markers GLAST and glutamate 
transporter GLT1 (ANOVA p<0.05), as well as trends toward increased 
GFAP expression (ANOVA p = 0.0858) were observed after treatment with 
Aβ25-35, but not with the peptide sequence control, Aβ35-25 (Fig. 4.2), 
suggestive of Aβ-induced astrocyte activation. The inconsistency between the 
changes in the expression profile of these astrocytic markers could be 
attributed to the heterogeneity of astrocytes in these mixed cultures. Different 
subtypes of astrocytes are known to express varying levels of the astrocytic 
markers and therefore may respond differently upon treatment with Aβ (Walz 
and Lang, 1998, Perego et al., 2000, Abe and Misawa, 2003, Scimemi et al., 
2013). On the other hand, Aβ25-35, but not Aβ35-25 reduced expression of 
neuronal marker tubulin β3 (TUBB3, ANOVA p < 0.05), with trends toward 
decreases in RBFOX3 (NeuN gene, ANOVA p = 0.0618) and microtubule-
associated protein 2 (MAP2, ANOVA p = 0.0976, see Fig. 4.2), suggestive of 












































































































Figure 4.2 Gene expression changes in Aβ25-35-treated primary rat mixed 
cortical culture. Primary rat mixed cortical cultures were treated with 20 μM 
Aβ25-35 or Aβ35-25 or without treatment (Ctrl) for 24 h and 48 h and monitored 
for gene expression using real-time RT-PCR for astrocytic markers GFAP, 
GLAST and GLT1, and neuronal markers RBFOX3/NeuN, TUBB3 and 
MAP2. Fold change was calculated by setting the normalized relative signal 
intensity of Ctrl as 1. Values are mean ± SEM of 3-4 independent experiments. 






4.4.3 Aβ25-35-induced astrocytic FynT induction in primary rat mixed 
cortical culture 
Interestingly, Aβ25-35 treatment selectively upregulated FynT expression while 
FynB remained unchanged (Figure 4.3A). The experiment was repeated once 
using full length Aβ1-42 and Aβ42-1 control peptides with comparable results 
(data not shown). Similarly, IF staining of Aβ25-35-treated primary mixed 
cortical culture showed pronounced FynT immunoreactivity with no 
detectable changes in FynB immunoreactivity (Figure 4.3B). Furthermore, 
quantitative image analyses showed increased FynT mean fluorescence 
intensity in Aβ25-35-treated primary mixed culture compared to untreated 
control (Figure 4.3C).  
In order to identify the cell types associated with induced FynT 
immunoreactivity after Aβ25-35 treatment, FynT was co-stained separately with 
astrocytic and neuronal markers. Pronounced FynT immunoreactivity was 
localized to GFAP-positive astrocytes after Aβ25-35 treatment, showing clearly 
discernible yellow signals in the merged image (Figure 4.4A, top right panel). 
In contrast, image captured using fixed microscope and camera settings 
demonstrated that only weak FynT immunoreactivity was detected in GFAP-
positive cells treated with control peptide Aβ35-25 treatment (Figure 4.4A, 
bottom right panel), suggesting that Aβ25-35 was able to induce FynT 
expression in astrocytes. For neurons, MAP2 was selected as a marker as it is 
a neuron-specific cytoskeletal protein highly enriched in dendritic processes 
(Kosik and Finch, 1987). Under control peptide Aβ35-25 treatment, the outline 
of the neurons including cell bodies and elongated processes can be clearly 
labelled by MAP2 (Figure 4.4B, bottom panels). Upon Aβ25-35 treatment, 
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reductions in neuronal processes were evident as MAP2 staining was confined 
to cell bodies (Figure 4.4B, top panels), suggestive of an Aβ-induced neuritic 
dystrophy (Pike et al., 1992). Interestingly, FynT immunoreactivity did not 
seem to be modulated by Aβ25-35 treatment in MAP2-positive cells (Figure 
4.4B, white arrows in top panel), suggesting that under in vitro conditions, the 












Figure 4.3 Specific upregulation of FynT in Aβ25-35-treated primary rat 
mixed cortical culture. Primary rat mixed cortical cultures were treated with 
20 μM Aβ25-35 or Aβ35-25 or without treatment (Ctrl) for 24 and 48 h and 
monitored for FynT and FynB expression. (A) Real-time RT-PCR results as 
represented by fold change, was calculated by setting the normalized relative 
signal intensity of Ctrl as 1. Values are mean ± SEM of 3-4 independent 
experiments. *Significantly different (one-way ANOVA with Bonferroni’s 
post-hoc test p < 0.05). (B) At 48h, Ctrl and Aβ25-35 treated primary rat mixed 
cortical cultures were stained for FynT or FynB (green). Cell nuclei stained by 
DAPI (blue) were shown to ensure similar cellular content in each tissue 
section. Scale bars = 100 µm. (C) The paired dot plot presents the mean of 
FynT mean fluorescence intensity in Aβ25-35-treated primary culture and 
vesicle treatment control in 4 independent experiment (p=0.0329, Student’s 
paired t-test). The mean value in each experiment is calculated by the FynT 






















































































Figure 4.4 Increased FynT immunoreactivity in Aβ25-35-treated astrocytes 
but not neurons. Primary rat mixed cortical cultures were treated with 20 μM 
Aβ25-35 or Aβ35-25 for 48 h. Representative double IF staining of treated cells 
was demonstrated for FynT (green) and (A) astrocytic marker, GFAP (red) or 
(B) neuronal marker, MAP2 (red). Cell nuclei stained by DAPI (blue) were 
shown in the merged images. White arrows indicated selected neurons. Scale 







4.4.4 FynT expression significantly and positively correlated with glial 
markers in primary mixed cortical culture  
To determine whether FynT induction under treatment could be associated 
with increased astrocyte population in the mixed cortical culture, we 
maintained the culture in the presence of AraC mitotic inhibitor to inhibit 
astrocyte propagation, as well as in media with increasing FBS concentration 
to promote astrocyte propagation and monitored for FynB and FynT 
expression. Three batches of DIV 7-10 mixed cortical cultures were 
investigated. Immunofluorescence was performed using anti-GFAP and anti-
NeuN antibody to qualitatively detect the relative amount of astrocytes and 
neurons, respectively in the mixed rat cortical cultures containing AraC or 
different FBS concentrations (Figure 4.5A). IF staining revealed that 1 μM 
AraC could effectively inhibit astrocyte propagation, as shown by the absence 
of GFAP immunoreactivity compared with other culture conditions without 
AraC (Figure 4.5A). The addition of FBS in culture increased amount of 
astrocytes as shown by the corresponding elevation of GFAP 
immunoreactivity (Figure 4.5A). 
In line with the IF data, real-time RT-PCR data showed that in the absence of 
AraC, increased expression of astrocytic markers GFAP and GLAST were 
detected correspondingly with the increase of FBS concentration in the 
cultures, with the greatest increment at 1% FBS (Figure 4.5B). Similar trend 
of expression was also found for microglial marker CD11B. On the other hand, 
neuronal marker RBFOX3/NeuN appeared to decrease in the presence of FBS, 
with the lowest expression at 1% FBS (Figure 4.5B).  
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Interestingly, a corresponding increment of FynT expression was also detected 
in mixed cultures maintaining in increasing FBS concentration in the absence 
of AraC, with the greatest increment at 1% FBS (Figure 4.5B). On the other 
hand, FynB expression remained unchanged in all culture conditions. A 
similar trend of expression between FynT and glial markers prompt us to 
speculate that increase of FynT expression may be associated with the 
increased propagation of astrocyte or microglia population in the mixed 
culture in response to FBS. We thus carried out correlation analysis for FynT 
and cellular markers to access the possible link. Note that correlation analysis 
was performed in a batch wise manner due to variability across the different 
batches of cortical cultures, seen in Table 4.1. Significant positive correlation 
of FynT with both astrocytic markers GFAP and GLAST (Pearson correlation 
coefficient (r) 0.6795 to 0.7886, p ≤ 0.01) was consistently found in all three 
batches of culture. We also identified positive correlation between FynT and 
microglial marker CD11B in two batches of the culture (Pearson correlation 
coefficient (r) between 0.5709 to 0.7322, p < 0.01). As for neuronal marker 
RBFOX3/NeuN, significant negative correlation of FynT with 
RBFOX3/NeuN was found in one of the batches (Pearson correlation 













































































































































































































































































Figure 4.5 Increased astrocyte propagation concomitant with induction of 
glial markers and FynT expression in primary rat mixed cortical culture. 
(A) Double IF staining revealed that increased GFAP (red) positive astrocytic 
population concomitant with increase serum concentration (0, 0.1 and 1% FBS) 
in primary rat mixed cortical cultures and decreased in the presence of 1 μM 
AraC (mitotic inhibitor), whereas no obvious changes of NeuN (green) 
A 
B 
AraC No AraC 1% FBS 0.1% FBS 
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positive population under these conditions. Scale bars =50 µm. (B) Real-time 
RT-PCR determined expression of astrocytic markers (GFAP and GLAST), 
microglial marker (CD11B), and neuronal marker (RBFOX3/NeuN), as well 
as FynT and FynB in four culture conditions mentioned in (A), in three 
independent batches of DIV 7-10 cortical cultures. Horizontal lines with error 
bars in dot plots indicate mean and SEM. *Significantly different (one-way 
ANOVA with Bonferroni’s post-hoc test p < 0.05).   
 
Table 4.1 FynT expression significantly and positively correlated with 
astrocytic and microglial markers in primary rat mixed cortical cultures 
as determined using Pearson’s correlation  

















GFAP Astrocyte 0.6795* 0.0010 0.7886* < 0.0001 0.7418* 0.0002 
GLAST Astrocyte 0.7000* 0.0006 0.7584* 0.0001 0.7494* 0.0001 
CD11B Microglia 0.1715 0.4696 0.5709* 0.0086 0.7322* 0.0002 
RBFOX3 
(NeuN) 





indicates significant correlation with FynT expression 
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4.4.5 Aβ25-35 may not act directly on astrocytes to induce FynT expression  
As seen earlier (see 4.4.3), FynT induction in primary rat mixed cortical 
culture by Aβ25-35 treatment was found to be localized in astrocytes but not in 
neurons (Figure 4.4).  In this study, we would like to further validate the Aβ 
effects on astrocytic FynT induction using relatively pure primary rat astrocyte 
cultures (more than 97% purity, determined by GFAP-positive cells).  We 
observed no significant changes of FynT expression in the astrocyte culture 
treated with Aβ25-35 over 24 h and 48 h, whereas FynB appeared to be slightly 
increased after Aβ25-35, although the increase was also not significant (Figure 
4.6). We have performed independent batches of experiment and confirmed 
the findings. Our findings suggested that Aβ25-35 may not act directly on 






































Figure 4.6 Aβ25-35 may not act directly on astrocytes to induce FynT 
expression. Primary rat astrocyte cultures were treated with 20 μM Aβ25-35 or 
Aβ35-25 or without treatment (Ctrl) for 24 and 48 h and monitored for FynT 
and FynB expression. Real-time RT-PCR results as represented by fold 
change, was calculated by setting the normalized relative signal intensity of 




4.4.6 Selective induction of FynT expression in astrocytes by TNFα 
treatment 
TNFα has been shown to be associated with the pathogenesis of AD. It is 
known to stimulate glial response resulting in the activation of pro-
inflammation pathways and secretion of inflammatory mediators, which plays 
an important role during neuroinflammation (Olmos and Llado, 2014). In this 
study, primary rat astrocyte cultures were treated with TNFα and gene 
expression of both FynT and FynB were monitored from 1 h up to 72 h. 
Interestingly, we observed that TNFα significantly induced FynT expression at 
24 h and maintained the elevation at later time points, whereas no significant 











Figure 4.7 Selective induction of FynT expression in astrocytes by TNFα 
treatment. Primary rat astrocyte cultures were treated with  5 or 50 ng/ml of 
TNFα or without treatment (Ctrl) for various time points (1 h, 6 h, 24 h, 48 h 
and 72 h) and monitored for gene expression using real-time RT-PCR for 
FynT and FynB.  Fold change was calculated by setting the normalized 
relative signal intensity of Ctrl as 1. Values are mean ± SEM of 3 independent 
experiments. *Significantly different (one-way ANOVA with Bonferroni’s 
post-hoc test p < 0.05).  
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4.4.7 TNFα-induced alternative expression of FynT and FynB in 
astrocytes may be dependent on de novo protein synthesis 
We would like to explore the possible mechanism underlying alternative 
expression of FynT and FynB under TNFα treatment.  We identified that 
cycloheximide (CHX) was able to completely block TNFα-induced FynT 
mRNA expression (Figure 4.8), suggesting that de novo protein synthesis was 
required for FynT mRNA induction under TNFα treatment. Furthermore, 
TNFα-induced inflammatory cytokines gene expression of IL1B and IL6 were 
also attenuated by CHX treatment (Figure 4.8). Most interestingly, the 
inhibition of FynT expression by CHX was accompanied by the induction of 
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Figure 4.8 TNFα-induced alternative expression of FynT and FynB, as 
well as pro-inflammatory cytokines expression were modulated by de 
novo protein synthesis. Rat primary astrocytes were pre-incubated with 1 or 
10 μg/ml of Cycloheximide (CHX) or vehicle control for 2 h, followed by 
additional of 5 ng/ml of TNFα treatment for 24 h. Gene expression was 
monitored using real-time RT-PCR for FynT, FynB, IL1B and IL6.  Fold 
change was calculated by setting the normalized relative signal intensity of 
Ctrl as 1. Values are mean ± SEM of 3 independent experiments. 








4.5.1 Limitations of using in vitro approach to recapitulate AD-associated 
neuronal FynT induction. 
Accumulating evidence suggests that Fyn is a crucial player mediating  Aβ-
induced neuronal dysfunction (Ittner, 2010, Roberson, 2011, Yang, 2011, Um 
et al., 2012, Wang et al., 2013a, Xia and Gotz, 2014). Moreover, results from 
the previous chapter revealed that NFT-bearing neurons displayed high FynT 
immunoreactivity concomitant with reduced FynB immunoreactivity, 
suggesting an induction of alternative splicing of Fyn that favoured FynT 
transcript in these neurons. We aimed to recapitulate AD-associated neuronal 
FynT induction through treating neuron-enriched primary cortical culture with 
Aβ. However, when primary cortical culture was treated with Aβ25-35, no 
changes of FynB and FynT expression in neurons was observed. It can be 
speculated that this in vitro approach may not be able to recapitulate the 
induction of alternative splicing machinery and/or NFT formation as found in 
the AD brain. Alternatively, the negative results may be due to differences in 
the nature or extent of Fyn isoform regulation by alternative splicing between 
human and rodent.  
4.5.2 Aβ25-35 induced astrocytic FynT induction in mixed cortical culture 
but not in astrocyte-enriched culture.  
To the best of our knowledge, no study has been done on determining the role 
of Fyn in astrocytic activation in association with AD. We identified that Aβ-
induced FynT induction was localized in astrocytes in mixed cortical culture. 
However, Aβ may not act directly on astrocytes to induce FynT expression 
because we failed to detect FynT induction in astrocyte-enriched cultures 
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under the same Aβ treatment. There is abundant literature on how astrocytes 
modulate neuronal events but little is known about the impacts of neurons on 
co-cultured astrocytes  (Wiedemann, 2009). For example, the expression of 
glutamate transporter GLT1 in astrocytes is dependent on axonal interactions 
(Yang et al., 2009). In addition, in vitro astrocytes co-cultured with neurons 
possess process-bearing morphology that is more characteristic of astrocytes 
in vivo and hence can be considered more differentiated (Swanson et al., 
1997). Taken together, these findings suggest to us that cell-cell interaction 
between neurons and astrocytes can possibly affect Aβ-induced responses in 
astrocytes.  
With regards to why Aβ could induced FynT expression in astrocytes of 
mixed cortical cultures, the etiologic links remain unclear, and may involve 
both pathogenic (e.g., neurotoxicity) and adaptive (e.g., response to oxidative 
stress) components. Nevertheless, the consistent observations of FynT 
association with astrocytic markers in our preliminary data (Table 1.2) suggest 
that up-regulation of FynT expression in AD may be associated in part with 
astrocytic activation which could likely be more evident in the mixed culture. 
Given that astrocytes have been shown to participate in cerebral innate 
immunity and inflammatory responses (Aschner, 1998, Farina et al., 2007), 
and that studies of FynT-specific knockout mice have demonstrated the crucial 
role of FynT in modulating the immune system (Cooke et al., 1991, Davidson 
et al., 2004, Chaimowitz et al., 2013), it can be postulated that the modulation 
of FynT expression may be associated with astrocyte-mediated 
neuroinflammatory responses in AD.   
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4.5.3 FynT expression significantly and positively correlated with 
astrocyte markers in primary mixed cortical culture   
Increasing serum concentration is known to induce astrocyte proliferation and 
GFAP expression in embryonic and neonatal cortical culture (Sakai et al., 
1990, Vergeli et al., 1995). Our in vitro approach made use of AraC and FBS 
to inhibit and promote astrocyte propagation, respectively in mixed cortical 
cultures, which allowed us to determine the significant correlation between 
FynT expression and astrocytic markers GFAP and GLAST in all batches of 
cortical cultures (Table 4.1). This observation was in line with our first 
hypothesis from chapter 3 that FynT upregulation is associated with 
astrogliosis in AD where astrocytes also increase in numbers and GFAP 
expression, conceding that the in vitro observation here is related to 
developmental regulation while post-mortem association was linked to 
pathological reactions. Nevertheless, all findings point towards that astrocytes 
do contribute to significant expression of FynT in the brain. 
A recent paper (Panicker et al., 2015) has reported that microglia expressed 
significantly more Fyn as compared to astrocytes using Western blot analyses 
of total Fyn levels, with no mention of the predominant Fyn isoform. 
Therefore, correlation analysis was also performed to look at the association of 
FynT with microglia marker CD11B. Of note, FynT was found to have 
positive significant correlation in only two batches of the mixed cortical 
cultures (Table 4.1). We speculate that the recovery of microglia, the minority 
cell type in embryonic cortex, may varied greatly between different batches of 
mixed cortical cultures preparation, thus resulted in inconsistency. It is 
difficult to conclude at this point whether microglial expression of FynT could 
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also contribute significantly to the overall increase in FynT expression in the 
mixed cortical culture since they constitute much lesser proportion of the cells 
as compared to astrocytes in brain and in culture (Hansson, 1984, Perry, 1998). 
4.5.4 TNFα-induced alternative expression of FynT and FynB in 
astrocytes may be dependent on de novo protein synthesis. 
Astrocytes are known to mediate innate immunity in the CNS and contribute 
to neuroinflammation. Hence, primary astrocyte cultures were treated with 
TNFα over a course of three days. Strikingly, specific transcriptional induction 
of FynT but not FynB was detected at 24 h and beyond but not at earlier time 
points (Figure 4.7). In line with our findings, Fyn expression was also reported 
to be induced by prolonged TNFα or lipopolysaccharide (LPS) stimulation in 
microglia alongside increased Fyn kinase activity although specific isoforms 
expression was not investigated (Panicker et al., 2015). Furthermore, the same 
group also found that Fyn-knockout mice as well as Fyn knockdown microglia 
culture exhibited diminished inflammatory cytokines expression when 
stimulated with both TNFα and LPS, ascertaining Fyn involvement in 
neuroinflammation (Panicker et al., 2015). 
TNFα is known to orchestrate gene expression in a time dependent manner 
and can be classified as “early”, “middle” and “late” response genes (Tian et 
al., 2005).  “Early” genes, generally consisting of cytokines encoding genes, 
are induced within an hour of stimulation, “middle” genes are genes with 
expression profiles peaking at three hours, while “late” genes consisting of cell 
surface receptors, adhesion molecules and signal adapters that peak at six 
hours or beyond. Based on Figure 4.7, FynT induction by TNFα was detected 
only after 6 h, and maintained up to 3 days of treatment, suggesting that it is a 
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“late” response gene likely to function as a signalling molecule (Tian et al., 
2005). Specific induction of FynT maintained after prolonged stimulation of 
TNFα suggests that FynT might possess a role in chronic neuroinflammation. 
Unlike “early” response genes, many “late” response genes induced by 
inflammatory stimuli require de novo synthesis of proteins involving in “late” 
genes transcription, which explains the temporal delay in their induction 
(Weinmann et al., 1999, Ramirez-Carrozzi et al., 2006, Tullai et al., 2007). 
Consistently, we observed that CHX was able to inhibit or attenuate FynT, as 
well as IL1B and IL6 expression induced by TNFα (Figure 4.8). 
This compelling observation of the reduction of FynT with concurrent 
induction of FynB suggests that CHX did not only inhibit de novo protein 
synthesis triggered by TNFα but also influenced the modulation of the 
alternative splicing machinery which apparently favoured the FynB isoform. 
To determine whether CHX on its own would also influence FynT and FynB 
basal expression without TNFα stimulation, rat cortical astrocytes were treated 
with CHX for 24 hours and FynT/FynB expression was determined with 
quantitative RT-PCR. Interestingly, CHX similarly lowered basal FynT while 
elevating FynB expression (data not shown). Protein synthesis inhibitors have 
been reported to regulate alternative splicing of a number of genes including 
Bcl-x, CD45, TRPM-2 (Kimura and Yamamoto, 1996, Lynch and Weiss, 
2000, Boon-Unge et al., 2007), however, whether alteration of Fyn splicing by 
CHX is solely dependent on its de novo protein synthesis inhibition property 
or by other mechanisms of action is still not clear. Further experiments using 





Using in vitro approaches, by treating mixed cortical culture with Aβ, or 
exposing astrocyte-enriched culture to TNFα, we were able to recapitulate 
astrocytic FynT induction in associated with pathogenesis of AD. Astrocytes 
have been known to mediate neuroinflammation, which has been one of the 
hallmarks of AD. The strong correlation between FynT and astrocytic markers, 
as well as the late FynT induction by TNFα treatment prompt us to speculate 
that FynT may play a role in chronic neuroinflammatory response in 











CHAPTER 5-  
The functional role of FynT tyrosine 
kinase in modulating TNFα-induced 
inflammatory response in astrocytes   
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CHAPTER 5- The functional role of FynT tyrosine kinase in 
modulating TNFα-induced inflammatory response in 
astrocytes 
5.1 Background 
We observed FynT induction in association with reactive astrogliosis in post-
mortem AD brains (Chapter 3). Furthermore, TNFα-induced FynT expression 
in astrocytes at the late phase was likely to be associated with chronic 
inflammatory response (Chapter 4).  Fyn is well recognized as a signalling 
molecule in various signalling pathways, including modulation of 
inflammatory markers expression (Davidson et al., 1994, Resh, 1998, Picard et 
al., 2004, Rajasekaran et al., 2013, Panicker et al., 2015). In this study, we 
would like to use recombinant approach to study whether FynT kinase activity 
might have a role in modulating inflammatory markers expression in response 
to TNFα stimulation in astrocytes. 
5.2 Hypothesis 
FynT kinase activity may modulate inflammatory responses at the late phase 
of TNFα treatment in astrocytes. 
5.3 Experimental designs/ Approaches 
1. To generate immortalized normal human astrocyte (iNHA) clones 
stably expressing FynT mutants of kinase constitutively active (CA) or 
kinase dead (KD) for studying the role of FynT tyrosine kinase activity 
in modulating TNFα-induced expression and secretion profiles of 
inflammatory markers, as determined by real-time RT-PCR and 
multiplex immunoassays. (See Results at 5.4.1 to 5.4.3) 
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2. To validate FynT kinase activity in facilitating TNFα-induced 
inflammatory responses at the late phase, iNHA FynT clones were 
treated with either PP2 tyrosine kinase inhibitor or specific DsiRNAs 
for silencing FynT and monitored for the attenuation of TNFα-induced 
inflammatory responses. (See Results at 5.4.4 and 5.4.5) 
3. To determine whether FynT kinase activity modulates TNFα-induced 
NF-κB signalling by employing luciferase-based genetic reporter assay 







5.4.1 FynT kinase activity may facilitate TNFα-induced biphasic 
induction of pro-inflammatory cytokines expression at the late phase 
Selective FynT induction was detected in astrocytes at the late phase of TNFα 
treatment (Figure 4.7).  In order to determine  the functional role of FynT 
tyrosine kinase activity in modulating TNFα signalling, we generated 
immortalized normal human astrocytes (iNHA) clones that stably expressed  
FynT-wild type (WT), FynT mutants of kinase constitutively active (CA) or 
kinase dominant negative/ kinase dead (KD), as well as empty vector (EV), 
and compared their responses to TNFα treatment. As shown in Figure 5.1, 
positive immunoreactivities of Tyr-416 antibodies were detected solely in 
representative FynT-WT and FynT-CA clones that exhibited 
autophosphorylation of tyrosine 417, but not in representative FynT-KD and 
EV clones which were devoid of ectopic FynT kinase activity.    
TNFα is a known strong activator of NF-B signalling which  mediates the 
transcription of a vast array of proteins involved in inflammatory response 
(Lawrence, 2009). First, we investigated TNFα-induced inflammatory 
responses in parental iNHA cells, using high and low concentrations of TNFα 
for treatment and monitored the mRNA expression profiles of IL1B and IL6 
pro-inflammatory cytokines from early time points (as short as 15 min) to 3 
days. Consistent with reported findings, TNFα treatment stimulated IL1B and 
IL6 induction at the early time points, which peaked at 6h and 1h post-
treatment, respectively (Figure 5.2). However, we observed that only higher 
concentrations of TNFα (50, 100 ng/ml) treatment were able to exhibit 
biphasic induction of IL1B and IL6 expression, with the late phase induction 
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detected at day 3 post-treatment (Figure 5.2). Subsequent studies were 
performed by treating the iNHA clones with 50 ng/ml TNFα.  
When comparing TNFα-induced pro-inflammatory responses between the 
iNHA clones, FynT-CA clone demonstrated greatest induction of IL1B and 
IL6 expression at the late phase (red line in Figure 5.3A), as compared to basal 
induction found in EV and FynT-KD clones (green and blue lines in Figure 
5.3A). In contrast, there were no obvious differences in the induction of IL1B 
and IL6 at the early phase between the iNHA clones (Figure 5.3A), suggesting 
that FynT kinase activity may facilitate IL1B and IL6 induction only at the 
late phase of TNFα treatment. Using independent batches of TNFα treatment, 
we confirmed that FynT-CA clone demonstrated significantly higher fold 
change for IL1B and IL6 induction as compared to EV and FynT-KD clone 
























Figure 5.1 Establishment and characterization of iNHA clones that stably 
expressed empty vector (EV), FynT-wild type (WT), FynT mutants of 
constitutively active (CA) or kinase dead (KD). Exogenous expression of 
the Myc-FLAG tagged FynT transgenes were detected by total Fyn antibody 
(red arrows) and anti-Myc-tag antibody in representative clones. 
Autophosphorylation of tyrosine-417 corresponding to FynT kinase activity 
was determined by immunoreactivity of Tyr-416. β-actin was served as an 








Figure 5.2 iNHA exhibited biphasic induction of pro-inflammatory 
cytokines expression under TNFα treatment. iNHA treated with 0, 5, 10, 50 
and 100 ng/ml TNFα were monitored for IL1B and IL6 mRNA expression at 
early time points (15 min, 30 min, 1 h, 6 h) and late time points (1 day, 2 day 
and 3 day) using real-time RT-PCR. Relative expressions of genes were 
normalized by geometric means of housekeeping genes. This was a 

























































































Figure 5.3 FynT kinase activity may facilitate TNFα-induced biphasic 
induction of pro-inflammatory cytokines expression at the late phase. (A) 
iNHA clones stably expressing empty vector (EV, green) or  FynT mutants of 
constitutively active  (FynT-CA, red) or kinase dead (FynT-KD, blue) were 
treated with  50 ng/ml TNFα (+, coloured lines) or without TNFα (-, black 
lines) and monitored for  IL1B and IL6 mRNA expression at early time points 
(0min, 15min, 30min, 1h and 6h) and at late time points (1d, 2d and 3d) using 
real-time RT-PCR. Relative expressions of genes were normalized by the 
geometric means of housekeeping genes, setting the expression level of non-
treated control of each clone at 0 min as 100.  This was a representative data 
of two independent studies. (B) iNHA clones were treated with or without 50 
ng/ml TNFα for 3 days and determined for IL1B and IL6 expression by real-
time RT-PCR. Fold changes were shown as the means and ± SEM from seven 
independent experimental repeats. *Significantly different (one-way ANOVA 










































































































5.4.2 FynT tyrosine kinase activity facilitated TNFα-induced differential 
expression of inflammatory markers  
To reinforce the observation that FynT tyrosine kinase activity facilitates 
TNFα-induced pro-inflammatory cytokines expression at the late phase, EV 
control, FynT-WT,  FynT-CA and FynT-KD clones were treated with or 
without TNFα for 3 days and subjected to expression profiles of a panel of 14 
inflammatory markers using Biomark HD system’s high-throughput real-time 
RT-PCR. The inflammatory markers investigated could be broadly 
categorized into pro-inflammatory chemokines (CCL2, CCL5, CCL7, 
CXCL10, CXCL12, IL8), pro-inflammatory cytokines (CSF2, CSF3, IL1B, 
IL6, IL23), anti-inflammatory cytokines (IL1ra, LIF) and TNFα receptor, 
TNFR1 (Quan et al., 2003, Klein, 2004, Knapp et al., 2004, Pan et al., 2008, 
Soria and Ben-Baruch, 2008, Thompson and Van Eldik, 2009, Timotijevic et 
al., 2012, Vom Berg et al., 2012, Ramesh et al., 2013, Shiomi and Usui, 2015). 
Of note, some of these inflammatory markers are known to exhibit divergent 
pro- as well as anti-inflammatory functions depending on different cell types 
and the state of disease progression (e.g. CXCL12, CSF3, IL6, LIF) (Knight, 
2001, Knapp et al., 2004, Scheller et al., 2011, Timotijevic et al., 2012).  
Using Principal component analysis (PCA), the variation of TNFα-induced 
differentially expressed inflammatory markers in iNHA clones with different 
FynT kinase activity could be clearly visualized in a 3D scatter plot, allowing 
the clones with distinct expression profiles to be identified easily. In Figure 
5.4A, the PCA 3D scatter plot showed to account for 81% of the variation in 
the dataset. Most of the untreated clones (spheres) were visibly clustered 
together and well separated from TNFα-treated clones (cubes), suggesting a 
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general observation of TNFα-induced differential expression of inflammatory 
markers (Figure 5.4A). Furthermore, we observed that upon TNFα treatment, 
FynT-CA clone (red cubes) exhibited the greatest distance from the other 
clones (Figure 5.4A), suggesting that FynT kinase activity may facilitate 
TNFα-induced inflammatory responses.    
We also employed unsupervised hierarchical clustering to allow delineation of 
clones that share similar characteristics in response to TNFα treatment. Using 
the 14 inflammatory markers, samples could be well clustered into two 
independent branches, as untreated (-) and treated (+) on the left dendrogram 
(Figure 5.4B). Consistently, FynT-CA was shown to exhibit greater gene 
changes of inflammatory-associated markers in response to TNFα treatment as 
compared to others, and was found to cluster as an independent sub-branch in 





























Figure 5.4 FynT tyrosine kinase activity facilitated TNFα-induced 
differential expression of inflammatory markers. iNHA stable clones with 
different FynT kinase activity (empty vector (EV), FynT wild-type (WT), 
FynT kinase constitutively active (CA) and FynT kinase dead (KD)) were 
treated with or without 50 ng/ml of TNFα for 3 days in four independent 
experiments and determined the expression profile of a panel of inflammatory 
markers (CCL2, CCL5, CCL7, CXCL10,  CXCL12, CSF2, CSF3,  IL1B, 







time RT-PCR system. (A) Principal component analysis (PCA) identified the 
first 3 principal components (PCs) that explained 81% of the variation in the 
dataset. Each object represents an iNHA stable clone (EV= green, WT= 
yellow, CA= red, KD= blue) with TNFα (cubes) or without TNFα treatment 
(spheres). The variation of four biological replicates in each clone could be 
visualized by the size of each ellipse. TNFα-treated clones (cubes) were well-
segregated from untreated clones (spheres), with TNFα-treated FynT-CA 
showing the greatest distance from the others. (B) Two-dimensional 
unsupervised hierarchical clustering analysis for segregation of iNHA clones 
based on their characteristics in response to TNFα treatment. The gene 
expression levels of 14 inflammatory-associated markers were shown with the 
columns (genes) and rows (samples) in cluster order. The relative value to the 
median among all samples are shown in colour with a continuum of 
expression levels from dark blue (lowest) to bright red (highest) and missing 
data are shown in white. Corresponding gene names are listed at the bottom. 
The left dendrogram lists the clones studied and provides a measure of the 
relatedness (untreated (-) and treated (+)) of expression in each clone.  
 
5.4.3 FynT tyrosine kinase activity facilitated TNFα-induced secretion of 
inflammatory markers  
To investigate whether FynT kinase activity may facilitate  the TNFα-induced 
secretion of inflammatory markers, culture media collected from iNHA clones 
at day 3 post-treatment were examined for 14 inflammatory markers (gene 
expression of the majority of the genes were covered earlier) using multiplex 
immunoassays (MILLIPLEX®). PCA 3D scatter plot showed to account for 
76.8% of the variation in the dataset (Figure 5.5A), showing clear segregation 
of untreated clones (spheres) from treated clones (cubes). Under TNFα 
treatment, FynT-CA clone (red cubes) exhibited the greatest distance from the 
others (Figure 5.5A), consistent with the findings from the expression profile 
of inflammatory markers (Figure 5.4A). At a closer look at four inflammatory 
markers secretion profiles plotted in bar charts, FynT-CA clone consistently 
showed the greatest secretion of all four inflammatory markers IL-1β, IL-6, 
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CSF3 and CXCL10 upon TNFα treatment (Figure 5.5B). Of note, even though 
TNFα-induced significant secretion of IL-1β in all clones, the secretion level 
of FynT-CA was still the highest (Figure 5.5B). On the other hand, although 
FynT-CA clone exhibited greater IL6 induction as compared to other clones at 
the late phase (Figure 5.3), the detected IL-6 secretion was similar to other 
clones, indicating that the measured inflammatory markers might not be solely 




























Figure 5.5 FynT tyrosine kinase activity facilitated TNFα-induced 
secretion of inflammatory markers. iNHA stable clones with different FynT 
kinase activity (empty vector (EV), FynT wild-type (WT), FynT kinase 





without 50 ng/ml of TNFα for 3 days in three biological replicates and 
determined for secretion profile of a total of 14 inflammatory markers (CCL2, 
CCL3, CCL4, CCL5, CCL7, CXCL10, CXCL12, FGF, CSF2, CSF3, IL-1Ra, 
IL-1β, IL-6, IL-8) using MILLIPLEX® Multiplex Assays with Luminex 
platform. (A) Principal component analysis (PCA) identified the first 3 PCs 
that explained 76.8% of the variation in the dataset. Each object represents an 
iNHA stable clone (EV= green, WT= yellow, CA= red, KD= blue) with TNFα 
(cubes) or without TNFα treatment (spheres). The variation of three biological 
replicates in each clone could be visualized by the size of each ellipse. TNFα-
treated clones (cubes) are well-segregated from untreated clones (spheres), 
with TNFα-treated FynT-CA (red cubes) showing the greatest distance from 
the others. (B) Bar charts display modulation of TNFα-induced secretion of 
IL-1β, IL-6, CSF3 and CXCL10 in iNHA FynT clones. Data shown are the 
means and ± SEM taken from three independent experimental repeats. 






5.4.4 Pharmacological inhibition of Fyn tyrosine kinase activity decreased 
TNFα-induced inflammatory markers expression in FynT-CA clone 
To validate that ectopic FynT kinase activity plays the main role in modulating 
TNFα-induced inflammatory responses at the late phase in FynT-CA clone, 
we treated the clone with PP2, a selective SFK inhibitor and monitored for the 
attenuation of TNFα-induced inflammatory responses. PP2 was found to 
inhibit FynT kinase activity in a dose dependent manner, as shown by the 
attenuation of Tyr-416 immunoreactivities but, without affecting total Fyn 
expression in FynT-CA clone (Figure 5.6A). We also observed that the 
inhibition of FynT kinase activity by 10 µM of PP2 was accompanied by the 
attenuation of TNFα-induced IL1B expression (Figure 5.6B).  
FynT-CA and FynT-KD clones were then treated with PP2 to further confirm 
that the attenuation of TNFα-induced inflammatory responses was not 
associated with other endogenous SFKs. PP2 significantly attenuated TNFα-
induced expression of a range of cytokines and chemokines (IL1B, IL6, CSF3 
and CXCL10) (Student’s paired t-test p<0.05) in  FynT-CA clone (red bars in 
Figure 5.7), suggesting that FynT kinase activity in FynT-CA clone may play 
the main role in facilitating TNFα-induced inflammatory responses. Given that 
iNHA FynT-KD clone was already devoid of FynT kinase activity, no changes 
in TNFα-induction of cytokines and chemokines were observed with the 




















Figure 5.6 PP2 (Src-family kinase inhibitor) exhibited dose-dependent 
inhibition of Fyn tyrosine kinase activity in FynT-CA clone which was 
accompanied by the attenuation of TNFα-induced IL1B expression at the 
late phase. (A) FynT-CA clone treated with PP2 with concentrations of up to 
50 μM were studied for inhibition of ectopic FynT tyrosine kinase activity as 
determined by attenuation of positive immunoreactivities of Tyr-416 using 
Western blot analysis. β-actin was used as a loading control. (B) 10 μM of PP2 
effectively inhibited TNFα-induced IL1B expression in FynT-CA at 3 days 
post-treatment. Relative expressions of genes were normalized by geometric 
means of housekeeping genes. Data shown are the means and ± SEM from 
















































Figure 5.7 Inhibiting tyrosine kinase activity by PP2 inhibitor led to 
attenuated TNFα-induced inflammatory markers expression in FynT-CA 
clone and relatively no change in TNFα-induced inflammatory markers 
expression in FynT-KD clone. iNHA FynT-CA (red bars) and KD (blue bars) 
clones were pre-treated with 10 μM PP2 or vehicle control for 6 h, followed 
by treatment with (+) or without (-) 50 ng/ml of TNFα for a further 3 days and 
monitored for gene expression of IL1B, IL6, CSF3 and CXCL10  using real-
time RT-PCR. Relative expressions of genes were normalized by geometric 
means of housekeeping genes. Values are the means and ± SEM of 3 
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5.4.5 Specific silencing of FynT attenuated TNFα-induced inflammatory 
markers expression in FynT-CA clone and increased TNFα-induced 
inflammatory markers expression in FynT-KD clone 
To confirm that ectopic FynT mutant expression in FynT-CA contributes 
mainly for its sensitive response to TNFα treatment at the late phase, we tried 
to specifically silence FynT expression in FynT-CA clones and monitored the 
attenuation of TNFα-induced inflammatory markers expression.   
Pooled 30 nM of Dicer-substrate RNAs (DsiRNAs) mixture consisting of 
three sequences specific to FynT was able to specifically silence the 
overexpressed FynT in iNHA FynT-CA clone with an efficiency of more than 
90%  as compared to control randomized sequence (NC), and showed no 
effect on FynB expression as determined by real-time RT-PCR (Figure 5.8).  
Consistently, specific silencing of FynT in FynT-CA clone was accompanied 
by the attenuation of TNFα-induced expression of IL1B, IL6 and CSF3 
(Student’s paired t-test p<0.05) (red bars in Figure 5.9). In contrast, although 
the overall expression of inflammatory markers in FynT-KD clone remained 
much lower than FynT-CA clone after FynT silencing, we observed modest 
increased induction of all inflammatory markers by TNFα after silencing of 
the ectopic kinase dead FynT mutant (blue bars in Figure 5.9). Of note, the 
attenuation of TNFα-induced inflammatory markers expression in FynT-CA 
clone was less effective by specific silencing of FynT by DsiRNA transfection 
as compared to inhibiting FynT kinase activity by PP2 treatment. This could 
be due to some unknown reasons that these clones, particularly for FynT-CA 
that underwent transfection procedure, had increased basal level of 
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Figure 5.8 Specific silencing of FynT expression by FynT-DsiRNA in 
FynT-CA clone. Real-time RT-PCR was used to determine the specificity of 
FynT-Dicer-substrate RNAs (DsiRNAs). 30 nM of FynT-DsiRNA mixture 
consisting of three sequences specific to FynT was used to silence 
overexpressed FynT in iNHA FynT-CA clone and 30 nM of NC (randomized 
sequence) was used as a negative control. Relative expressions of genes were 
normalized by geometric means of housekeeping genes. Values are the means 
and ± SEM of 3 independent biological replicates. *Significantly different 
(Student’s paired t-test p<0.05).  
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Figure 5.9 Specific silencing of FynT expression by DsiRNA led to 
attenuated TNFα-induced inflammatory markers expression in FynT-CA 
clone and increased TNFα-induced inflammatory markers expression in 
FynT-KD clone. iNHA FynT-CA  (red bars) and FynT-KD clones (blue bars) 
were treated with (+) or without (-) 50 ng/ml of TNFα for 3 days in the 
presence of either 30 nM FynT-specific Dicer-substrate siRNAs mix (DsiRNA) 
or 30 nM Negative Control duplex (NC) and monitored for gene expression of 
IL1B, IL6, CSF3 and CXCL10 using real-time RT-PCR. Relative expressions 
of genes were normalized by geometric means of housekeeping genes. Values 
are the means and ± SEM of 3 independent biological replicates.  
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5.4.6 FynT kinase activity may modulate activation of NF-κB signalling at 
the late phase of TNFα treatment.  
NF-κB is one of the key regulators of pro-inflammatory signalling activated 
during inflammation and its activation is critical for TNFα-induced 
inflammatory response (Kempe et al., 2005, Lawrence, 2009). To determine 
whether FynT kinase activity may modulate TNFα-induced NF-κB signalling 
pathway at the early or late phase, FynT-CA and FynT-KD iNHA clones were 
co-transfected with inducible NF-κB-responsive firefly luciferase (pNF-κB-
luc) vector and constitutively expressing Renilla luciferase (pRL-CMV) 
control vector and treated with TNFα for 6 hours (early phase) and 3 days (late 
phase). Both FynT-CA and FynT-KD showed similar induction of NF-κB 
activity at 6 hours post-treatment as determined by NF-κB reporter assay, 
indicating that FynT kinase activity may not have impact at the early phase of 
TNFα treatment (Figure 5.10). Interestingly, at 3 day time point (late phase),  
FynT-CA clone showed significantly higher NF-κB activity, in contrast to  
hardly any induction of NF-κB activity found in FynT-KD clone (Figure 5.10).   
Activation of  NF-κB signalling can also be detected by phosphorylation-
dependent-IκB degradation as well as phosphorylation states of its subunits, 
e.g. Serine-536 of p65 subunit (Karin, 1999, Sakurai et al., 1999, Hu et al., 
2004, Mattioli et al., 2004). Both FynT-CA and FynT-KD clones 
demonstrated an absolute degradation of IκB shortly after TNFα stimulation 
(15min), which was accompanied by the induction of p65 phosphorylation 
(Figure 5.11A), again suggesting that FynT kinase activity may not modulate 
activation of NF-κB signalling at the early phase. Interestingly, TNFα-induced 
p65 phosphorylation in FynT-CA clone at the late phase, from day 1 onwards 
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and were maintained up to 3 days (Figure 5.11B). In contrast, FynT-KD clone 
demonstrated no further induction of phospho-p65 at the late phase (Figure 
5.11B and 5.11C). In addition, protein level of p65 in FynT-CA but not FynT-
KD clone appeared to be increasing at late time points up to 3 days of TNFα 
treatment (Figure 5.11B). Taken together, these findings suggest that FynT 

















Figure 5.10. FynT kinase activity may modulate NF-κB activation at the 
late phase of TNFα treatment as determined by NF-κB reporter assay. 
iNHA FynT-CA and KD clones were co-transfected with pNF-κB-luc vector 
and pRL-CMV vector. 24 h post-transfection, these cells were treated with (+) 
or without (-) 50ng/ml TNFα for 6 h and 3 days. NF-κB derived luciferase 
activities were measured after normalizing for transfection efficiency against 
Renilla luciferase activity. Values are the means and ± SEM of 3 replicates of 
a representative experiment from 3 independent biological repeats. 
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Figure 5.11 FynT kinase activity may modulate NF-B activation at the 
late phase of TNFα treatment as determined by Western blot analyses. 
iNHA FynT-CA, FynT-KD clones were treated with (+) or without (-) 50 
ng/ml TNFα and monitored for the activation of NF-B signalling pathway 
using Western blot analyses at the (A) early time points of 0 min, 15 min, 30 
min, 1 h and 6 h and (B) late time points of day 1, 2 and 3 (included 6 h time 
point for comparison). β-actin was used as a loading control. (C) Graph shows 
mean ± SEM of phosphorylated NF-B p65 immunoreactivity normalized to 
β-actin in iNHA FynT-CA and FynT-KD clones treated with 50 ng/ml TNFα. 
Data shown are representative blots from 2 independent biological replicates. 
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5.5.1 TNFα-induced biphasic induction of pro-inflammatory cytokines in 
iNHA 
TNFα has been shown to induce biphasic induction of gene expression 
through activation of NF-κB in multiple types of cells including, human 
glioblastoma cells-U373, mouse microglial cell line-BV2, human cervical 
cancer cells- HeLa and murine C2C12 myoblasts (Ladner et al., 2003, 
Schwamborn et al., 2003, Tian et al., 2005). This biphasic induction of gene 
expression observed in these cell lines was attributed to the effect of 
oscillatory NF-κB activation by prolonged TNFα stimulation (Tian et al., 2005, 
Cheong et al., 2008). Biphasic activation of NF-κB has also been observed in 
primary murine astrocytes and is regulated by nuclear translocation of NF-κB, 
dependent on IκBα degradation and resynthesis (Kemler and Fontana, 1999). 
The time frame for biphasic activation of NF-κB and downstream activation of 
gene transcription differs across different cell type (Han and Brasier, 1997, 
Kemler and Fontana, 1999, Tian et al., 2005). In iNHA, TNFα-induced 
activation of NF-κB signalling occurs within 15 min of simulation as detected 
by IκBα degradation and phospho-p65 increment (Figure 5.11A) while 
downstream expression of acute inflammatory genes, IL1B and IL6 peaked at 
6 h and 1 h respectively (Figure 5.2). Interestingly, when monitored up to 
three days post-TNFα stimulation, only higher concentrations (50 ng/ml and 
above) of TNFα could induce a biphasic induction of IL1B and IL6 gene 
expression in iNHA. It has been reported that saturating doses of TNFα is 
required to generate late gene expression because the expression of later genes 
requires persistent nuclear localization of NF-κB which is dependent on the 
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initial concentration of TNFα (Hao and Baltimore, 2009, Tay et al., 2010). The 
biological relevance of this would be in the context of chronic inflammation 
where persistent presence of NF-κB activating stimuli, TNFα, could surmount 
the inhibitory feedback mechanism leading to elevated constitutive activity of 
NF-κB (Hoesel and Schmid, 2013). In AD brain tissues, elevated levels of 
TNFα in both CSF and cortex and activated NF-κB could be detected in senile 
plaques even in early plaque stages as well as surrounding in neurons and 
astrocytes (Fillit et al., 1991, Kaltschmidt et al., 1997, Tarkowski et al., 1999). 
Moreover, the presence of IL-6 and IL-1β, both NF-κB inducible cytokines, 
were also detected in senile plaques.  These evidence support the idea that 
persistent NF-κB activation occurs during neuroinflammation in AD (Strauss 
et al., 1992, Griffin et al., 1995). 
5.5.2 FynT kinase activity modulates TNFα-induced biphasic induction of 
multiple inflammatory markers at the late phase. 
In Figure 5.3A, the overt differences in the gene induction of inflammatory 
cytokines (IL1B and IL6) between FynT-CA and FynT-KD clone was 
observed only at the late phase (3 days) but not during the early phase of 
induction (6 h). Therefore, subsequent experiments only focused on TNFα-
induced gene expression during the late phase. TNFα-induced differential 
expression of 14 inflammatory-associated markers were analysed using PCA 
which is a data reduction technique that allows the major sources of variation 
in a multi-dimensional dataset to be analysed without introducing inherent bias 
(Helmy et al., 2012), as well as using unsupervised hierarchical clustering 
analysis to display the gene expression data. From these data, it could be 
inferred that FynT-CA exhibited FynT kinase activity that facilitate TNFα-
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induction in various inflammatory markers which could be easily be identified 
using the PCA 3D plot (Figure 5.4A) and unsupervised hierarchical clustering 
analysis (Figure 5.4B). These suggest that the FynT kinase activity may 
modulate the expression profile of TNFα-induced inflammatory markers. 
Generally, mRNA transcript level can only partially correlate with protein 
abundance (Vogel and Marcotte, 2012). Moreover, many cytokines can only 
exert biological effects following secretion and binding to their respective 
receptors. Therefore, secretion profiles of the cytokines and chemokines from 
the FynT clones were examined using multiplex immunoassays on the 
Luminex platform. However, we need to keep in mind that the secreted 
inflammatory markers detected in the collected culture media at day 3 might 
be an accumulation of inflammatory markers that were secreted at both the 
early and late phase upon stimulation, which may result in inconsistency of the 
expression and secretion profile. Furthermore, synthesis and secretion of 
inflammatory markers were also dependent on downstream translation and 
post-translational modification; both processes could contribute to less 
predictable secretion profile. Nonetheless, we observed that FynT-CA could 
be well segregated from other clones using the expression profiles (Figure 
5.4A), as well as the secretion profile of TNFα-induced inflammatory markers 
(Figure 5.5A) as determined by PCA 3D scatter plots. Consistently, when 
analysed closely, we observed that certain cytokines and chemokines (e.g. IL-
1β, CSF3 and CXCL10) exhibited similar trends in both expression and 
secretion profiles, with FynT-CA showing the greatest response to TNFα 
treatment (Figure 5.4B and 5.5B).  In summary, our findings supported that 
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FynT kinase activity may modulate TNFα-induced inflammatory response at 
the late phase.    
Consistently, both inhibition of FynT kinase activity by PP2 treatment and 
specific silencing of ectopic FynT mutant by DsiRNA transfection in FynT-
CA clone were able to effectively attenuate TNFα-induced inflammatory 
markers expression (Figure 5.7 and Figure 5.9).  We noticed that during gene 
silencing, the transfection procedure itself affected basal expression levels of 
certain cytokines and hence likely to confound the findings. This observation 
has been previously reported where certain chemokine genes, such as 
CXCL10, CCL2 and CCL5 as well as type I interferons are known to be 
induced upon cationic liposome transfection methods of double stranded 
nucleic acid due to activation of innate immune response (Ishii et al., 2006). 
On a side note, when ectopic kinase dead FynT mutant were ablated by 
specific silencing of FynT, FynT-KD clone showed significant increment of 
TNFα-induced expression of inflammatory markers which suggest that FynT, 
in its kinase dominant negative form, exhibited a certain inhibitory role in the 
modulation of inflammatory markers (Figure 5.9). Taken together, these 
findings confirmed our observation that FynT kinase activity modulates 
TNFα-induced inflammatory markers expression at the late phase.  
5.5.3 NF-κB activation is altered in clones of different FynT kinase 
activity at the late phase of TNFα-induction 
TNFα is one of the most potent physiological inducers of the canonical 
signalling of NF-κB during inflammation (Lawrence, 2009).  To determine 
whether FynT could act through NF-κB signalling to modulate TNFα-induced 
inflammatory markers production, NF-κB activity was investigated at both 
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early and late phase of induction. Both luciferase reporter assay as well as 
Western blot results, demonstrated that the difference between the NF-κB 
activities could be observed only during the late phase (3 days) of TNFα-
induction, implying that early activation of NF-κB was independent of FynT 
kinase activity.  SFKs are not known to regulate classical activation of NF-κB 
proteins directly (Abu-Amer et al., 1998). However, overexpression of certain 
SFKs (e.g. v-Src) have been shown to activate  NF-κB signalling, while SFK 
knockouts (e.g. c-Src and Fyn), dominant negative expression of SFKs (e.g., 
c-Src) and SFK inhibitor PP2 are found to reduce and delay TNFα-induced 
NF-κB activation in vitro (Eicher et al., 1994, Abu-Amer et al., 1998, Huang 
et al., 2003, Itoh et al., 2005, Panicker et al., 2015). The exact mechanism on 
how SFKs modulate NF-κB signalling is not clear but it has been proposed 
that SFKs could activate upstream signalling molecules, such as protein kinase 
C-δ and also phosphorylate non-classical tyrosine phosphorylation of IκBα, 
leading to NF-κB activation (Abu-Amer et al., 1998, Panicker et al., 2015). 
Here, our findings demonstrated that constitutive active FynT led to prolonged 
NF-κB activation in iNHA even after 3 days of TNFα-induction (Figure 5.10, 
5.11B and 5.11C), while dominant negative FynT kinase showed complete 
reversion to basal state of NF-κB activity after 3 days (Figure 5.10). These 
findings paralleled with previous studies to show kinase activity in SFKs 
positively regulates NF-κB signalling. In addition, our findings further 
emphasized that at least in iNHA, FynT kinase activity regulates TNFα-
induction of biphasic of NF-κB activation at the late phase. This also 
explained why overt induction of inflammatory markers was observed in 
FynT-CA clone but not in FynT-KD clone during late phase of TNFα-
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induction as many inflammatory markers are target genes of NF- B signalling 
(Figure 5.4) (Pahl, 1999). The significance of this would be that FynT kinase 
activity could potentially propagate inflammatory response mediated by 
astrocytes in the presence of TNFα.  
5.6 Summary 
Using recombinant FynT mutant approaches in iNHA, FynT kinase activity 
was demonstrated to positively regulate inflammatory markers induction by 
TNFα, hence leading to increased secretion of inflammatory cytokines and 
chemokines during the late phase of inflammatory markers induction. This 
biphasic induction of inflammatory markers was found to correspond with NF-
κB activity where FynT-CA clone showed biphasic induction of NF-κB which 
was not observed in FynT-KD clone. This indicates that ectopic FynT kinase 
activity can propagate prolonged inflammatory response in astrocytes leading 




















CHAPTER 6- General conclusion and future directions 
6.1 Summary 
Numerous studies have elucidated plausible pathological roles of Fyn in AD 
as mentioned in the introduction in Chapter 1. This has led to strong interest in 
the field, delegating Fyn as a potential therapeutic in AD.  Fyn is known to be 
alternatively spliced to generate two major isoforms, namely FynB and FynT. 
It is therefore convenient to assume that the brain-predominant FynB isoform 
is involved in the disease. This could explain why no study has attempted to 
delineate possible isoform-specific roles of Fyn in AD thus far.  
In this thesis, the flow of my research follows a post-mortem-to-bench 
translational approach, where we first identified our research target from post-
mortem brain tissues (Chapter 3) and then investigated and validated its 
function using primary cell culture (Chapter 4) and recombinant approaches 
(Chapter 5). Our preliminary exon array data revealed that FynT, the non-
brain predominant isoform was upregulated in AD brains while FynB 
remained unchanged. Subsequent gene ontology term enrichment analyses of 
the exon array data and cellular markers correlation revealed that FynT was 
positively correlated with markers of associated with reactive astrogliosis and 
negatively correlated with neuronal function. Therefore, we hypothesized that 
the differentially regulated FynT in AD possess an isoform-specific role in the 
pathogenesis of AD. Ultimately, we aim to elucidate the isoform-specific role 




In the first part of my findings (Chapter 3), validation of exon array data was 
performed using real-time RT-PCR and capillary electrophoresis to confirm 
that FynT is indeed upregulated in AD.  Since we found FynT to be positively 
correlated with markers of associated to reactive astrogliosis and negatively 
correlated with neuronal function, cell-type specific expression of FynT versus 
FynB ratio in the two major cell-types of the brain (astrocytes and neurons) 
were determined. As anticipated, astrocytes were found to express 
proportionately higher amount of FynT to FynB as compared to neurons. 
Subsequently, FynT immunoreactivity in association with cellular markers and 
neuropathological hallmarks in post-mortem AD brains was investigated. This 
led to the first major finding of this thesis that the isoform-specific 
upregulation of FynT was likely to be independently associated with 
neurofibrillary degeneration and reactive astrogliosis in AD. The results also 
highlighted that the alternative splicing of Fyn may be an important 
mechanism in disease pathogenesis or response in AD as neurons are known 
to predominantly expressed FynB, but FynT was in fact increased with 
concomitant decrease of FynB in NFT-bearing neurons. Moreover, the 
observation that reactive astrocytes in AD brain displayed brighter FynT 
immunoreactivities as compared to control brain further emphasized FynT 
involvement in reactive astrogliosis. For these reasons, further studies are 
required to elucidate the upstream signalling and molecular mechanisms 
underlying FynT modulation as well as the precise nature of its involvement in 
NFT formation and astrocyte activation.  
Based on the findings from Chapter 3, it could be speculated that certain 
pathological conditions in the AD brain can result in specific upregulation of 
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FynT. In addition, FynT expression could be associated with increased 
astrocyte numbers due to astrogliosis. Thus, we aimed to delineate the 
isoform-specific role of FynT in neurons and astrocytes using primary cortical 
cultures exposed to pathological conditions associated with AD. Treatment of 
Aβ was found to induce FynT expression in astrocytes but not in neurons from 
primary rat mixed cortical cultures. Although Aβ is known to induce tau 
hyperphosphorylation in multiple cell lines including rat neurons (Zheng et al., 
2002, Hernandez et al., 2009, Tokutake et al., 2012), it is difficult to 
recapitulate NFT formation in vitro even in neurons obtained from transgenic 
mice that express mutant human tau protein prone to aggregation (Ko et al., 
1990, Guo and Lee, 2013). This could explain why FynT was not found to be 
induced in neurons using this approach. On the other hand, we could still 
observe Aβ-induced FynT but not FynB expression in astrocyte, emphasizing 
that upregulation of FynT expression in AD may be associated in part with 
astrocytic activation. In mixed cultures with increasing numbers of astrocytes, 
positive correlation of FynT expression with astrocytic markers was observed, 
further supporting FynT as a marker of astrogliosis. Moreover, treatment of 
astrocytes with TNFα induced FynT upregulation at the late phase but no 
change in FynB expression advocates that modulation of FynT expression may 
be associated with astrocyte-mediated neuroinflammatory responses. 
Lastly, we wanted to investigate the functional role of FynT by employing 
iNHA that stably expressed FynT mutants of kinase constitutively active and 
kinase dead to study the role of FynT kinase activity in modulating TNFα-
induced pro-inflammatory signalling. Upon TNFα treatment, FynT kinase 
activity was found to positively regulate the expression and secretion of a 
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number of inflammatory markers at the late phase, likely through modulating 
NF-κB signalling pathway. Thus, it can be deduced that the upregulation of 
FynT expression in the AD brain may propagate prolonged inflammatory 
response and was closely associated with chronic inflammation. 
In summary, our findings have added new perspectives to the pathogenic role 
of Fyn in AD. The identification of FynT isoform being closely associated 
with NFT pathology and astrocyte-mediated neuroinflammation, prompt us to 
speculate that FynT could be a potential pharmacotherapeutic target for AD.   
 
 
Figure 6.1 A pictorial summary of the main findings in this study. FynT 
mRNA and protein expression was found to be upregulated in post-mortem 
brain tissues, independently associated neurofibrillary degeneration and 
reactive astrogliosis (Chapter 3). FynT was observed to be specifically 
induced in Aβ-treated activated astrocytes in mixed cortical cultures as well as 
in TNFα-treated astrocytes cultures (Chapter 4). Aberrant FynT kinase activity 
in iNHA was found to facilitate prolonged TNFα-induced inflammatory 
response in astrocytes (Chapter 5). Figure readapted from online graphical 





6.2 General Limitations  
Identification of FynT and FynB protein expression in post-mortem 
brains:  
Western blot analyses of Fyn isoforms in post-mortem brains were not 
included in our studies. This was because the custom-made FynB and FynT 
antibodies failed to detect specific immunoreactivity from the crude protein 
extracted from the brain tissues. We suspected that the preparation of brain 
lysate could be the main reason for the high background signals detected in the 
immunoblots. However, due to limited availability of tissues in this cohort, we 
did not explore different types of brain lysate preparation. We believed that 
localization of upregulated FynT expression in AD brain using IF could be 
more important than protein quantitation in the crude brain lysate using 
Western blot analyses. Indeed, using IF approach, we identified that FynT 
induction was independently localized to NFT-bearing neurons and activated 
astrocytes, two important hallmarks in AD pathology.    
In-vitro cell culture models:  
Primary cortical cultures treated with Aβ could be considered as an in vitro 
system of cellular constituents of the brain for AD studies. As the pathological 
characteristics of AD takes many decades to become apparent, exposing Aβ to 
primary cortical culture for just a few days may not be able to recapitulate the 
process of AD pathology. As mentioned in Chapter 4, Aβ was not able to 
induce FynT expression in neurons, probably because this in vitro system 
might not be able to activate alternative splicing machinery and/or NFT 
formation in neurons. Moreover, the observation that Aβ could induce FynT 
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expression in astrocytes from mixed cortical cultures and not from pure 
astrocyte cultures further emphasized that the induction of biological 
responses can be distinctively different in vitro and in vivo due to cell-cell 
interaction. Therefore, it is crucial to validate cell culture results with animal 
models when modelling disease conditions. 
Overexpression of recombinant FynT in iNHA:  
We have chosen iNHA over other glioma cells as a model in this study 
because although iNHA is immortalized, they are not transformed and are less 
likely to have massive genomic aberrations as compared to glioma cell lines 
derived from tumours. iNHA clones that stably expressing FynT-WT or FynT-
mutants of CA and KD, as well as EV were established for our study. We 
observed that the stability of ectopic FynT expression in each clone might vary, 
for example FynT-CA might reduce sensitivity to TNFα treatment after long 
term passages in cultures. Thus, early passages of the clones were used. All 
clones (FynT-WT, -CA, -KD and EV) were cultured, treated at the same batch 
for fair comparison. We also used at least two independent clones in the 
beginning of the study to rule out the possibility that the observation was not 
due to ectopic expression of FynT but solely due to clonal differences. Due to 
massive cell culture involved, we only focus on one clone each for subsequent 
experiments. To validate our findings that the distinct responses of FynT-CA 
and FynT-KD to TNFα treatment were indeed due to ectopic FynT mutant 
expression, we showed that the phenomenon can be reverted by silencing 
FynT expression or inhibiting FynT kinase activity. In addition, by using an 
overexpression system to study functional differences in FynT kinase activity, 
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it is important to keep in mind that certain overt phenotypes observed in this 




6.3 Future directions 
Role of FynT in neurofibrillary degeneration:  
IF results in Chapter 3 revealed that the upregulation of FynT in AD was 
likely to be independently associated with neurofibrillary degeneration and 
reactive astrogliosis. This thesis, however, did not address how FynT is 
involved in neurofibrillary degeneration and at which stage of NFT formation. 
Fyn has been shown to directly phosphorylate tau at Tyrosine 18 residue (Lee, 
1998, Lee et al., 2004) but isoform-specific difference has never been 
elucidated. It will be interesting to study regulatory mechanism of FynT 
induction in NFT-bearing neurons using transgenic animal models that carry 
tau protein mutation (e.g. P301S) (Gotz and Ittner, 2008). The greatest 
advantage of using animal models to study NFT pathology is that tau 
pathology progression can be monitored over time and expression patterns of 
FynB or FynT can be determined unlike in post-mortem brain tissues. 
Furthermore, genetic ablation of FynT can be performed by crossing the tau 
transgenic models with FynT knockout mice to determine if FynT regulates 
NFT formation.  
Furthermore, it will also be meaningful to look at FynT versus FynB 
expression in other tauopathies such as in Frontotemporal dementias (FTD) to 
determine whether FynT is purely associated with NFT across different 
tauopathies or is only specific to AD. Tau pathology in Frontotemporal 
dementia with parkinsonism-17 (FTDP-17) is associated with tau mutation 
while in AD it is not (Wolfe, 2009); this might offer new molecular insights to 
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the similarities or differences in neurofibrillary degeneration across the 
diseases.   
Role of FynT in neuroinflammation: 
To address FynT role in neuroinflammation mediated by astrogliosis, in vivo 
models of neuroinflammation can be employed. Specific FynT knockout mice 
and wild-type mice can be subjected to inflammatory stimuli in the brain in 
vivo (e.g. intracranial injection of TNFα, LPS) and monitor the extent of 
astrogliosis and the expression inflammatory markers between the two groups. 
Similarly, to investigate role of FynT in chronic neuroinflammation related to 
AD, FynT knockout mice can be crossed with AD transgenic mouse models 
known to exhibit gliosis (e.g. APPPS1, 5XFAD, P301S) (Oakley et al., 2006, 
Radde et al., 2006, Yoshiyama et al., 2007) and monitor at different stages for 
inflammatory responses.  
Studying alternative splicing mechanism of Fyn: 
Currently, the exact mechanism on how Fyn undergoes alternative splicing is 
unknown. To identify possible regulators of Fyn splicing, samples obtained 
from both human as well as cell culture that displayed altered FynT expression 
in disease condition (e.g. NFTs and reactive astrocytes isolated by laser 
capture microdissection in brain tissues) or when treated with factors 
(astrocytes treated with Aβ or TNFα) can be collected. Subsequent proteomics 
(e.g. liquid chromatography-tandem mass spectrometry) and genomics 
technologies (e.g. exon array profiling) can be employed for the analysis of the 
samples, focusing on proteins or genes that regulates splicing mechanism and 
RNA processing.  
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Functional differences of FynT and FynB: 
Majority of the work in this thesis have focused on FynT, since it is the 
isoform that is pathologically associated with AD. So far, only a few studies 
have pointed out that FynT and FynB exhibited functional differences which 
can be attributed to region encoded by exon 7 due to alternative splicing  
(Davidson et al., 1994, Brignatz et al., 2009). Specifically, FynB structure 
favours a closed auto-inhibited conformation as compared to FynT hence 
affecting substrate accessibility (Brignatz et al., 2009). Certain substrates of 
Fyn (e.g. Sam68 RNA binding protein) can bind to each isoform with different 
affinities and hence be phosphorylated differentially (Brignatz et al., 2009). 
Functional studies can be done to elucidate investigate FynT and FynB 
differences in substrate binding particularly those substrates that are 
therapeutic targets in AD which include, Tau and NMDA receptor. This can 
be achieved by performing co-immunoprecipitation experiments to determine 
binding affinities and phosphorylation statuses. It will also be worthwhile to 
look at whether FynB possesses equivalent roles in modulating inflammatory 
response as FynT in astrocytes by generating stable clones of FynB or 
specifically silencing each isoform and monitor for inflammatory responses. 
These experiments will give us an idea whether it is wise to target Fyn in 
diseases in a non-isoform specific manner and uncover potential unwanted 
side-effects. 
Therapeutic potential of FynT: 
Ongoing AD clinical trials targeting Fyn uses tyrosine kinase inhibitors which 
are not specific to Fyn are likely to result in side-effects as tyrosine kinases are 
ubiquitously expressed in the brain. By identifying FynT as the pathological 
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isoform of Fyn in AD, we hope to highlight to the field and that FynT as 
opposed to FynB might be a better drug target of Fyn in the FynB predominant 
brain tissue. Although currently there are no Fyn specific drugs, isoform-
selective inhibitors for other kinases (e.g. p38αMAPK) (Roy et al., 2015) has 
been discovered which indicates it is possible to identify more specific 
inhibitors for FynT in the near future. Moreover, with the development of 
better drug delivery systems to the CNS, side-effects to the peripheral tissues 
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Abstract
Alzheimer’s disease (AD) is the leading cause of dementia in
old age and is characterized by the accumulation of b-amyloid
plaques and neuroﬁbrillary tangles (NFT). Recent studies
suggest that Fyn tyrosine kinase forms part of a toxic triad with
b-amyloid and tau in the disease process. However, it is not
known whether Fyn is associated with the pathological
features of AD in an isoform-speciﬁc manner. In this study,
we identiﬁed selective up-regulation of the alternative-spliced
FynT isoform with no change in FynB in the AD neocortex.
Furthermore, gene ontology term enrichment analyses and
cell type-speciﬁc localization of FynT immunoreactivity sug-
gest that FynT up-regulation was associated with neuroﬁbril-
lary degeneration and reactive astrogliosis. Interestingly,
signiﬁcantly increased FynT in NFT-bearing neurons was
concomitant to decreased FynB immunoreactivity, suggesting
an involvement of alternative splicing in NFT formation.
Furthermore, cultured cells of astrocytic origin have higher
FynT to FynB ratio compared to those of neuronal origin.
Lastly, primary rat mixed neuron-astrocyte cultures treated
with Ab25-35 showed selective up-regulation of FynT expres-
sion in activated astrocytes. Our ﬁndings point to an isoform-
speciﬁc role of FynT in modulating neuroﬁbrillary degeneration
and reactive astrogliosis in AD.
Keywords: Alzheimer’s disease, dementia, Fyn tyrosine
kinase, neuroﬁbrillary tangle, reactive astrogliosis.
J. Neurochem. (2016) 136, 637–650.
Alzheimer’s disease (AD) is a complex, progressive neu-
rodegenerative disease characterized by cognitive impair-
ments, neuropsychiatric behaviors and loss of functional
independence. Its neuropathological hallmarks include extra-
cellular b-amyloid (Ab)-containing neuritic plaques, intra-
cellular neuroﬁbrillary tangles (NFT) consisting of
abnormally phosphorylated tau protein, along with neuronal
loss, synaptic dysfunction, gliosis, and neuroinﬂammation
(Whitehouse et al. 1982; Selkoe 2002; Perrin et al. 2009).
Research on the amyloid cascade hypothesis, which ascribes
a major pathogenic role to the accumulation of neurotoxic
Ab aggregates, has been central in advancing our under-
standing of AD (Reitz 2012). Recent evidence suggests that
Fyn, a member of the Src family tyrosine kinases, forms part
of a ‘toxic triad’ (Haass and Mandelkow 2010) together with
Ab and tau in exacerbating AD. For example, Fyn was
shown to be an essential mediator in signaling cascades
induced by binding of Ab to postsynaptic prion protein,
leading to altered phosphorylation and translocation of
glutamatergic receptors and tau, together with associated
impairment of synaptic plasticity and excitotoxicity (Ittner
et al. 2010; Roberson et al. 2011; Yang et al. 2011; Pooler
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et al. 2012; Um et al. 2012; Wang et al. 2013; Xia and Gotz
2014).
Fyn exists in two major alternatively spliced isoforms,
with FynB as the predominant isoform found in the brain
while FynT is mainly expressed in cells of hematopoietic
origin (Cooke and Perlmutter 1989; Resh 1998). FynB and
FynT differ exclusively within a short sequence of 55 and 52
amino acids, respectively, spanning the end of the SH2
region, the SH2-kinase linker segment and the beginning of
the tyrosine kinase domain (Brignatz et al. 2009). Structural
analyses of intramolecular interactions of Fyn revealed that
the linker region of FynB engages the SH3 domain with
higher afﬁnity and favors a closed auto-inhibited conforma-
tion as compared to FynT (Brignatz et al. 2009). Corre-
spondingly, FynT exhibits enhanced kinase activity
compared to FynB (Davidson et al. 1994; Brignatz et al.
2009). Furthermore, biological functions speciﬁc to FynT,
such as mobilization of cytosolic calcium and T cell-
stimulated lymphokine secretion have been identiﬁed
(Davidson et al. 1992, 1994).
A putative pathogenic role of Fyn in AD has been
suggested by studies showing exacerbation of disease by Fyn
over-expression and amelioration by Fyn depletion in
transgenic models (Lambert et al. 1998; Chin et al. 2004,
2005). Increased Fyn expression in postmortem AD brain has
also been demonstrated by the detection of intense Fyn
immunoreactivity in NFT-bearing neurons (Shirazi and
Wood 1993; Ho et al. 2005). However, no study to date
has attempted to delineate possible isoform-speciﬁc roles of
Fyn in AD. Interestingly, an analysis of alternative splicing
events associated with AD using our previously published
exon microarray data revealed Fyn to be differentially spliced
in the AD temporal cortex (Lai et al. 2014), and this study
now shows that the FynT isoform is speciﬁcally up-regulated
in AD while FynB remains unchanged. Our data also suggest
that FynT alterations may be associated with NFT and




Postmortem brain tissues were derived from twelve AD patients
(ﬁve women, seven men) and eight elderly controls (three women,
ﬁve men) originally recruited by OPTIMA (Oxford Project to
Investigate Memory and Ageing, http://www.medsci.ox.ac.uk/op-
tima). Additional control tissues (n = 3; from two women and one
man) were obtained from the newcastle brain tissue resource,
Newcastle Brain Tissue Resource (NBTR), Newcastle upon Tyne,
UK, both sites being part of the UK Brains for Dementia Research
(BDR) network (see Table S1). Informed consent had been obtained
from the patients’ next-of-kin before collection of brains, and
appropriate Institutional Review Board approvals were obtained for
work carried out in Singapore (Singhealth IRB 2011/576/A). One
hemisphere of each subject was processed for pathological assess-
ments, including conﬁrmation of AD using the Consortium to
Establish a Registry for AD (CERAD) criteria (Mirra et al. 1991).
Additionally, neocortical tissue sections of all AD subjects also
underwent semi-quantitative scoring (0–3) of neuritic plaques (NP)
and NFT using a methenamine silver/modiﬁed Palmgren stain as
previously described (Lai et al. 2001). The majority of AD subjects
(ten of twelve) were assessed to be Braak stage V–VI (Braak and
Braak 1991) while none of the controls had higher than Braak stage
I–II (Table S1). Fresh frozen tissues from prefrontal (Brodmann area
BA9) and temporal (BA22) cortices of the contralateral hemisphere
were dissected and stored at 80°C in TRIzol reagent (Thermo-
Fisher Scientiﬁc, Waltham, MA, USA) before processing for real-
time reverse transcription polymerase chain reaction (RT-PCR).
Blocks of BA9 was also frozen in OCT medium for subsequent
sectioning and immunoﬂuorescence (IF) staining. A subset (BA22
in eight controls and eight AD) of this study cohort has been
included in a previous study proﬁling genome-wide changes in gene
expression and alternative splicing in AD (Tan et al. 2010; Lai et al.
2014).
Exon microarray data analysis and gene ontology (GO) term
enrichment analysis
To identify differential expression of alternate splice-variants in AD
from our previously reported microarray studies (Tan et al. 2010), a
dataset was generated and analyzed using the Exon workﬂows of the
PartekGenomics Suite 6.6 software (Partek Inc,MO,USA) (Lai et al.
2014). This dataset is publicly available from the Gene Expression
Omnibus (GEO) website (http://www.ncbi.nlm.nih.gov/geo/) using
accession number GSE37264. The Gene View module of the
Genomic Suite was used to localize differentially expressed probesets
in the context of the transcript variants of Fyn, and probesets which
were highly correlated with both FynT-speciﬁc probesets (2969915
and 2969916, with Pearson’s product-moment coefﬁcients, R > 
0.65) were retrieved. Genes with at least two representative probesets
found in the list of 497 FynT-positively correlated genes and 692
FynT-negatively correlated genes were included in Gene Ontology
(GO) term enrichment analysis using DAVID Bioinformatics
Resouces 6.7 (http://david.abcc.ncifcrf.gov/) with Benjamini’s
enrichment p-values adjustment for multiple testing, using false
discovery rate of 5% (Huang et al. 2009a,b), before submitting to a
web server REVIGO (http://revigo.irb.hr/) (Supek et al. 2011) to
remove redundant GO terms.
Antibodies
Custom-made rabbit polyclonal antibodies raised speciﬁcally
against FynB and FynT were generated by GenScript Corporation
(Piscataway, NJ, USA). FynB and FynT-speciﬁc rabbit polyclonal
antibodies were prepared against synthetic peptide CRESLQ-
LIKRLGNGQ (NP_002028, residues 268–281) and QTSGLAK-
DAWEVAC (NP_694592, residues 252–264), respectively, which
are conserved among human, mouse, and rat. Both peptides were
conjugated with keyhole limpet hemocyanin to increase immuno-
genicity for immunization. Pre-immune serum and test bleed serum
from rabbits after third immunization with enzyme-linked
immunosorbent assay (ELISA) titer of 1 : 256 000 were tested for
FynB and FynT-speciﬁcity using western blot analyses. The
antibodies with low background and high speciﬁcity were afﬁnity
puriﬁed and dissolved in phosphate buffer saline (PBS), pH 7.4 at a
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concentration of 0.428 mg/ml with 0.02% sodium azide as preser-
vative. Aliquots were stored at 80°C until use. Dilutions and
sources of other commercially available primary and secondary
antibodies are listed in Table S2.
Primary rat mixed cortical culture and Ab25-35 treatment
Primary rat mixed neuron-astrocyte cortical cultures were established
from embryonic (E18) Sprague Dawley rats after protocol approval
from the Singhealth Institutional Animal Care and Use Committee
(2014/SHS/950). Brieﬂy, cortices were dissected and meninges were
removed in ice cold Hank’s balanced salt solution, then treated with
0.2 mg/mL trypsin and 40 lg/mL deoxyribonuclease in Hank’s
balanced salt solution supplemented with 7.4 mM glucose, 1 mM
sodium pyruvate, 10 mM HEPES, 4.2 mM NaHCO3, 1.2 mM
MgSO4, and 0.3% bovine serum albumin at 37°C for 5 min. The
trypsin digestion was terminated by the addition of trypsin inhibitor
before mechanical trituration using ﬁre-polished Pasteur pipettes.
Dissociatedcellswere thencentrifugedand resuspended inNeurobasal
(NB) medium supplemented with 10% heat-inactivated fetal bovine
serum, 2.5% B27 and 0.25%GlutaMAXTM with penicillin-streptomy-
cin (all reagents from ThermoFisher Scientiﬁc, Waltham, MA, USA).
Cellswere seeded at densities of approximately 1 9 106 cells perwell
in 6-well plates coated with 0.1 mg/mL poly-D-lysine and cultured at
37°C in a humidiﬁed 5%CO2 incubator. Two hours after adherence of
the cells, the mediumwas replaced with NBmedium in the absence of
fetal bovine serum. After 7 days, medium was replaced with NB
medium minus phenol red supplemented with 2.5% B27 without
antioxidants,0.25%GlutaMAXTMandpenicillin-streptomycin.ForAb
incubation assays,Ab25-35 andAb35-25 (SigmaAldrich,St. Louis,MO,
USA)weredissolvedindistilledwateratastockconcentrationof1 mM
and aged by incubating at 37°C for 24 h. Primary rat mixed cortical
cultures were treated with or without 20 lMofAb25-35 or Ab35-25 and
harvestedforanalysisat24 hand48 h.Unlessotherwisestated,allcell-
based data were obtained from 3 to 4 independent experiments.
Real-time RT-PCR
Two micrograms of total RNA was extracted from human brain
tissue or primary rat cultures using TRIzol reagent (Life
Technologies) according to manufacturer’s instructions, then
reverse-transcribed (RT) using High-Capacity cDNA RT kit
(ThermoFisher Scientiﬁc). Semi-quantitative measurements of gene
expression were performed on the Applied Biosystems 7500 Fast
Real-time PCR system (ThermoFisher Scientiﬁc) using either SYBR
Green PCR master mix (ThermoFisher Scientiﬁc) or GoTaq qPCR
Master Mix (Promega, Fitchburg, WI, USA). The primer sequences
used in this study are listed in Table S3. All real-time RT-PCR
assays were performed in duplicate. Standard curves of each gene
were generated independently by 109 serial dilution of template
DNA. The relative signal intensity of each sample was calculated
according to the corresponding standard curve. Normalization was
performed in each sample by dividing the relative signal intensity of
gene of interest to 18S rRNA (human brain samples), or geometric
mean of b-actin, GAPDH and 18S rRNA (primary rat culture).
Determination of FynT to FynB ratios
Using a pair of common primers spanning the alternative spliced exon
of Fyn (forward: 50-GGCCCAGTTTGAAACACTTC-30; reverse:
50-GTGTTTCCATTCCAGGTACC-30 with 50 labeled 6-FAM), both
FynB and FynT isoforms were ampliﬁed under 23 cycles of RT-PCR
(see above) with cDNA from human brain tissues and cultured cells.
Then, 1 lL of PCR product and 1 lL of ABI Genescan 500 Rox size
standard (Applied Biosystems, NY, USA) were added to 12 lL of Hi-
DiTM formamide (Applied Biosystems). After denaturing at 95°C for
4 min and snapped cooling on ice, samples were assayed by capillary
electrophoresis using thePRISM-310GeneticAnalyzer (ThermoFisher
Scientiﬁc). The product size and quantity of eachDNA amplicon in the
capillary electropherograms were analyzed, using GeneScan analysis
software (ThermoFisher Scientiﬁc). Peak areas of FynT (219 bp DNA
amplicon) and FynB (228 bp DNA amplicon) in each electrophero-
gramwere translated into expression level and used to determine ratios
of FynT to FynB expression.
Immunofluorescence (IF) staining and image analysis
10 or 20 lm brain sections from frozen control or AD postmortem
brain tissues or cultured cells grown on coverslips were ﬁxed with
3.7% formaldehyde for 10 min at 25C. Due to limited tissue
availability, only BA9 were used for IF staining. Brain tissues were
post-ﬁxed and permeabilized in ice-cold acetone: methanol (1 : 1)
for 10 min, whereas cultured cells were permeabilized in 0.1%
Triton-X-100 for 5 min at 25C. After washing twice with PBS,
tissue sections or cells on coverslips were blocked with 10% normal
goat serum in PBS at 25C for 1 h and incubated overnight with
primary antibodies at stated dilutions (see Table S2) in 10% normal
goat serum/PBS at 4°C. Detection was performed using Alexa
Flour 488 (green) or 555 (red-orange)-conjugated secondary
antibody after incubated for 45 min at 25C. Tissue sections were
treated with autoﬂuorescence eliminator reagent (Merck Millipore,
Darmstadt, Germany) according to the manufacturer’s instructions.
Lastly, sections or culture cells were washed and mounted with
Vectashield mounting medium with DAPI nuclear stain (Vector
Laboratories, Cambridgeshire, UK). Samples were visualized and
captured using Nikon A1R confocal microscopy system (Nikon,
Japan), and images were analyzed using Nikon NIS-Element
software (Nikon, Japan). Five representative images per sample
from three AD and three control brains were analyzed using ‘Object
Count’ to obtain total cell count as well as mean ﬂuorescence
intensity of individual cell in each channel. For primary culture
imaging, three representative images per treatment derived from
four independent experiments were analyzed using the ‘Threshold’
function to obtain the mean ﬂuorescence intensity of ROI (Regions
of interest) after applying a ﬁxed signal intensity cut-off across all
samples.
Statistical analyses
Bioinformatics analysis of the microarray database has been
described in its own section (see above). For neurochemical,
pathologic variables and gene expression levels, the differences
between AD and control samples were analyzed using Mann–
Whitney tests. Data are presented as mean  SEM. Spearman’s
rank correlation was used to evaluate signiﬁcant correlation between
FynT/FynB expression and neuritic NP ratings, NFT ratings, and
pre-death cognitive (MMSE, see below) scores. For comparisons of
gene modulation in primary cultures among the different Ab
treatment groups, we used one-way analyses of variance (ANOVA)
with Bonferroni’s post hoc tests. For all analyses, two-tailed p-
values of < 0.05 were considered to be statistically signiﬁcant.
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Results
Selective up-regulation of FynT isoform expression in AD
brain
Figure 1a shows the Gene View visualization of each probe
set in the context of the transcript variants of Fyn, which has
been identiﬁed to be signiﬁcantly and differentially spliced in
AD based on analyses of our exon microarray database (Lai
et al. 2014). The two signiﬁcantly and differentially
expressed probesets with up-regulated expression in AD were
found to be localized to the FynT-speciﬁc exon (2969915 and
2969916, indicated as 1* and 2*, respectively in Fig. 1a). In
contrast, three probesets speciﬁc for FynB (2969918,
2969958, 2969977, indicated as 1^, 2^ and 3^ respectively
in Fig. 1a) showed no change between AD and controls.
We then validated the exon microarray data by real-time
RT-PCR using FynB- and FynT-speciﬁc primer sets, and
conﬁrmed that expression of the FynT isoform was signif-
icantly increased in AD (p = 0.0155, Mann–Whitney test);
while FynB did not show signiﬁcant changes in AD
(Fig. 1b). Furthermore, relative levels of FynB and FynT
transcripts in each sample were measured by RT-PCR
followed by capillary electrophoresis as described above.
Figure 1c shows representative electropherograms of FynT
and FynB, with an elevated FynT peak in AD compared with
negligible FynT in control. In contrast, FynB peaks were
Fig. 1 Selective up-regulation of FynT isoform expression in AD
brain. (a) A Gene View display of differential alternative splicing of Fyn
was generated from Affymetrix exon array data with AD (red) and
control (blue) samples (n = 8 for both groups). Two FynT-speciﬁc
probeset IDs (1* and 2*) were signiﬁcantly up-regulated in AD as
compared to control samples. FynB-speciﬁc probeset IDs (1^, 2^ and
3^) showed no signiﬁcant changes in AD. The y-axis is a log2 scale
intensity value. (b) Real-time RT-PCR determined the relative signal
intensities of FynB and FynT in AD and control brain. (c) The
proportional amount of FynT and FynB in AD and control brain was
determined by RT-PCR followed by capillary electrophoresis. A
representative electropherogram showed the relative ﬂuorescence
units (RFU) of FynT peak (219 bp DNA amplicon) and FynB peak
(228 bp DNA amplicon) in AD and control samples. (d) Peak areas of
FynT and FynB in each electropherogram were translated into
expression level and used to determine FynT to FynB ratio of
expression. The dot plot showed that AD samples have signiﬁcantly
higher FynT to FynB ratio than control samples (p = 0.0009,
Mann–Whitney test). Available samples for RT-PCR and capillary
electrophoresis were 10 AD and 8 controls.
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high in both groups. Correspondingly, AD was found to have
a signiﬁcantly higher FynT to FynB ratio compared to
controls (p = 0.0009, Mann–Whitney test, Fig. 1d), thus
corroborating the earlier exon array and real-time RT-PCR
results and conﬁrming the up-regulation of FynT, but not
FynB isoform in AD. Lastly, correlational analyses of gene
expression data with neuropathological parameters revealed
that FynT levels positively correlated with semi-quantitative
NP (Spearman q = 0.72, p < 0.01) and NFT scores
(q = 0.78, p < 0.01), and negatively correlated with pre-
death cognitive Mini-Mental State Examination (MMSE)
(Folstein et al. 1975) scores (q = 0.63, p = 0.012). In
contrast, there was no signiﬁcant correlation between FynB
gene expression and the neuropathological and cognitive
scores (data not shown).
Associations of FynT expression with astrocyte activation
and neuronal dysfunction
To further explore the putative role of FynT in AD, GO term
enrichment analyses on FynT-correlated genes from the exon
array database were performed. Table 1 shows an overview
of the biological features of genes associated with FynT
expression in AD (see also Table S4 for gene lists
corresponding to each GO term). In summary, genes which
positively correlated with FynT expression were mainly
associated with cytoskeleton organization, cell adhesion,
cellular movement and extracellular matrix. The positive
correlated gene category with the highest fold enrichment
was ‘basolateral plasma membrane’ (Table 1), a component
of cell adhesion, cytoskeleton organization and cell move-
ment (See Table S4). Additionally, we also observed that
FynT positively correlated with astrocytic markers including
glial ﬁbrillary acidic protein (GFAP) and glutamate aspartate
transporter (GLAST, see Table 2). Furthermore, higher
proportions of endogenous FynT expression were found in
primary rat astrocytes and cell lines of astrocytic lineage as
compared to primary rat neurons and neuronal cell lines (see
Fig. 2). In contrast, genes associated with synaptic vesicles
and various neuronal markers were negatively correlated
with FynT expression (Tables 1 and 2). Given the endoge-
nous expression of FynT in T-lymphocytes and other
hematopoietic cells (Cooke and Perlmutter 1989), the results
may also reﬂect T-cell inﬁltration in the AD brain. However,
expression levels of T-cell associated markers such as CD3,
CD4, CD8 and CD45 were either very low or did not
correlate with FynT (see Table 2). Taken together, these
Table 1 Genes which correlate with FynT expression in AD categorized by GO terms
Genes positively correlated with FynT expression
GO Term ID (Category)a Description Countb Fold Enrichmentc Benjamini pd
GO:0008092 (MF) Cytoskeletal protein binding 44 3.011 7.20E-08
GO:0015629 (CC) Actin cytoskeleton 26 3.479 4.83E-05
GO:0048522 (BP) Positive regulation of cellular process 96 1.708 3.39E-05
GO:0007010 (BP) Cytoskeleton organization 36 2.742 3.18E-05
GO:0016323 (CC) Basolateral plasma membrane 22 3.900 4.17E-05
GO:0042127 (BP) Regulation of cell proliferation 51 2.152 6.50E-05
GO:0006928 (BP) Cellular component movement 36 2.517 1.30E-04
GO:0048523 (BP) Negative regulation of cellular process 84 1.681 1.77E-04
GO:0031012 (CC) Extracellular matrix 27 2.817 3.01E-04
GO:0007155 (BP) Cell adhesion 44 2.088 6.18E-04
GO:0016563 (MF) Transcription activator activity 29 2.440 4.21E-03
Genes negatively correlated with FynT expression
GO Term ID (Category) Description Count Fold Enrichment Benjamini p
GO:0043005 (CC) Neuron projection 43 3.454 7.04E-10
GO:0045202 (CC) Synapse 41 3.173 1.66E-08
GO:0031982 (CC) Vesicle 53 2.173 8.18E-06
GO:0019717 (CC) Synaptosome 15 4.849 6.04E-05
GO:0005794 (CC) Golgi apparatus 58 1.827 2.75E-04
GO:0016192 (BP) Vesicle-mediated transport 46 2.076 1.13E-03
GO:0050804 (BP) Regulation of synaptic transmission 19 3.632 1.21E-03
aGene ontology (GO) category: biological process (BP), cellular component (CC), molecular function (MF).
bTotal number of genes correlated with FynT in the GO term.
cFold enrichment is used for measuring the magnitude of enrichment.
dp-values adjusted for multiple testing using a false-discovery rate of 5% (see Huang et al. 2009a,b).
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results suggest that up-regulation of FynT expression in AD
brain is associated with astrocyte activation as well as
impairment of synaptic plasticity.
Increased FynT immunoreactivity in AD prefrontal cortex
Using HEK293T cells transiently transfected with either
FynT or FynB, we showed that the custom-made antibodies
were able to speciﬁcally recognize their respective Fyn
isoforms (see Figure S1). Furthermore, FynT but not FynB
antibody stained positive in CD3-positive cells, suggesting
that FynT antibody can speciﬁcally recognized endogenous
FynT protein (data not shown). In subsequent IF staining
with the antibodies, we observed a general, weak FynT
immunoreactivity in control prefrontal (BA9) cortex
(Fig. 3a, top left panel); whilst in AD, a subgroup of cells
with intense staining could be detected (Fig. 3a, top right
panel). Image quantitation revealed that a signiﬁcantly higher
percentage of strong FynT-staining cells (4.8  0.6%) was
found in AD (Fig. 3b, red circle) compared to control brains
Table 2 Expression of speciﬁc cellular markers in AD versus Ctrl brain (n = 8 per group), as well as their signiﬁcant correlation with FynT




symbol Speciﬁc cellular marker
log2 base
intensitya AD vs. Ctrl
# probesets correlated
with FynT (p < 0.01)b
Pearson correlation
coefﬁcient (r)Ctrl AD Fold p-value
3393744 CD3D T cell 1.846 1.995 1.11 0.27349 None in 6
3351280 CD3E T cell 3.258 3.168 1.06 0.62740 None in 6
3351300 CD3G T cell 1.729 2.124 1.32 0.05716 1 out of 4 0.62503
3402786 CD4 T cell 3.746 3.746 1.00 0.99716 None in 12
2562932 CD8A T cell 4.080 4.276 1.15 0.13054 1 out of 11 0.62481
2562965 CD8B T cell 1.460 1.571 1.08 0.40684 None in 4
2328841 LCK T cell 3.361 3.668 1.24 0.02322* None in 17
2495187 ZAP70 T cell 2.894 3.231 1.26 0.01812* None in 17
2373842 CD45 Hematopoietic 2.812 2.872 1.04 0.64841 None in 38
3655109 CD19 B cell 3.289 3.539 1.19 0.17463 None in 19
2878437 CD14 Monocyte/macrophage 6.573 6.637 1.05 0.86321 None in 4
3442706 CD163 Monocyte/macrophage 3.143 4.475 2.52 0.01540* 3 out of 18 0.65404 to 0.71018
3656990 CD11b Microglia 3.431 3.627 1.15 0.16383 None in 2
2902444 iba1 Microglia 4.235 4.271 1.03 0.87870 None in 9
2806643 GLAST Astrocyte 8.805 9.132 1.25 0.25089 9 out of 15** 0.65104 to 0.79985
3759410 GFAP Astrocyte 10.729 11.327 1.51 0.02510* 14 out of 14** 0.65573 to 0.78003
2525533 MAP2 Neuron 8.721 8.091 1.55 0.02259* 2 out of 26 0.63944 to 0.64138
3128271 NEFL Neuron 9.035 8.076 1.94 0.02170* 10 out of 12** 0.62376 to 0.73384
3090436 NEFM Neuron 8.965 8.186 1.71 0.04663* 2 out of 11 0.65343 to 0.71241
3432394 RPH3A Neuron 7.737 5.986 3.37 0.00045* 27 out of 28** 0.64750 to 0.88786
3674504 TUBB3 Neuron 5.686 5.409 1.21 0.10308 1 out of 6 0.65120
aLog2 base intensity is gene-level data.
bCorrelation between cellular markers and FynT expression was analyzed at the exon-level using probesets in each transcript ID. Only those with
signiﬁcant correlation (p < 0.01) were indicated with Pearson correlation coefﬁcient (r) in last column.
*Indicated signiﬁcant differentially expressed between AD vs. Ctrl (p < 0.05).
**Indicated cellular marker with more than half of the probesets showing signiﬁcant correlation with FynT expression.
Fig. 2 Higher proportions of FynT expression in cells of astrocytic
origin. Endogenous FynT to FynB ratios were determined by RT-PCR
followed by capillary electrophoresis (see Methods) in untreated cells
of neuronal (primary rat neurons, SH-SY5Y line) or astrocytic (primary
rat astrocytes, U-87MG and U-251MG lines, shaded bars) origins.
Data are mean  SEM of at least three independent experiments for
each cell type.
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(0.8  0.5%, Fig. 3b, blue circle). In contrast, FynB
immunoreactivities were uniformly prominent in both AD
and control sections (Fig. 3, bottom panels), with no
signiﬁcant differences in percentage of stained cells (Fig. 3b,
red and blue triangles).
FynT localization to a subset of neurons in AD
To compare cell type-speciﬁc expression of FynT and
FynB in AD and control brains, we performed double IF
staining with neuronal marker NeuN. We observed that
strong FynT immunoreactivities were found in NeuN-
positive stained neurons (Fig. 4a, white arrows). Note that
only a subset of NeuN-positive neurons co-stained with
FynT. In contrast, the majority of neurons stained positive for
FynB (Fig. 4b), supporting the previously established neu-
ronal localization for FynB (Cooke and Perlmutter 1989).
Therefore, FynT up-regulation in AD seems to occur in a
subset of neurons, most of which showed unchanged levels
of FynB.
FynT localization to reactive astrocytes in AD
Besides neurons, Fig. 5 shows that FynT immunoreactivities
were localized to cells that stained positive for GFAP at the
thickened processes (white arrows in top panels) and
hypertrophic cytoplasm (white arrows in middle panels),
both of which are characteristic of reactive astrocytes. We
observed that FynT immunoreactivity was relatively stronger
in hypertrophic cytoplasm than in the GFAP-positive
processes. However, the weaker but speciﬁc FynT staining
of the astrocytic processes in AD brain could still be resolved
(white arrows, Fig. 5 top left panel) even in the presence of
strong FynT signals in adjacent non-GFAP cells (putatively
neurons, see Fig. 4a). In contrast, corresponding GFAP-
positive processes in control brain appeared thinner and
showed non-speciﬁc background stain for FynT (Fig. 5,
white arrows in bottom panels). Our data showed that at least
a proportion of FynT immunoreactivities were localized to
reactive astrocytes.
Increased FynT in NFT-bearing neurons concomitant with
decreased FynB immunoreactivity
Fyn is known to co-stain with NFTs (Shirazi and Wood
1993; Ho et al. 2005). Using FynT and FynB-speciﬁc
antibodies, we can now investigate the speciﬁc isoform of
Fyn involved in these associations. Neuropil threads as well
as NFT-bearing neurons can be detected using AT8, a
phosphorylated tau (pS202/pT205)-speciﬁc antibody in the
AD prefrontal cortex (Fig. 6a, red channels). Interestingly,
cells with intense FynT immunoreactivity in AD sections
were exclusively co-stained with AT8, manifesting as
yellow ﬂuorescence signals of NFT-bearing neurons in
merged images (Fig. 6a top right panel, white arrows).
In contrast, FynB immunoreactivity was relatively weak in
NFT-bearing neurons (Fig. 6a bottom panels, white arrows)
compared to the adjacent AT8-negative stained neurons.
Mean ﬂuorescence intensities of FynB and FynT in
AT8-positive versus adjacent AT8-negative cells were
both signiﬁcantly different but in opposite directions,
with increased FynT and decreased FynB in AT8-positive
cells (Fig. 6b). Furthermore, FynT immunoreactivity also
co-localized with another antibody (Tyr18) speciﬁc for tau
phosphorylated at tyrosine 18 (pY18), a site previously
shown to be directly phosphorylated by Fyn (Lee et al.
2004), see Figure S2).
Fig. 3 Increased FynT immunoreactivity in AD prefrontal cortex. (a)
Representative IF staining of prefrontal cortex using FynT-speciﬁc
antibody (green, upper panel) or FynB-speciﬁc antibody (green, lower
panel) with nuclear DAPI counterstain (blue) were compared between
AD and control. Scale bars = 50 lm. (b) Dot plot presents the mean of
percentage of cells (deﬁned by DAPI-positive staining) that stained
positive for FynT (circle) and FynB (triangle) in AD (red, n = 3) and
control (blue, n = 3) prefrontal cortex. The mean value in each sample
is calculated by the percentage of positive cells in ﬁve representative
images. *Signiﬁcantly different (Student’s t-tests).
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Induction FynT and astrocytic markers in primary rat mixed
neuron-astrocyte cortical culture by Ab25-35
Ab treatment is known to induce neuronal degeneration and
activate astrocytes in vitro (Pike et al. 1992, 1994, 1996).
We therefore measured expression levels of Fyn isoforms as
well as neuronal and astrocytic markers in a primary rat
mixed neuron-astrocyte cortical culture treated with Ab25-35
(the toxic moiety of Ab, see Kaminsky et al. 2010) using
real-time RT-PCR. At 48 h, signiﬁcant induction of astro-
cytic markers glutamate aspartate transporter and glutamate
transporter GLT1 (ANOVA p < 0.05), as well as trends toward
increased GFAP expression (ANOVA p = 0.0858) were
observed after treatment with Ab25-35, but not with the
peptide sequence control, Ab35-25 (Fig. 7). On the other
hand, Ab25-35, but not Ab35-25 reduced expression of
neuronal marker tubulin b3 (TUBB3, ANOVA p < 0.05), with
trends toward decreases in RBFOX3 (NeuN gene, ANOVA
p = 0.0618) and microtubule-associated protein 2 (MAP2,
ANOVA p = 0.0976, see Fig. 7), suggestive of Ab-induced
neurotoxic effects. Interestingly, Ab25-35 treatment selec-
tively up-regulated FynT expression while FynB remained
unchanged (Fig. 8a). The experiment was repeated once
using full length Ab1-42 and Ab42-1 control peptides with
comparable results (data not shown). Similarly, IF staining of
Ab25-35-treated primary mixed cultures showed pronounced
FynT immunoreactivity with no detectable changes in FynB
immunoreactivity (Fig. 8b). Furthermore, quantitative image
analyses showed increased FynT mean ﬂuorescence intensity
in Ab25-35-treated primary mixed culture compared to the
vehicle-treated control (Fig. 8c).
Lastly, to identify the cell types associated with induced
FynT immunoreactivity after Ab25-35 treatment, we per-
formed FynT co-immunostaining separately with astrocytic
and neuronal markers. Pronounced FynT immunoreactivity
was localized to GFAP-positive astrocytes after Ab25-35
treatment, showing clearly discernable yellow signals in the
merged image (Fig. 9a, top right panel). In contrast, the
image captured using identical microscope and camera
Fig. 4 FynT localization to a subset of
neurons in AD. Representative double IF
staining of (a) FynT and (b) FynB (green)
with neuronal marker NeuN (red) in AD and
control prefrontal cortex. Nuclei were
counterstained with DAPI (blue). White
arrows in (a) indicated cells that were
positively co-stained with FynT and NeuN.
Scale bars = 20 lm.
© 2015 International Society for Neurochemistry, J. Neurochem. (2016) 136, 637--650
644 C. Lee et al.
settings demonstrated that only weak FynT immunoreac-
tivity was detected in GFAP-positive cells treated with
Ab35-25 control peptide treatment (Fig. 9a, bottom right
panel), suggesting that Ab25-35 was able to induce FynT
expression in astrocytes. For neurons, we selected MAP2
as a marker as it is a neuron-speciﬁc cytoskeletal protein
highly enriched in dendritic processes (Kosik and Finch
1987). Under control peptide (Ab35-25) treatment, the
outline of the neurons including cell bodies and elongated
processes can be clearly labeled by MAP2 (Fig. 9b, bottom
panels). Upon Ab25-35 treatment, reductions in neuronal
processes were evident as MAP2 staining was conﬁned to
cell bodies (Fig. 9b, top panels), suggestive of an Ab-
induced neuritic dystrophy (Pike et al. 1992). Interestingly,
FynT immunoreactivity did not seem to be modulated by
Ab25-35 treatment in MAP2-positive cells (Fig. 9b, white
arrows in top panel), suggesting that under in vitro
conditions, the induction of FynT expression by Ab25-35
was localized to astrocytes.
Discussion
FynT associations with tau phosphorylation and NFT
formation
Fyn kinase is postulated to be involved in several aspects of
AD pathogenesis, and the current study has further eluci-
dated an isoform-speciﬁc role for Fyn in identifying a
selective up-regulation of the FynT isoform in AD brain. In
view of a previous report showing an increase in Fyn kinase
activity but no change in Fyn protein levels in the AD brain
(Larson et al. 2012), we postulate that the abundant,
unchanged expression of FynB in AD could have masked
an increase in FynT expression when using non-isoform-
speciﬁc antibodies. It is also possible that the reported
increase in Fyn kinase activity in AD could be contributed by
FynT up-regulation because FynT has been shown to exhibit
enhanced kinase activity as compared to FynB (Davidson
et al. 1994; Brignatz et al. 2009).
The staining pattern of FynT in relation to tau pathology
was consistent with a previous report showing phosphory-
lation of tau at Tyr18 was localized in NFT but not neuropil
threads (Lee et al. 2004). Hence, it is conceivable that FynT
may be the major modulator of tau hyper-phosphorylation as
pTau immunoreactivities (AT8 and Tyr18) co-localized
exclusively with FynT, but not with adjacent neurons
strongly staining for FynB. Furthermore, Bhaskar et al.
(2005) also demonstrated that Fyn may bind tau isoforms
with different afﬁnities, suggesting the possibility of complex
interactions between the Fyn and tau isoforms. An indepen-
dent study demonstrated that Tyr18 phosphorylation is
important in mediating the Fyn–tau interaction and inﬂu-
ences the cellular trafﬁcking of tau (Usardi et al. 2011).
However, whether the co-staining of FynT and phosphory-
lated tau may implicate their interaction and affecting their
cellular trafﬁcking is unknown which warrant further inves-
tigation.
Fig. 5 FynT localization to reactive
astrocytes in AD. Representative double IF
staining of FynT (green) and astrocytic
marker glial ﬁbrillary acidic protein (GFAP)
(red) in the prefrontal cortex of AD (top two
panels) and control brain (bottom panel).
Nuclei were counterstained with DAPI
(blue). White arrows indicated astrocytes.
Scale bars = 20 lm.
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Fig. 6 Increased FynT in neuroﬁbrillary tangles (NFT)-bearing
neurons concomitant with decreased FynB immunoreactivity. (a)
Representative double IF staining of phosphorylated tau marker AT8
(red) and FynT (green, top panel) or FynB (green, bottom panel)
counterstained with DAPI (blue) in the prefrontal cortex of AD brain.
White arrows indicated NFT-bearing cells. Scale bars = 20 lm.
(b) Mean ﬂuorescence intensities of FynT or FynB in NFT-bearing
neurons (deﬁned by AT8-positive staining) and surrounding
AT8-negative cells within each representative image are analyzed
in pairs. Five representative images were included in each sample
for three AD subjects. *Signiﬁcantly different (Student’s paired
t-tests).
Fig. 7 Gene expression changes in Ab25-35-treated primary rat mixed
neuron-astrocyte cortical culture. Primary rat mixed cortical cultures
were treated with 20 lM Ab25-35 or Ab35-25 or without treatment (Ctrl)
for 24 and 48 h and monitored for gene expression using real-time RT-
PCR for astrocytic markers (GFAP, GLAST and GLT1) and neuronal
markers (RBFOX3/NeuN, TUBB3 and MAP2). Fold changes were
calculated by setting the normalized relative signal intensity of Ctrl as
1. Values are mean  SEM of at least three independent experiments.
*Signiﬁcantly different (one-way ANOVA with Bonferroni’s post hoc test
p < 0.05).
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Furthermore, whilst previous studies reported higher Fyn
immunoreactivity in NFT-bearing neurons in AD (Shirazi
and Wood 1993; Ho et al. 2005), our data now suggest that
FynT is the predominant isoform associated with the NFT.
Intriguingly, the increased FynT expression was accompa-
nied by apparently weaker FynB immunoreactivity in the
NFT-bearing neurons (Fig. 6a), suggesting that the up-
regulated FynT reﬂects a modulation of the alternative
splicing machinery which favors the FynT isoform, and that
this ‘switching’ to FynT may be associated with AD
pathogenesis. Differential alternatively spliced transcripts in
human brains associated with aging and neurodegeneration
including AD have been detected simultaneously with
altered expression of various splicing regulators (Tollervey
et al. 2011). Furthermore, aberrant tau exon 10 splicing
found in some sporadic AD was associated with a
dysregulation of alternative splicing (Glatz et al. 2006). In
view of the close relationship between FynT and tau in
NFT-bearing neurons, we speculate that during NFT
formation, alternative splicing machinery may be activated
to modulate tau exon 10 splicing, as well as Fyn exon 7
splicing to favor FynT expression. However, whether these
are the cause or consequence associated with NFT forma-
tion is still unclear.
Ab-treated primary cortical culture showed no changes of
FynB and FynT expression in neurons. We speculate that this
in vitro approach may not be able to recapitulate the
induction of alternative splicing machinery and/or NFT
formation as found in the AD brain. Alternatively, the
negative results may be because of differences in the nature
or extent of fyn isoform regulation by alternative splicing
between human and rodent. Furthermore, association of Fyn
alterations with soluble Ab should also be investigated in the
AD brain.
FynT in association with astrocyte activation
A second major ﬁnding of this study relates to FynT and
astrocyte activation. Astrocyte-mediated neuroinﬂammatory
responses have long been postulated to play a role in AD
(Fuller et al. 2009; Steele and Robinson 2012; Medeiros and
LaFerla 2013). In this study, we speculate that the increased
FynT expression may be partly due to higher numbers of
reactive astrocytes in the AD brain, which is corroborated by
signiﬁcant positive correlation between FynT and astrocytic
markers, as well as cell adhesion and extracellular matrix
proteins (Tables 1 and 2), both of which are known to be
highly associated with reactive astrogliosis (Zamanian et al.
2012). Furthermore, higher proportions of endogenous FynT
Fig. 8 Speciﬁc up-regulation of FynT in Ab25-35-treated primary rat
mixed neuron-astrocyte cortical culture. Primary rat mixed cortical
culture were treated with 20 lM Ab25-35 or Ab35-25 or without
treatment (Ctrl) for 24 and 48 h and monitored for FynT and FynB
expression. (a) Real-time RT-PCR results as represented by fold
change, was calculated by setting the normalized relative signal
intensity of Ctrl as 1. Values are mean  SEM of 3-4 independent
experiments. *Signiﬁcantly different (one-way ANOVA with Bonferroni’s
post hoc test p < 0.05). (b) At 48 h, Ctrl and Ab25-35-treated
primary rat mixed cortical culture were stained for FynT or FynB
(green). Cell nuclei stained by DAPI (blue) were shown to ensure
similar cellular content in each tissue section. Scale bars = 100 lm.
(c) The paired dot plot presents the mean of FynT mean ﬂuores-
cence intensity in Ab25-35-treated primary culture and vesicle treat-
ment control in 4 independent experiment (p = 0.0329, Student’s
paired t-test). The mean value in each experiment is calculated by
the FynT mean ﬂuorescence intensity in three representative
images.
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expression were found in primary rat astrocytes and glioma
cell lines as compared to primary rat neurons and neurob-
lastoma cell lines (Fig. 2). Additionally, while comparing the
modulation of astrocytic FynT expression between AD and
control prefrontal cortex, we observed that FynT immunore-
activity was clearly localized to the thickened processes and
hypertrophic cytoplasm of activated astrocytes in the AD
brain (in addition to NFT-bearing neurons), compared to
only weak signals in the control sections, suggesting that
FynT may be up-regulated during reactive astrogliosis. This
postulate was further supported by the observation of
increased FynT expression co-localized with GFAP in
primary rat astrocytes under Ab treatment (Fig. 9a).
Accumulating evidence suggests that Fyn is a crucial
player mediating soluble Ab-induced neuronal dysfunction
(Ittner et al. 2010; Roberson et al. 2011; Yang et al. 2011;
Pooler et al. 2012; Um et al. 2012; Wang et al. 2013; Xia
and G€otz 2014). However, to the best of our knowledge, no
study has focused on the role of Fyn in astrocytic activation
in association with AD. Although we observed Ab-induced
FynT expression in astrocytes of mixed cortical cultures, the
etiologic links remain unclear, and may involve both
pathogenic (e.g., neurotoxicity) and adaptive (e.g., response
to oxidative stress) components. Nevertheless, the consistent
observations of FynT association with astrocytic markers in
our study suggest that up-regulation of FynT expression in
AD may be associated in part with astrocytic activation.
Given that astrocytes have been shown to participate in
cerebral innate immunity and inﬂammatory responses
(Aschner 1998; Farina et al. 2007), and that studies of
FynT-speciﬁc knockout mice have demonstrated the crucial
role of FynT in modulating the immune system (Cooke et al.
1991; Davidson et al. 2004; Chaimowitz et al. 2013), we
postulate that the modulation of FynT expression may be
associated with astrocyte-mediated neuroinﬂammatory
responses in AD.
Fig. 9 Increased FynT immunoreactivity in
Ab25-35-treated astrocytes but not neurons.
Primary rat mixed cortical culture were
treated with 20 lM Ab25-35 or Ab35-25 for
48 h. Representative double IF staining of
treated cells was demonstrated for FynT
(green) and (a) astrocytic marker, glial
ﬁbrillary acidic protein (GFAP) (red) or (b)
neuronal marker, MAP2 (red). Cell nuclei
stained by DAPI (blue) were shown in the
merged images. White arrows indicated
selected neurons. Scale bars = 20 lm.
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Conclusion
This study provides the initial evidence that isoform-speciﬁc
up-regulation of FynT may be associated with both NFT and
reactive astrogliosis in AD, and that alternate splicing may be
an important mechanism in disease pathogenesis or response.
However, further studies are needed to elucidate the
upstream signaling and molecular mechanisms underlying
FynT modulation as well as the precise nature of its
involvement in NFT formation and astrocyte activation. In
the longer term, characterization of the effects of FynT
activity in the AD process may provide the rationale for
isoform-speciﬁc targeting of Fyn in inﬂammation-focused
therapeutic strategies.
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